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ABSTRACT OF THE DISSERTATION
The Role of RNA Interference in the Control of
Leishmania RNA virus 1 Infection
By
Erin Acino Brettmann
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2017
Professor Stephen M Beverley, Chair

The presence of Leishmania RNA virus 1 (LRV1) in parasites of the Leishmania (Viannia)
subgenus increases the virulence of the parasite in mouse models of leishmaniasis and is
correlated with treatment failure, relapse, and the development of mucocutaneous disease in
humans. LRV1 is not shed or infectious; rather, the infection is persistent, and as yet it is
unknown how the parasite controls virus levels. Many eukaryotic organisms use RNA
interference (RNAi) to limit virus replication, and Leishmania (Viannia) parasites have an active
RNAi pathway. To determine whether Leishmania are capable of using RNAi to control LRV1,
we sequenced sRNAs from LRV1-containing L. braziliensis and L. guyanensis and found that
these cells have abundant LRV1-derived sRNAs. Further, I targeted LRV1 using an RNAi
transgene in these species, which resulted in a loss of virus. Together, these data suggest that
RNAi can limit LRV1 replication. In contrast, knockout of the RNAi effector protein gene
Argonaute1 resulted in only a small increase in LRV1 levels, as opposed to the expected
dramatic increase. While we did not find evidence of a role for Dicer1/2 or Piwi in control of
xii

LRV1, we cannot rule out that such a role exists. These studies suggest that RNAi may play a
role in control of LRV1, but that other mechanisms may contribute more or be redundant. In
addition to these studies, I also developed a new genetic tool for the manipulation of Leishmania
in the laboratory. These “popout constructs” use GFP expression to facilitate the removal of the
construct after it has been integrated into the parasite genome, and will allow short-term
expression of genes and RNAi transgenes in Leishmania (Viannia) species. Finally, I present
investigations into the effect of RNAi transgenes on parasite biology and virulence. I found that
the presence of an RNAi transgene impairs knockdown of an unrelated target, results in an
accumulation of stable dsRNA and transposable element transcripts, and may increase parasite
virulence. These findings suggest that caution is warranted when using these constructs.
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Chapter 1: Introduction

1

Preface
The first draft of this chapter was written by EAB. Comments from SMB were incorporated into
the final version, presented here.

2

1.1 – Leishmaniasis: a global health threat
Leishmaniasis is a group of diseases caused by the protozoan parasite Leishmania and
spread by sand flies that occurs in tropical and sub-tropical regions around the world (1), with
nearly a billion (2) to 1.7 billion (1) people at risk for infection. Official figures compiled by the
World Health Organization total nearly 300,000 new infections every year and 20,000-40,000
deaths (3). Underreporting is rampant, however, and true case numbers are likely to be much
higher (3, 4). Further, large numbers of asymptomatic infections go unrecognized and untreated
(5, 6). While strategies such as indoor spraying and insecticide-treated bed nets show promise in
limiting cases of leishmaniasis (7, 8), they require a high rate of compliance (9), and resistance
of the sand flies to insecticides is increasing (10). Situations of mass displacement, such as the
civil war in Sudan and current Syrian refugee crisis, frequently result in outbreaks of
leishmaniasis (11), sometimes with huge loss of life (12). Infections are likely to increase in the
future as urban sprawl and deforestation increase contact of people to infected sand flies (13–15).
Further, climate change is likely to increase the range of the sand fly vector and reservoir hosts
into areas that previously had no known transmission (16), including the United States (17).
Indeed, while cases are still rare, there are increasing reports of autochthonous transmission of
leishmaniasis in Texas and Oklahoma (18).
Leishmaniasis has three main disease phenotypes, which correlate largely with infecting
species. In the relatively mild cutaneous disease (CL), ulcerating skin lesions ultimately heal,
leaving significant scarring. In mucocutaneous disease (MCL), parasites metastasize to and cause
destruction of the mucous membranes of the nose, throat, and mouth (19). MCL can occur
simultaneously with a cutaneous lesion, or can present years to decades later, even after
apparently-successful treatment of the cutaneous lesion (20). In both CL and MCL, the resulting
3

disfigurement can have substantial social repercussions (21). In visceral disease, parasites
metastasize to the lymphatic and vascular systems and cause hepatosplenomegaly, anemia, and
ultimately death when left untreated (22).
While attempts to create a vaccine to prevent leishmaniasis are underway (23, 24), there
is not one currently available. Chemotherapies for the treatment of leishmaniasis leave much to
be desired: they are expensive, cannot be delivered orally, have significant toxicities, and/or
require cold storage, all of which serve to limit their usefulness in the healthcare settings where
they are most needed (reviewed in (25–27)). Additionally, more severe cases of MCL appear to
be refractory to standard treatment (20), and recurrence is common (28). As metastasis of
parasites from the site of the sand fly bite is required for the progression to MCL, it is possible
that prevention of metastasis could improve cure rates and prevent the necessity of further or
more intense treatment regimens.
1.2 – Leishmania life cycle and infection of the mammalian host
Leishmania parasites are digenetic, with cycles of replication in two hosts: the sand fly
midgut and the mammalian macrophage. When a sand fly bites an infected mammal, parasites
are ingested with the bloodmeal and differentiate into the replicative procyclic promastigote
stage (reviewed in (29, 30)). Over time, these differentiate into non-dividing, infectious
metacyclic promastigotes. When the infected sand fly bites another mammal, the metacyclic
promastigotes are regurgitated into the wound (31). They are phagocytosed by endocytic
immune cells such as macrophages, neutrophils, and dendritic cells, where they differentiate into
the amastigote stage, replicate within the phagolysosome, and infect neighboring cells (32, 33).
The mammalian host immune response to Leishmania infection plays a large role in
disease progression and parasite clearance. For example, increasing levels of TNF-α and IFN-γ
4

production are correlated with increasing disease severity. Patients with subclinical infections
have very low IFN-γ and TNF-α production compared to patients with CL disease (34), while
patients with MCL have elevated levels of these cytokines compared to patients with CL.
Modulation of this response could serve as a therapeutic tool for the treatment of leishmaniasis
or the prevention of disease progression to MCL. One parasite factor that modulates the host
immune response is Leishmania RNA virus, which will be explored in further detail through this
work.
1.3 – Viruses of microbes – Leishmania RNA virus and the Totiviridae
Leishmania parasites can be infected with a virus of the Totiviridae family, Leishmania
RNA virus (LRV) (35). Within the Leishmaniavirus genus, LRV1 occurs in New World parasites
of the Leishmania (Viannia) subgenus (36–38), including L. braziliensis and L. guyanensis,
while LRV2 occurs in Old World Leishmania (Leishmania) parasites (39–41), including L.
major and L. aethiopica. This work will focus on LRV1 infecting L. braziliensis and L.
guyanensis.
LRV1 consists of a dsRNA genome (42) approximately 5.3 kb in length that encodes
only two proteins, a capsid protein and an RNA-dependent RNA polymerase (RDRP), in
overlapping open reading frames (43). It is located in the parasite cytoplasm (35) and assembles
into ~30nm viral particles that can be purified by sucrose (35) or CsCl (44) gradient . A related
virus from the family Totiviridae found in Saccharomyces cerevisiae, L-A virus, is the type
species of the Totiviridae family, and has been characterized much more extensively than has
LRV. Due to the similarities between the two, it is assumed that the replication cycle of LRV
matches that of L-A (reviewed in (45)) (Figure 1). Where direct evidence exists for LRV, I have
noted it. Briefly, the RDRP transcribes a plus-strand transcript from the dsRNA genome
5

contained within the capsid and extrudes it into the cytoplasm (42, 46), where its genes are
translated by host translational machinery. This single transcript encodes both the capsid and
RDRP, and the RDRP is likely translated via frameshift as a fusion protein (39, 43, 47). Finally,
the plus-strand transcript is encapsidated (48, 49) and used by the RDRP as a template for
synthesis of the minus-strand (42), regenerating the dsRNA genome. Importantly, the dsRNA
genome remains enclosed within and protected by the protein capsid, and only (+)-strand mRNA
is exposed to the contents of the cytoplasm.
Like most viruses of the Totiviridae family, LRV is not shed in culture, nor are viral
particles infectious (48). Only a select few viruses of this family, such as Giardiavirus (50) and
piscine myocarditis virus (51) have extracellular routes of infection. Fungal totiviruses, such as
L-A, can be transmitted by cytoplasmic fusion, as during mating (52). Leishmania genetic
exchange can occur at low frequency during sand fly passage (53, 54). Crosses done in
collaboration with David Sacks between L. major strains 5-ASKH (containing LRV2) and Sd
resulted in hybrid progeny containing LRV2, suggesting that LRV2 can likewise be transmitted
by mating (Owens, Lye, Inbar, Akopyants, Sacks, Beverley, unpublished data). Attempts to
super-infect parasites with LRV1 or to introduce LRV1 into parasites not naturally containing
the virus, however, have not produced persistent virus infections (48, 55). Prior to this work,
there had been one report in the literature of loss of LRV1 from an infected L. guyanensis strain
(56); however, the mechanism by which this occurred is unclear, and it could not be replicated
by the same or other laboratories. Because LRV1 cannot be introduced into uninfected parasites,
and cannot be reliably “cured” from strains that contain it, research on its biological effects has
relied on either non-isogenic, naturally-occurring isolates or on the single isogenic L. guyanensis
strain that arose cryptically. The field would benefit from a reliable method with which to
6

generate LRV1+ lines from an LRV-negative strain, or LRV-negative lines from a strain
containing LRV1. I address this topic in Chapter 2 of this dissertation.
1.4 – The role of LRV1 in parasite biology & virulence
Despite its long history in the literature, very little was known about the effect of LRV1
on parasite biology. Recently, it has become clear that LRV affects the pathogenesis of
Leishmania, and therefore has large implications for human disease. Much of the mechanistic
work has been done in mouse models of infection using the single isogenic pair of L. guyanensis
lines. Experiments were either in vitro infections of murine bone marrow-derived macrophages
or in vivo injection of parasites into hind footpad of mice.
L. guyanensis parasites that contain LRV1 produce larger lesions with higher parasite
burdens than do LR1-negative strains in WT C57BL/6 mice (57). Similarly, LRV1+ parasites
induce higher pathology and parasite burden in IFN-γ knockout mice, and metastasize earlier in
the course of infection than do LRV1-negative parasites (58). LRV1+ parasites also stimulate the
release of a number of proinflammatory cytokines, including TNF-α, CXCL-10, IL-6 (57), and
IL-17A (58). Recent work by Eren et al. found that the presence of LRV1 induced the expression
of miR155, which led to phosphorylation of Akt and promoted the survival of macrophages (59).
The induction of cytokine release, miR155 expression, and Akt phosphorylation all depended on
Toll-like receptor 3 (TLR3) in the mouse (57–59), which senses dsRNA. Induction of miR155
appears to occur via a separate downstream pathway than the LRV1-induced hyperinflammatory
response, however, as ΔmiR155 macrophages display a cytokine profile similar to that of WT
macrophages upon infection with LRV1+ parasites (59). These findings provide direct
mechanistic links between LRV1 and increased virulence of the LRV1-containing parasites.
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Research into the implications of LRV on human disease relies on correlative
associations in clinical samples. The impact of LRV1 on the progression of disease to MCL is
not black-and-white, as many factors, both in the parasite and in the human host, contribute to
metastasis (60). In some regions, MCL is relatively common, but LRV is absent (61, 62); in
these cases, MCL is clearly triggered by other factors. Surveys in other regions have given
conflicting results, with one finding no correlation between the presence of LRV1 and MCL
(63), and another finding LRV1 in a higher percentage of cases of MCL than cases of CL (64).
Consistently, though, studies have found that the presence of LRV1 correlates with treatment
failure (63, 65) and relapse (65). Some of these correlative studies show similar immune
responses to LRV1 in patients as were seen in mice. In one study, patients infected with LRV1+
L. guyanensis had higher levels of IL-17A and lower IFN- γ in lesion tissue than patients
infected with LRV1-negative L. guyanensis, as occurred in mice (59). In another, patients
infected with LRV1+ L. guyanensis had higher levels of intralesional cytokines (65), including
IL-6 and CXCL-10.
While the role of LRV1 in promoting MCL disease in humans is unclear, the evidence
from mouse studies supporting LRV1’s effect on parasite virulence is strong, and has real-world
implications for the treatment of leishmaniasis. There are a number of open questions on the
subject, however, that could improve patient treatment. First, we need a diagnostic tool that can
identify LRV1 in patient samples at high accuracy and low cost. This would enable us to identify
patients that might be at high risk of treatment failure, relapse, or metastasis. Second, we need to
understand the mechanisms by which LRV1 is maintained within LRV1. By understanding these
mechanisms, we may be able to develop ways to eliminate the virus from the infection and
improve treatment outcomes. Third, we need drug treatment regimens that are optimized for
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infections containing LRV1. This would decrease the incidence of treatment failure and relapse,
and improve quality of life for affected patients. This work focuses on the second need,
understanding the mechanisms by which LRV1 is maintained, and uses as its basis an antiviral
mechanism common within eukaryotic life, RNA interference (RNAi).
1.5 – RNA interference – RNA-based gene regulation
The RNAi pathway is an RNA-directed posttranscriptional regulation mechanism that is
ubiquitous across eukaryotic life, with only isolated instances of loss. It can be divided into three
main branches: the short interfering RNA (siRNA)-, micro RNA (miRNA)-, and piwi-interacting
RNA (piRNA)-mediated pathways. Each pathway uses a characteristic small RNA to direct the
regulation of another RNA. The piRNA pathway is found in the germline of multicellular
animals and primarily restricts the mobilization of transposable elements (66). The miRNA
pathway is found in both plants and animals, and regulates the translation of mRNAs (67). The
siRNA pathway is the most evolutionarily widespread pathway, and uses dsRNA to trigger the
cleavage and degradation of a complementary ssRNA (68). The remainder of this work will
focus on the siRNA-mediated RNAi pathway, and all references to “RNAi” will refer to this
mechanism, unless otherwise specified. siRNA-mediated RNAi begins with the production of
siRNAs from long dsRNA by the RNaseIII protein Dicer, which bind to the RNaseH nuclease
protein Argonaute (Figure 2). Perfectly-complementary base pairing between the siRNA and a
target RNA causes Argonaute to cleave the target RNA, triggering its degradation.
1.6 – RNAi as an antiviral defense
Many organisms, including fungi (69), plants (70), and insects (71), use RNAi as an
antiviral defense pathway. Upon infection with an RNA virus, Dicer cleaves viral dsRNA into
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viral siRNAs (vsiRNAs) which are loaded onto Argonaute. Base pairing between the vsiRNAs
and the viral mRNA guides Argonaute to the transcript, which is cleaved and subsequently
degraded. RNAi is well-suited to the task of defense against viruses for two main reasons: 1) it is
sequence independent – any dsRNA will trigger a response, and mutation of the virus does not
enable it to evade the RNAi pathway; and 2) it is specific – vsiRNAs only target perfectly
complementary sequences for degradation, leaving host genes unaffected. Mutations in RNAi
pathway genes in these organisms result in increased susceptibility to viruses, virus titers, and/or
lethality (72–75), demonstrating their importance in the control of viruses. The role of RNAi in
the control of viruses in mammalian somatic cells is not settled; some studies have found RNAi
to not be antiviral in mammalian somatic cells (76), while others have found evidence suggesting
mammalian RNAi may serve an antiviral function (77–79).
In response to the pressure by the RNAi pathway, most, if not all, RNA viruses infecting
organisms with an antiviral RNAi pathway encode an RNA Silencing Suppressor (RSS). These
suppressors operate through diverse mechanisms: some bind to viral RNA or siRNA, preventing
cleavage by Dicer or Argonaute (80, 81); others directly interact with and inhibit RNAi pathway
proteins (82, 83); other viruses produce high levels of subgenomic transcripts that suppress
RNAi (84).
1.7 – RNAi in Leishmania and the trypanosomatids
RNAi is highly conserved throughout eukaryotic life, with only infrequent instances of
loss. Some of these losses occurred in the trypanosomatid lineage, and include Trypansosma
cruzi and the Leishmania (Leishmania) subgenus of parasites. Other trypanosomatids, including
T. brucei and Leishmania (Viannia) species, have active RNAi pathways (85, 86) (Figure 3).
RNAi was first identified within the trypanosomatid lineage by the Ullu and Tschudi laboratories
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when the introduction of an inverted repeat containing sequence from the alpha-tubulin transcript
resulted in a “FAT” cell phenotype and marked reduction in alpha-tubulin mRNA (86). They
identified a protein in the T. brucei genome with the PAZ and Piwi domains indicative of
Argonaute, which they showed to bind siRNAs and to be required for RNAi, and which they
named Argonaute1 (AGO1) (87). It was soon clear that T. cruzi and L. major did not have
functional RNAi pathways (88, 89), and these organisms also lacked the AGO1 gene (90).
Further database mining from the Ullu and Tschudi labs identified two RNaseIII domain genes
present in T. brucei but not T. cruzi or L. major and showed that these genes encoded Dicer
proteins (91, 92). Peacock et al. identified an AGO1 and Dicer gene in the completed L.
braziliensis genome sequence (93), and our lab showed that L. braziliensis and L. guyanensis
both have functional RNAi pathways (85). A final attempt to identify new RNAi pathway genes
in trypanosomatids by comparative genomics returned only the three previously-identified
components and two additional genes, RNA Interference Factor (RIF) 4 and RIF5, an
exonuclease required for loading of siRNAs onto Argonaute and a Dicer 1 cofactor, respectively
(94). Interestingly, while AGO1, Dicer1, Dicer2, RIF4, and RIF5 are found only in RNAiproficient species, a second Argonaute protein containing a readily-identifiable PIWI domain and
a highly divergent PAZ domain (95) is also present in the RNAi-null T. cruzi and L.
(Leishmania) species (90). This protein was termed “Piwi” because it was initially thought to
lack the PAZ domain (90). It is evolutionarily distinct from the mammalian Piwi protein (95),
and its role in the RNAi pathway is unclear. It is not essential in the RNAi-null L. major (96), but
attempts in our lab to knock PIWI out in L. braziliensis were unsuccessful (Tsang, Anderson, and
Beverley, unpublished data). If this result can be shown to be meaningful (rather than technical),
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this suggests that Piwi may serve an additional, essential function in RNAi-competent species.
The distribution of known RNAi components in trypanosomatids is summarized in Table 1.
Attempts in the Beverley lab to reconstitute the RNAi pathway in L. major by
introduction of the missing pathway components were unsuccessful (Lye and Beverley,
unpublished data). While technical issues may contribute to this, it also suggests that more
pathway machinery has yet to be identified. It is possible that there are additional RNAi
components that serve dual functions in RNAi-proficient species. These proteins would still be
present in RNAi-null species, but have lost their RNAi functionality, such as may be the case
with Piwi. In trypanosomatids, RNAi appears to function in the silencing of active transposable
elements and repeats (97–99) which are not present in Leishmania (Leishmania) species (93).
The lack of active transposable elements in Leishmania (Leishmania) species likely removed the
selective pressure maintaining the activity of the RNAi pathway in these species. Until now, the
role of the parasite RNAi pathway in control of viruses has not been investigated.
1.8 – Toolkit for the study of Leishmania biology and virulence
Leishmania is a genetically-tractable organism amenable to many manipulations both in
vitro and in vivo. Procyclic promastigote parasites can be grown in suspension in the laboratory
using media supplemented with components for which they are auxotrophic. The L. guyanensis
and L. braziliensis strains used in this work have doubling times of 7-8 hours and reach densities
of 107 – 108 cells/mL in culture, enabling large amounts of cells to be obtained in a short period
of time and small culture volume.
The Beverley lab pioneered the transfection and genetic manipulation of Leishmania
parasites (100, 101). Leishmania can be plated on semisolid media (i.e. agarose plates) to obtain
clonal lines, and antibiotics are available for selection of desired mutants. Experiments in this
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work utilize the following drug/gene pairs: nourseothricin/SAT, hygromycin B/HYG, blasticidin
S/BSD, and puromycin/PAC. Because of these capabilities, a number of genetic manipulations
are possible, and will be used in this work.
Leishmania parasites do not appear to repair double-stranded break via non-homologous
repair to any significant extent (102); instead, homologous recombination is the default DNA
repair pathway (103). The field has taken advantage of this feature to stably integrate transfected
linear DNA into the parasite genome using regions of homology ranging from 250-1,000 bp.
This method allows for two manipulations that will be used extensively in this work: allelic
replacement to generate gene knockouts and ectopic expression from the ribosomal small subunit
(SSU) locus.
Non-essential genes can be readily knocked out by replacement with gene knockout
cassettes (101), which are targeted to the appropriate gene using regions of homology 5’ and 3’
of the gene of interest (GOI). The regions of homology flank a drug resistance gene (Figure 4A),
allowing the desired replacement mutants to be selected. Leishmania are “diploid-ish” – most
chromosomes

are

disomic,

but

cells

display

substantial

aneuploidy

of

individual

chromosomesome, leading to trisomic and even tetrasomic tetrasomic chromosomes (104, 105).
Most gene knockouts require two rounds of replacement with separate drug resistance genes, but
some genes require further replacements. In addition, since gene regulation occurs posttranscriptionally in Leishmania (106, 107), entire chromosomes can be duplicated in response to
stress, such as antibiotic pressure (108, 109). Some attempts at gene knockout result in
chromosome or whole genome amplification (110–112), which can be a sign that the GOI is
essential. Even for non-essential genes, there are factors that can make proper targeting a
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challenge, including poorly assembled flanking regions and flanking regions containing repeats.
These factors come into play in this work, and will be addressed in Appendix A.
Many species of cultured promastigotes can be transfected with circular plasmid DNAs
(episomes), which are maintained extrachromosomally (100, 113, 114) and drive expression of
exogenous genes. This is particularly useful for tests of essentiality when attempts to replace a
gene fail to yield viable null mutants. In these cases, an episome encoding GFP and the gene to
be knocked out (GOI) is transfected into cells under selection conferred by a drug resistance
cassette (Figure 4B). The GOI is expressed from the episome while the chromosomal alleles are
replaced by homologous recombination, and once a chromosomal null mutant is obtained the
drug selection maintaining the episome is removed. The cells are cultured for a time to allow the
episome to be lost and then sorted on the basis of GFP expression. If the GOI is not essential,
this process will yield viable GFP-dim clones that have lost the episome; if the GOI is essential
any GFP-dim cells will not survive or will still contain low levels of episome (115).
The parasites used in this work, L. braziliensis and L. guyanensis, do not support the
maintenance of episomes, likely due to the presence of an active RNAi pathway (85). In these
species, a gene is assumed to be essential if repeated attempts to knock it out fail, but succeed
when the gene is integrated into (and expressed from) the ribosomal small subunit locus. While
this assumption is sound, it has two major drawbacks. First, transfection efficiency is low and
homologous recombination is a relatively rare event, and therefore it is possible that too few cells
were examined to obtain the desired mutant. Second, there have been instances where genes
appeared to be essential by this criteria, but the episome segregation test revealed them to be not
essential (116, 117). Therefore, it would be advantageous to have an analogous system for the
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Viannia subgenus species to facilitate genetic manipulations, which will be discussed further in
Chapter Four.
Another tool that utilizes homologous recombination is the pIR expression system, in
which a construct is integrated into the ribosomal SSU locus, which is transcribed at high levels
by RNA polymerase I. These constructs contain a drug resistance gene for selection of mutants,
sequences enabling proper splicing and translation of genes, and two cloning sites that can each
carry a gene to be expressed (Figure 4C). This system was originally developed for the
expression of genes, such as luciferase, at high levels, with little clone-to-clone variation. More
recently, it is also used to drive transgenic RNAi in Leishmania (Viannia) species.
As described above, species of the Viannia subgenus have an active RNAi pathway that
can be harnessed to knock down parasite genes (85). To do this, sequence from the GOI is
cloned as an inverted repeat into one of the expression sites of an IR vector (Figure 4D). The
sequence is transcribed at high levels by RNA polymerase I, and it is believed that the inverted
repeat folds into a long hairpin structure (“stem-loop,” StL). Dicer cleaves this dsRNA StL into
siRNAs, which are incorporated into Argonaute and guide cleavage and degradation of the
GOI’s transcript. Reduction in target mRNA scales approximately linearly with the length of the
sequence in the stem (Lye, unpublished data), but the stem requires a minimum length of
approximately 250 nt for appreciable reductions. The caveat of knockdown using StL vectors, as
with all RNAi experiments, is that reductions in mRNA do not always generate equivalent (or
any) reductions in protein level and therefore do not always result in an observable phenotype.
After the desired mutant parasites have been generated, the effects of the manipulation on
parasite virulence can be investigated by infection of laboratory mice. To achieve infection,
luciferase-expressing procyclic promastigote parasites are grown to stationary phase in vitro,
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which causes them to differentiate into metacyclic promastigotes (118, 119), and injected into
the hind footpad of mice. The mice are monitored over the course of infection for luciferase
activity, which correlates with the number of parasites present at the site of infection, and the
thickness of the footpad, which is a measure of the host immune response. The L. guyanensis
parasites used in this work cause a self-limiting infection in wild-type C57B6 mice that does not
metastasize and ultimately resolves. In contrast, the same parasites in IFN-γ knockout mice cause
chronic infections with a relatively high rate of metastasis (58).
1.9 – Aims and Scope
LRV1 plays a substantial role in the virulence of Leishmania parasites, and a deeper
understanding of the mechanisms by which it is maintained and controlled within Leishmania
could provide targets for the improvement of patient treatment outcomes. As LRV1 is a dsRNA
virus and Leishmania (Viannia) species have active RNAi pathways, it is logical to suspect that
the RNAi plays a major role in control of LRV1. The primary aim of this work is to investigate
the relationship between LRV1 and the Leishmania RNAi pathway and determine to what extent
it functions in control of LRV1.
For RNAi to serve an antiviral purpose, siRNAs must be generated from LRV1 sequence
and competent for the targeting and degradation of the LRV1 transcript. In Chapter 2, I
investigated whether siRNAs with LRV1 sequence can reduce LRV1 levels in both L.
braziliensis and L. guyanensis, and show that LRV1 can indeed be targeted and eliminated by
transgenic RNAi, suggesting that the parasite RNAi pathway may well be antiviral. Further,
targeting by RNAi provides a mechanism by which LRV1-negative lines can be generated at will
from Leishmania isolates. In Chapter 3 I disrupted the L. guyanensis RNAi pathway by knocking
out Argonaute 1 (AGO1) and show that, contrary to predictions, there was little change in the
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level of LRV1, suggesting that AGO1-dependent RNAi is not the major mechanism by which
LRV1 levels are regulated in Leishmania. In Appendix A I describe experiments to map the
region immediately 3’ of Argonaute 1 in L. guyanensis, facilitating the experiments described in
Chapter 3. In Appendix B, I describe a protocol that I developed to isolate genomic DNA from
small numbers of Leishmania cells, facilitating the validation of transfectants in situations where
transfection efficiency was predicted to be particularly low. In Appendices C and D, I describe
preliminary attempts to investigate the roles of additional RNAi pathway components and their
roles in the control of LRV1.
Investigation of gene function in Leishmania (Viannia) species is made more difficult by
the inability of these species to support extrachromosomal circular DNAs (85), which are used in
Leishmania (Leishmania) species in tests of essentiality. In Chapter 4 I present a plasmid system
analogous to the above-described episome sort, which I term “pop-outs.” Further, I harness the
pop-out system to investigate whether transgenic RNAi has previously-unrecognized
consequences to Leishmania biology that should be considered during further use of transgenic
RNAi. Finally, in Appendix E, I describe experiments investigating the knockdown of flagellar
genes in Leishmania braziliensis, which occupied my earliest work in the laboratory.
The experiments described in this dissertation add to our understanding of the
interactions between Leishmania parasites and the RNAi pathway, as well as to our
understanding of the possible interactions between viruses and their hosts, more generally.
Further, they provide new tools for the future investigations of Leishmania biology and gene
function.
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1.10 – Table Legends
Table 1-1: Summary of known RNAi components in the trypanosomatid parasites.
Components present in a given species are denoted by a “+” while absent components are
denoted by a “-“. L. major is representative of Leishmania subgenus species, while L.
braziliensis is representative of Viannia subgenus species, as indicated in Figure 3.
1.11 – Figure Legends
Figure 1-1: Replication cycle of LRV1.
The dsRNA genome is enclosed within the protein capsid (circle), where the RDRP
(arrow shape) synthesizes a plus-strand transcript. The transcript is extruded into the
cytoplasm, where it is translated into protein. The transcript in encapsidated, and the
RDRP generates a minus strand, yielding dsRNA. Figure modified from (45).
Figure 1-2: Biogenesis of siRNAs.
Long dsRNA is cleaved by Dicer into duplex siRNAs. The siRNA duplex is loaded onto
Argonaute, and the passenger strand is ejected. Base pairing between the siRNA and a
ssRNA target causes cleavage of the target by Argonaute and subsequent degradation.
Figure from (120).
Figure 1-3: Presence and absence of RNAi and LRV1 in select species of Leishmania and
Trypanosoma.
Species are marked with a + when RNAi or LRV1 is consistently present and a – when
consistently absent. +/- indicates that isolated occurrences have been identified. For LRV,
the species present is indicated.
Figure 1-4: Schematics of constructs used in the genetic manipulation of Leishmania parasites.
A) Gene of interest (GOI) knockout by homologous recombination. An allele is replaced
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with a gene conferring resistance to a selective antibiotic (here, HYGR confers resistance
to hygromycin B).
B) Episomes encode a GOI, GFP, and resistance to a selective antibiotic. When cells
containing the episome are grown without selection, a portion of cells lose the episome,
and can be recovered by single cell sorting on GFP expression.
C) IR constructs integrate into the 18S rRNA small subunit (SSU) locus by homologous
recombination. Two sites (A and B) are available for cloning of genes to be expressed.
Splice acceptor (SA) sequences enable proper trans-splicing of transcripts. A drug
resistance cassette (here, mediating resistance to hygromycin B) enables positive
selection of transfectants.
D) Stem-loop (StL) constructs use the pIR backbone to drive RNAi knockdown of a GOI.
Sequence from the GOI is cloned into an inverted repeat in the A cloning site using
Gateway technology (Invitrogen, Thermo Fisher).
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Chapter 2: Tilting the balance between RNA interference and replication eradicates
Leishmania RNA virus 1 and mitigates the inflammatory response
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2.1 – Abstract
Many Leishmania (Viannia) parasites harbor the double-stranded RNA virus Leishmania RNA
virus 1 (LRV1), which has been associated with increased disease severity in animal models and
humans, and drug treatment failures in humans. Remarkably, LRV1 survives in the presence of
an active RNAi pathway, which in many organisms controls RNA viruses. We found significant
levels (0.4-2.5%) of small RNAs derived from LRV1 in both L. braziliensis and L. guyanensis,
mapping across both strands and with properties consistent with Dicer-mediated cleavage of the
dsRNA genome. LRV1 lacks cis or trans-acting RNAi inhibitory activities, suggesting that virus
retention must be maintained by a balance between RNAi activity and LRV1 replication. To tilt
this towards elimination, we targeted LRV1 using long-hairpin/stem-loop constructs similar to
those effective against chromosomal genes. LRV1 was completely eliminated, at high efficiency,
accompanied by a massive overproduction of LRV1-specific siRNAs, representing as much as
87% of the total. For both L. braziliensis and L. guyanensis, RNAi-derived LRV1-negative lines
were no longer able to induce a Toll-like receptor 3-dependent hyper-inflammatory cytokine
response in infected macrophages. This is the first demonstration of a role for LRV1 in L.
braziliensis virulence in vitro, the Leishmania species responsible for the vast majority of
mucocutaneous leishmaniasis cases. These findings establish the first targeted method for
elimination of LRV1, and potentially of other Leishmania viruses, which will facilitate
mechanistic dissection of the role of LRV1-mediated virulence. Moreover, our data establish a
third paradigm for RNAi-viral relationships in evolution, one of balance rather than elimination.
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2.2 – Introduction
Leishmania is a genus of early-diverging protozoan parasites that cause leishmaniasis in
many regions of the world, with an estimated 12 million symptomatic cases, at least 120 million
asymptomatic cases, and nearly 1.7 billion at risk (1-5). The disease has three predominant
clinical manifestations, ranging from the relatively mild cutaneous form to mucocutaneous
disease, where parasites metastasize to and cause destruction of mucous membranes of the nose,
mouth, and throat, and fatal visceral disease. Disease phenotypes segregate primarily with the
infecting species; however, it is not fully understood which parasite factors affect severity and
disease manifestations.
One recently identified parasite factor contributing to disease severity in L. guyanensis is
the RNA virus Leishmaniavirus (6, 7). This virus is a member of the Totiviridae family, and
consists of a single-segmented dsRNA genome that encodes only a capsid protein and an RNAdependent RNA polymerase (RDRP) (8, 9). It is most frequently found (as LRV1) in New World
parasite species in the subgenus Viannia such as L. braziliensis (Lbr) and L. guyanensis (Lgy),
which cause both cutaneous and mucocutaneous disease (6), but it has also been found
sporadically in Old World subgenus Leishmania species (as LRV2) (10, 11). Like most
totiviruses, LRV1 is neither shed nor infectious, and thus can be viewed as a long-term
evolutionary endosymbiont whose activities on the mammalian host arise indirectly through the
parasite, rather than by direct infection of the mammalian host by the virus (6). Previous work
has shown that mice infected with LRV1-bearing strains of Lgy exhibit greater footpad swelling
and higher parasitemia than mice infected with LRV1-negative Lgy (7). Similarly, macrophages
infected in vitro with LRV1+ Lgy or LRV2+ L.aethiopica release higher levels of cytokines,
phenotypes that were dependent on Toll-like receptor 3 (7, 10). The assignment of the LRV1
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specificity of these phenotypes benefited greatly from the availability of a single isogenic LRV1free line of Lgy (12). Importantly, recent studies have shown that disease severity is increased in
patients infected with LRV1+ Lgy, relative to LRV1-negative parasites (13).
In humans, Lbr is associated with cutaneous leishmaniasis, as well as the larger share of
the more debilitating mucocutaneous leishmaniasis (MCL) (14, 15). While in some studies
LRV1 was not correlated with MCL (16, 17), in others there was a strong association (6, 18, 19).
Recent studies show that LRV1 in Lbr and Lgy clinical isolates correlates with drug treatment
failure (16, 20). Thus, while other parasite or host factors may play a significant role in the
development of MCL (21, 22), current data support a role for LRV1 in exacerbating the
pathogenesis of human leishmaniasis caused by Lbr and Lgy. A similar role in pathogenicity has
been proposed for the Trichomonas vaginalis totiviruses (23). In contrast, endobiont viruses in
other systems more often impair the host or have no known effect on disease. Hypoviruses of
Cryphonectria parasitica are associated with decreased virulence of their fungal host whereas
the L-A totivirus of Saccharomyces cerevisiae is not thought to affect pathogenicity, instead
contributing to intermicrobial competition (24-27) .
Research into the role of LRV1 in Lbr disease is hampered by the fact that animal models
are less well developed than for other Leishmania (28) and by the absence of isogenic lines
bearing or lacking LRV1. Since reverse genetic systems for Totiviridae do not exist and attempts
to stably transfer LRV1 have proven unsuccessful (29), we asked whether RNA-interference
(RNAi) could be used to generate LRV1-free isogenic isolates. Unlike Old World Leishmania,
species of the Viannia subgenus, including Lbr and Lgy, retain an active endogenous RNAi
pathway (30). The RNAi pathway converts double-stranded RNA into siRNAs, which trigger the
degradation of an mRNA with complementary sequence (31). Importantly, the RNAi pathway
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acts as a defense against RNA viruses in plants and some animals, leading to great reductions or
complete elimination (32, 33). Further, introduction of RNAi pathway proteins from
Saccharomyces castellii into the naturally RNAi-null S. cerevisiae resulted in greatly decreased
levels of persistently-infecting L-A totivirus (26). In mammals, siRNA-mediated RNAi activity
appears to play a smaller direct role in antiviral responses in adult mice (34, 35), although
evidence of a direct response has been found in embryonic stem cells and young animals (36,
37).
Here we explore further the interactions of the RNAi pathway with LRV1 in both Lbr
and Lgy, and show first that LRV1 is indeed seen by the endogenous RNAi pathway, as judged
by the presence of significant levels of antiviral sRNAs. Thus and different than other systems,
RNAi and viral replication appear to be balanced. However, by increased siRNA expression
RNAi could be used to efficiently eliminate the virus. Importantly, these LRV1 negative
transfectants recapitulate the in vitro macrophage cytokine release defect seen in naturallyoccurring LRV1-negative lines, suggesting that the engineered LRV1-negative isogenic lines
will be valuable in studying the role of LRV1-mediated biology and virulence.
2.3 – Results
2.3.1 – Naturally abundant siRNAs directed against LRV1 of L. braziliensis and L. guyanensis
Previous siRNA studies in Leishmania analyzed RNAs using a tagged Argonaute inserted
into an ago1- knockout of Lbr M2903, which lacks LRV1 (9, 29, 38, 39). Because the lines
bearing LRV1 studied here had not been similarly modified, we sequenced total small RNAs
(sRNAs) as an alternative. Lbr siRNAs bear a 5’-P and 3’-OH, reflecting their origin through the
action of cellular Dicer nucleases (39), and we used these properties to make siRNA-focused
sRNA (<42 nt) libraries for next-generation sequencing (Table S1). For Lgy we chose the
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established LRV1+ Lgy M4147 strain (7), and three different Lbr shown to bear LRV1 by PCR
and/or anti-dsRNA antibody tests (40).
For sRNAs from Lbr M2903 mapping to the Lbr reference genome, read length displayed
a biphasic distribution, with a major peak centered around 23 nt (20-26 nt, 77.9% of total
mapped reads) and a minor one around 33 nt (30-36nt, 9.4% of total mapped reads) (Fig. 1A,
Table S1,S2). The 33 nt peak reads mapped primarily to structural RNA loci (62% of mapped
reads; Table S2) similar to a sRNA class described in many eukaryotes including trypanosomes
and Leishmania lacking the RNAi pathway (41-44). In contrast, reads from the 23 nt peak
showed properties similar to AGO1-bound siRNAs (39), including their size and the presence of
1-2 untemplated nucleotides at the 3’ end in about 21% of the reads (Fig. 1A; Table S1). The 3’
untemplated bases likely arise from the action of cellular terminal transferases, as Leishmania sp.
lack the HEN1 methyltransferase that normally blocks their action (39). When both AGO1bound siRNAs and the 23 nt sRNA peak reads were mapped to the Lbr genome their
distributions were very similar, with the vast majority mapping to transposable elements (Figs.
1B, S2; Table S2) (39). We concluded that the 23 nt peak sRNAs (23 nt sRNAs) provides a
reasonable proxy for siRNAs.
The properties of sRNAs from the LRV1-bearing Lgy M4147 and Lbr LEM2700,
LEM2780 and LEM3874 mapping to the Lgy or Lbr reference genomes were similar to those of
Lbr M2903, including the 23 and 33 nt sRNA peaks, genomic mappings, and the presence and
level of 3’ nt extensions in the 23nt sRNAs (Figs. 1, S1; Tables S1 & S2). Importantly, a
substantial fraction of sRNA reads obtained from the LRV1+ Lgy and Lbr lines mapped to the
LRV1 genomes, ranging from 0.4-2.5% of the 23nt mapped reads (Fig. 1B, Table S1). Unlike
those aligned to the nuclear genome, LRV1-mapped reads showed a single size distribution
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centered around 23 nt (Fig. 1A), with about 20% again showing short 3’ extensions (Table S1),
typical of Lbr siRNAs and 23 nt sRNAs (39). LRV1-mapping 23 nt sRNAs showed no consistent
strand- or region-specific biases in all four strains (Fig. S2), suggesting that they likely originated
from the action of DICERs on the viral dsRNA genome.
We previously showed that LRV1 does not encode a trans-acting inhibitor of RNAi
activity (30), and the presence of high levels of LRV1-directed sRNAs similarly suggests that it
does not encode a strong cis-acting inhibitor. Importantly, the levels of 23 nt sRNAs mapping to
LRV1s were in the same range as siRNAs mapping to an efficiently silenced Luciferase reporter
(0.4–2.5% vs. 0.8% targeted by long hairpin/stem loop transgene) (30, 39). Thus, LRV1 is able
to persist in the face of a significant RNAi response, as judged by 23 nt sRNA levels.
2.3.2 – LRV1 can be efficiently targeted by transgenic RNAi
These data are consistent with a model where RNAi activity and LRV1 replication has
achieved a ‘balance’ between viral synthesis and degradation, which might be shifted by
increasing or decreasing RNAi activity. With an eye towards virus elimination, we focused on
increasing LRV1-targeting siRNA levels through the use of transgenic RNAi methods developed
previously (30), in which long hairpin RNA is expressed at high levels from a stem-loop (StL)
construct containing LRV1 sequences integrated into the ribosomal RNA locus (Fig. 2A). We
targeted regions of LRV1 from the capsid or RDRP ORFs (Lgy M4147, Lbr LEM2700 and
LEM2780), or a region that spanned them (Lbr LEM3874), ranging in length from 794 to 1,143
bp (Fig. 2B & Table S3); since the two viral genes reside within the same RNA segment,
targeting either should lead to degradation of the entire LRV1 RNA. Since LRV1 sequences
diverge substantially between parasite strains (69-90% nt identity), ‘stems’ specific for each
species/strain were used. To assess non-specific effects, we integrated an StL construct for an
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AT-rich GFP (GFP65 StL), which efficiently silences expression of GFP65 (30). The
untransfected parental lines served as LRV1+ controls, and Lbr M2903 or Lgy M4147/HYG (12)
served as LRV1-negative controls.
To screen for loss of LRV1, StL transfectants were analyzed by flow cytometry of fixed,
permeabilized cells using an antibody raised against the Lgy M4147 LRV1 capsid (45), which
cross reacts with Lbr LRV1. For both Lgy M4147 (Fig. 3, top) and Lbr LEM2780 (Fig. 3,
bottom), there was a clear separation in capsid staining between the LRV1-positive (red) and
LRV1-negative controls (green). While control GFP65 StL lines (purple) had capsid protein
levels similar to WT, capsid protein was undetectable in LRV1-targeted StL lines (Fig. 3, light &
dark blue), indistinguishable from the LRV1-negative control. This was observed whether the
capsid or RDRP was targeted (Fig. 3). Similar results were obtained with LRV1 StL transfectants
from Lbr LEM2700 and Lbr LEM3874 (data not shown). In support of the flow cytometry data,
western blot analysis with an anti-capsid antibody showed high LRV1 levels in the Lgy parental
line and GFP65 StL transfectants, while capsid protein was undetectable in the capsid StL
transfectants (Fig. S3).
2.3.3 – StL constructs result in high levels of siRNAs mapping to the LRV1 stem
Despite the insensitivity of LRV1 to ‘natural’ levels of RNAi, as judged by the
abundance of 23nt sRNAs, introduction of StL constructs targeting LRV1 resulted in great
reduction in LRV1 levels. To understand the basis for this reduction, we analyzed 23 nt sRNA
peak reads mapping to the nuclear and LRV1 genomes, for one LRV1 StL transfectant of each
species (Fig. 4). Remarkably, the percentage of total 23 nt sRNAs mapping to LRV1 had
increased greatly from that seen in the WT parent, from 2.5% to 86.7% for Lgy and from 1.8% to
73.0% for Lbr LEM3874 (Figs. 4A, S1B). Concomitantly, the percentages of 23 nt sRNAs
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mapping to the nuclear genome was proportionately reduced, with some variability amongst loci
and/or lines (for example, rRNA reads were unchanged in both species, while tRNA reads
decreased in Lgy; Figs. 4A, S1B). While we did not measure the absolute levels of sRNAs,
previous studies show these are tightly controlled by the level of Argonaute 1 and thus are
unlikely to differ significantly (39). Essentially all LRV1-mapping sRNAs in LRV1 StL lines
now mapped only to the RNAi-targeted ‘stem’ region (Fig. 4B, dark grey), as expected since
LRV1 had been eliminated (below). This also argues against the occurrence of ‘transitive’
siRNA formation (46, 47).
The levels of LRV1 23 nt sRNAs (76-87%) in LRV1 StL-transfectants were much
greater than seen with siRNAs mapping to the LUC ORF/stem targeted using the same StL
transfection construct (0.8%) (39). To rule out the possibility that this arose from reliance on
23nt sRNAs, we analyzed these from a line bearing the LUC StL RNAi reporter used in the
siRNA studies (IR2-LUCStL(b)-LUC(a)). For this, 1.14% of the 23nt sRNA peak reads mapped
to the LUC ORF/stem, suggesting that use of 23nt sRNAs vs siRNAs did not significantly
impact quantitation. To assess the target-specific effects, we compared the results here with those
obtained in other studies, quantitating 23 nt peak sRNAs after RNAi StL targeting of a panel of
10 chromosomal genes. For these, 1.5-34% of 23 nt sRNAs mapped to the RNAi-targeted gene,
compared to less than 0.02% basally (unpublished data). Thus, the StL-bearing IR vectors
generate a high but variable level of sRNAs for all genes tested, with the LUC reporter being at
the low end and LRV1 at the high end. This may reflect the fact that while the LRV1 target is
typically eliminated by RNAi (Fig. 3 and below), chromosomal RNAi targets continuously
transcribe mRNAs. In other organisms, studies have shown that the presence of a cognate target
facilitates the turnover of sRNAs; thus, the absence of LRV1 target may lead to higher levels of
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siRNAs (48, 49). Future studies may address the factors contributing to the differences in sRNA
levels amongst genes and to the very high steady-state levels of LRV1-directed 23 nt sRNAs
seen here.
2.3.4 – Complete virus elimination following RNAi of LRV1
RNAi-mediated LRV1 knockdown would be most useful as a tool if it resulted in a
complete elimination of LRV1. To achieve a sensitivity beyond that of flow cytometry (~20
fold) or western blotting (~100 fold), we validated a sensitive quantitative RT-PCR assay (qRTPCR) for LRV1, using strain- and LRV1-specific primers to amplify a region located outside the
‘stem’ regions (Table S4; Fig. 2B). Since the melting temperatures of PCR amplicons are
sequence- and length-dependent, comparison of dissociation (melt) curves facilitated
discrimination between specific and non-specific amplification.
Because LRV1 copy number was estimated to be ~100/cell (50), a cutoff for
classification as LRV1-negative was set at 104-fold below WT. Analysis of Lbr qPCR data by
the ΔΔCt method (51) showed that most LRV1 StL transfectants had LRV1 RNA levels more
than 105-fold lower than WT (Figs. 5A, S5A,B). Raw C t values for LRV1 StL lines with LRV1specific primers were indistinguishable from mock cDNA preparations, and ΔC t values were
indistinguishable from those of negative controls. Melt curves show that products seen at C t
arose from non-specific amplification (Figs. 5A, S5A,B; white bars). As expected for control
GFP65 StL lines, LRV1 RNA levels were similar to those in WT (Figs. 5A, S5A,B; black bars).
Similar results were obtained with RNAi of LRV1 in Lgy M4147, with most transfectants
showing reductions below the 104-fold cutoff (Fig. 5B). However, low levels of LRV1 remained
in two lines where the RDRP was targeted, approximately 300- to 500-fold less than the parent
line (Fig. 5B, black bars); here melt curve analysis suggested these products were LRV1-specific
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(not shown). Alternate primers targeting other regions across the virus gave similar results (data
not shown), suggesting the presence of intact LRV1. We hypothesized that this was due to
heterogeneity in viral load, with most but not all cells lacking LRV1. In support of this, we
generated and showed that all clonal lines arising from one of the “weakly positive” lines were
negative for LRV1 by flow cytometry (data not shown) and satisfied the 10 4-fold cutoff by qPCR
(Fig. S5C). The occasionally incomplete LRV1 elimination is consistent with our prior
observation that RNAi was somewhat less efficient in Lgy than in Lbr (30). Nonetheless, even
for “weakly positive” Lgy transfectants, RNAi was sufficiently efficient for the ready isolation of
LRV1-negative lines (Fig. 3, top; 5B; S3).
2.3.5 – LRV1 knockdowns induce less cytokine production in in vitro macrophage infection
assays
Previous reports showed that LRV1+ Lgy stimulated the TLR3-dependent release of
higher levels of cytokines from bone marrow-derived macrophages (BMDMs) than LRV1negative strains (7). The availability of defined RNAi-derived LRV1-negative lines now allowed
tests of this in Lbr for the first time as well as confirmation of prior results obtained with a single
isogenic LRV1- Lgy. Briefly, BMDMs were infected in vitro with LRV1 StL and GFP65 StL
Lbr and Lgy transfectants, as well as positive and negative control lines, and the levels of two
cytokines known to be induced by LRV1 (TNF-α and IL-6) (7, 10) were measured.
Capsid StL and RDRP StL LRV1-negative lines of both Lbr and Lgy induced
significantly lower levels of cytokine production than did the LRV1-positive lines (both parental
and GFP65 STL) (Fig. 6, Fig. S5). Additionally, when macrophages from TLR3-deficient mice
were infected with Lbr LEM2700, the LRV1-positive parasites no longer elicited higher levels of
cytokine release (Fig. S5). Of note, all Lgy LRV1 StL lines induced background levels of
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cytokine release, including the two lines that retained low levels of LRV1 (Fig. 5B & 6B, Fig.
S5), consistent with the observation that high levels of LRV1 were necessary for cytokine
stimulation (7, 10).
2.4 – Discussion
In this study we have characterized the endogenous RNAi response in Leishmania
bearing the dsRNA virus LRV1, and used these insights to generate virus-negative lines that
facilitate the study of the role of LRV1 in parasite biology and host-parasite interactions.
Leishmania LRV1 and the endogenous RNAi pathway
We identified two populations of sRNA in Lbr and Lgy. The less abundant 33 nt sRNAs
mapped primarily to genes encoding structural RNAs (Table S2), as seen in other organisms
including trypanosomatids (41-44). In contrast, the more abundant 23 nt sRNA fraction exhibited
properties similar to authentic, AGO1-bound Lbr siRNAs (39), including size, the presence of 3’
untemplated bases at the same frequency (~20%), and mapping primarily to transposable
elements and repetitive sequences (Fig 1; Tables S1 & S2). Only 23 nt sRNA reads mapped to
the LRV1 dsRNA genome (Fig. 1A), and these also bore 3’ nucleotide extensions at the same
frequency, again consistent with an origin via the RNAi pathway (Table S1). Importantly, the
levels of 23 nt sRNAs mapping to LRV1 constituted a substantial fraction of total aligned 23nt
sRNAs (Fig 1B, Table S1), comparable to those targeting an efficiently-silenced LUC reporter
gene (30, 39). Thus, LRV1 can persist in the face of RNAi pressure that gives rise to sRNA
levels comparable to that which efficiently silences a chromosomal target gene.
In other organisms, sRNA/siRNA levels provide a gauge of RNAi pathway recognition
and targeting of viruses: when RNAi controls virus replication, as in plants, fungi, and insects
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(26, 32, 33), high levels of siRNAs accompany viral infections, leading to eradication of the
virus. In mammals, quantitatively fewer siRNAs are present, which do not effectively control
virus levels, at least in adult somatic tissues (34, 36, 37). In contrast, high levels of siRNA-like
23 nt sRNAs in Leishmania suggest an attack on LRV1 by the RNAi pathway, but the virus
persists. While many viruses encode trans-acting RNAi suppressors mediating their survival
(52), this seems unlikely for LRV1. There is no obvious coding potential for this in the compact
LRV1 genome, our studies here suggest there is no strong cis-acting inhibitory activity, and we
showed previously that a luciferase reporter was equally silenced in the LRV1+ and LRV1negative Lgy studied here (30). This suggests a third model where LRV1 is targeted strongly by
the RNAi pathway, but the RNAi-mediated degradation is ‘balanced’ by virus replication or
other factors. We are currently working to identify which component(s) of the RNAi machinery
mediate this balance. While the slicer activity of Argonaute is perhaps the most likely agent,
previous studies examining the role of RNAi in control of viruses frequently raise the possibility
of Dicer-mediated control as well (53-55). It is likely that the sequestration of the LRV1 dsRNA
genome within the capsid may also contribute by limiting the exposure of the LRV1 dsRNA to
the RNAi machinery and other degradative pathways.

In yeast, SKI genes act to prevent

deleterious effects of L-A viruses towards its fungal host through alterations in mRNA
degradation and/or surveillance (27), and homologous genes for several of these are evident in
the Leishmania genome.
In other organisms, persistent viruses can also be maintained in the face of an active
RNAi pathway, but at considerably reduced levels (26, 56). Over evolutionary time, this strong
pressure likely accounts for the inverse relationship in fungi between virus levels and the activity
and/or presence of the RNAi pathway, especially when associated with a selective advantage for
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viral retention, as seen with the yeast killer factors which are dependent on the L-A virus (26,
57). Similarly, in Leishmania we had originally proposed that RNAi pressure would be
sufficiently strong as to in some cases provide a driving force for loss of RNAi, in order to
maintain LRV1-dependent increases in pathogenicity (30). Given the greater ability of LRV1 to
survive in the presence of an active RNAi pathway, our data suggest that the magnitude of this
effect may be considerably less than envisioned. However, even small pressure could prove a
significant force towards down-regulating pathways impacting on LRV1 levels during evolution.
RNAi as a tool for generating LRV1-negative lines for biology
Following the predictions of the ‘balance’ hypothesis, we aimed to increase activity
against LRV1 through the increased synthesis of siRNAs targeting LRV1. This proved quite
successful; the fraction of 23 nt sRNAs targeting LRV1 rose dramatically in lines expressing StL
constructs targeting LRV1 (Figs. 1B & 4A). Correspondingly, the fraction of 23 nt sRNAs
mapping to the Leishmania genome dropped proportionately, most of which again mapped to
TEs and repeats (Fig. 4A). Importantly, LRV1 levels were dramatically reduced for all LRV1
StL transfectants, and in most cases the virus eliminated, as judged by protein and RNA methods
(Figs. 3, 5, S3, S5). Targeting of either the capsid or RDRP gene eliminated LRV1, as was
expected given that both are encoded by the same RNA (Fig. 2A). Only in Lgy were some
transfectants found that retained low levels of LRV1, which could reflect less RNAi activity in
this species, as was seen with reporter genes (30). However, most transfectants had completely
lost LRV1.
Viral infection has been reported for Giardiavirus (58), and stable viral transfer for
several fungal Totiviruses (59). However, de novo infection and stable viral transfer have been
unsuccessful with Lgy (29), and reverse genetic systems have yet to be reported for any
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Totivirus. Therefore, the ability to reproducibly mediate viral cure by RNAi is of great value for
biological studies of LRV1. Previous work used an LRV1-negative Lgy which was obtained
following transfection with an episomal Leishmania vector expressing resistance to hygromycin
B, followed by a long period of growth under selection (12); however, this method seems to have
been successful only once. Neither have we succeeded with several ‘stress-related’ treatments
that have proven effective in curing mycoviruses, such as yeast L-A (60) (F.M. Kuhlmann and
S.M. Beverley, unpublished data). Our studies establish RNAi as a viable strategy for cure of
LRV1 and perhaps other viruses in RNAi-competent Leishmania species.
LRV1+ but not LRV1-negative Lgy induce a ‘hyperinflammatory’ cytokine response in
infections of BMDMs in vitro, which is TLR3-dependent <sup>2</sup><sup>2</sup>(Ives et
al. 2011)(6, 7). Infectivity tests of mouse BMDMs in vitro showed that RNAi-generated LRV1negative Lgy lines likewise failed to induce a substantial cytokine response, as shown for two
cytokines (TNF-α and IL-6) known to be diagnostic for an LRV1-driven innate immune
response. Interestingly, this occurred with RNAi-derived lines where LRV1 loss was substantial
but incomplete (RDRP StL c3 & 4; 500- and 300-fold below parental levels, respectively; Fig
5B, 6B, S7), consistent with data from natural Lgy showing low LRV1 levels (7). Thus, a partial
reduction in LRV1 levels is sufficient to ameliorate LRV1-dependent virulence, which may
facilitate future efforts targeting LRV1 in human disease. Importantly, the continued presence of
the integrated StL constructs appeared to have no ‘off target’ effect in the BMDM infections,
despite the high levels of transgene-derived 23 nt sRNAs present in these lines; the LRV1 StL
“cured” lines induced the release of cytokines at a level similar to that of StL-negative, LRV1negative controls (Fig. 4), and control GFP65 StL lines that maintained LRV1 induced the
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release of cytokines at a level similar to the StL-negative, LRV1+ parent (Fig. 3, 5, 6). Future
studies will assess whether this also pertains to other cell types or host infections.
LRV1-dependent virulence in Leishmania braziliensis
Previous studies of LRV1-dependent virulence focused primarily on Lgy; however, in
humans, Lbr is associated with the larger share of MCL (14, 15). Our studies extend the
generality of LRV1-dependent virulence to Lbr, as LRV1+ Lbr likewise induce strong TLR3dependent cytokine responses. These findings are especially important in light of published work
on the association of LRV1 with MCL, with mixed results depending on the geographic region
and methods used (6, 16-19). Our data show that in in vitro infections, LRV1 contributes
strongly to the pro-inflammatory phenotype associated with elevated pathogenicity, as seen in
Lgy. This suggests that in human infections it may be informative to seek for correlations
between LRV1 and the severity of CL in Lbr infections in future studies. Indeed, recent studies
show that LRV1 in Lbr clinical isolates correlates with drug treatment failure (16), as was also
seen in Lgy (20). Thus, while other parasite or host factors may play a significant role in the
development of MCL (21, 22), current data now bolstered by our studies of isogenic
LRV1+/negative lines support a role for LRV1 in severity of human leishmaniasis caused by
Lbr.
2.5 – Materials and Methods
Parasites and in vitro culture
Lbr

LEM2700

(MHOM/BO/90/AN),

LEM2780

(MHOM/BO/90/CS)

and

LEM3874

(MHOM/BO/99/IMT252 n°3) were from Patrick Bastien (Université de Montpellier), Lbr
M2903 (MHOM/BR/75/M2903) was from Diane McMahon Pratt (Yale School of Public
52

Health), and Lgy M4147 (MHOM/BR/78/M4147) and its derivative Lgy M4147/HYG was from
Jean Patterson (Southwest Foundation for Biomedical Research, San Antonio, Texas). Prior to
introduction of StL constructs, parasites were transfected with the linear SSU-targeting SwaI
fragment from B6367 pIR2SAT-LUC(B) (30), and clonal lines were derived, validated, and
used. The luciferase-expressing clone of Lbr LEM2780 contained only LRV1-LbrLEM2780(b).
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heatinactivated fetal bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2 mM Lglutamine, 500 units/ml penicillin and 50 ug/mL streptomycin, and selective drugs as indicated
below.
RNAi Stem-loop Constructs
Regions of interest from LRV1 were screened using the RNAit target selection tool to ensure
that there was no homologous sequence in the parasite genome (61), amplified from cDNA by
PCR using KlenTaq-LA polymerase, and cloned into the pCR8/GW/TOPO cloning vector
(Thermo Fisher Scientific, Waltham, Massachusetts) using the protocol recommended by the
manufacturer and a 20 min ligation. The ‘stem’ segments and PCR primer sequences can be
found in Table S3. The ‘stems’ were transferred from the pCR8/GW/TOPO donor vector to the
pIR2HYG-GW(A) (B6365) destination vector (which contains sequence from the parasite rRNA
locus to enable integration into the genome and inverted LR recombinase sites for the generation
of inverted repeat through Gateway© technology) using LR Clonase II (Thermo Fisher) in an
overnight reaction at room temperature. Reactions were terminated by incubating with proteinase
K for 1 hour at 37°C. Constructs were verified by restriction digest.
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Transfections
Stable transfections were performed as previously described (30, 62). Clonal lines were obtained
by plating on semisolid media with 50 µg/mL hygromycin B. After colonies formed, cells were
grown to stationary phase in 1 mL media and passaged thereafter in 10 mL media with 30 µg/mL
hygromycin B.
RNA preparation and quantitative real-time PCR (qPCR)
Total RNA was prepared from log-phase cells dissolved in Trizol reagent (Thermo Fisher) at 3 x
108 cells/mL using the Direct-zol kit (Zymo Research, Irvine, California) and eluted in 50 µL of
nuclease-free water. The RNA was DNAseI-treated (Thermo Fisher) in a 200 µL reaction using
the provided buffer and 20 Units of enzyme for 1 hour at 37 °C, purified using the RNA Clean &
Concentrator - 25 kit (Zymo Research), and eluted in 50 µL of nuclease-free water. Reverse
transcription was performed using the Superscript III first-strand synthesis kit (Thermo Fisher)
according to the manufacturer instructions in a 20 µL reaction containing 0.25 ug purified RNA.
Control reactions contained the same amount of RNA but lacked reverse transcriptase enzyme.
For qRT-PCR, primers were designed to amplify ~100 bp regions of the LRV1 genome that lie
outside the stem regions (Table S4). qPCR reactions were performed with cDNA templates in 20
µL total reaction volume using the Power SYBR Green Master Mix (Thermo Fisher), 5 µL of
ten-fold diluted cDNA, and final primer concentrations of 0.2 µM. Reactions were run on the
ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Thermo Fisher). PCR
amplification conditions were as follows: 50 °C for 2 min and 95 °C for 10 sec followed by 40
cycles of 95 °C for 15 sec and 60 °C for 1 min. PCR products were confirmed to be specific by
melt curve analysis. All experiments were performed in triplicate. Amplification of KMP-11 was
used as an internal control to normalize parallel reactions.
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Small RNA (sRNA) sequencing
sRNA libraries were generated from total RNA as described (39); briefly, a primer (5'rApppATCTCGTATGCCGTCTTCTGCTTG/ddC for all samples except Lgy M4147, which
used primer rApppTGGAATTCTCGGGTGCCAAGG/ddC) was ligated first to the 3’ end using
truncated mutant T4 RNA Ligase (New England Biolabs), and then a second riboprimer (5'GUUCAGAGUUCUACAGUCCGACGAUC) to the 5’ end with T4 RNA Ligase. cDNA was
generated using reverse transcriptase and primer 5'-CAAGCAGAAGACGGCATACGA, and
then

PCR

was

performed

with

this

in

conjunction

with

AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA.

primer

5'-

Products

corresponding to inserts of 10-50 nt were purified, and taken for sequencing with Illumina
HiSeq2500 technology. Sequences have been deposited in the NCBI Short Read Archive
(accession SRP082553).
Bioinformatic analysis of sRNAs
The 5′ and 3′ adapter sequences were removed from the sRNA reads, those less than 15
nt removed, and the trimmed reads were mapped to homologous LRV1 or Leishmania genomes
(Lbr M2904 (63) or a draft Lgy M4147 genome (Bioproject PRJEB82; accession
CALQ01000001 – CALQ01004013)) using Novoalign software http://www.novocraft.com;
parameters were set as -F ILMFQ; -H; -g 40; -x 6; -R 5; -r; and -e 1000). A random strategy was
employed to align reads mapping to multiple regions and hard clipping of low coverage bases at
3’ end was performed. sRNA abundance was assessed directly, or after ‘collapsing’ to remove
duplicate

reads

using

algorithms

within

the

fastx

toolkit

(http://hannonlab.cshl.edu/fastx_toolkit/index.html ). To annotate transposable or repeated
elements, we used RepeatMasker ( http://www.repeatmasker.org) to identify known elements
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and/or BLAST to identify regions corresponding to Leishmania specific elements (SLACS, TAS,
and TATE (63)) . The annotations were collected in .bed file format for further use. Coverage
was calculated by counting the number of reads that align to each strand of the LRV1 genome.
LRV1 sequences
From the sRNA sequences we assembled whole or partial LRV1 contigs, which were confirmed
and completed by PCR amplification and sequencing. The sequences for LRV1-LbrLEM2700,
LRV1-LbrLEM2780(a) and (b), LRV1-LbrLEM3874, and a revision of the LRV1-LgyM4147
(formerly LRV1-4; (64)) genome sequences were deposited in GenBank (accession numbers
KX808483-KX808487).
LRV1 capsid flow cytometry.
The development and optimization of this protocol will be described elsewhere (F.M. Kuhlmann
et al. in preparation). Briefly, 1 x 107 cells were fixed at room temperature (RT) using 2%
paraformaldehyde (Thermo Fisher) in PBS for 2 min, and then then incubated in
blocking/permeabilization buffer (BPB) (10% normal goat serum(Vector Laboratories) and 0.2%
Triton X-100 in PBS) for 30 min, at RT. Anti-Lgy LRV1 capsid antibody (45) was added
(1:20,000 dilution) and incubated at RT for 1 hr. After two washes with PBS, cells were
resuspended in 200 μl BPB with Alexa488-labeled goat-anti-rabbit antibody (Thermo Fisher)
(1:2,000 dilution) and incubated 1 hr at RT. After two additional washes with PBS, cells were
subjected to flow cytometry and the data analyzed using CellQuest© software (BD Bioscience).
Western blot, macrophage infections and cytokine assays.
After an initial wash with PBS, 5x107 parasites were resuspended in 100 µL of 1x PBS. 1x107
cells (20 µL) were lysed with 7 µL of 4x Laemmli’s gel sample buffer. After heating for 5 min at
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95 °C, cell lysates were loaded and separated on a 10% polyacrylamide denaturing gel,
transferred to a nitrocellulose membrane and visualized by Ponceau Red staining. The membrane
was blocked for 1h in 5% powdered milk diluted in TBS + 0.05% Tween20, incubated overnight
at 4 °C with the g018d53 anti-capsid polyclonal antibody (1:5000 in 1% milk TBS-Tween20),
washed 4x 15 min at RT, incubated for 1h with an anti-rabbit IgG antibody coupled to
peroxidase (Promega) (1:2500 in 1% milk TBS-Tween20), washed again 4x and finally revealed
by ECL chemiluminescence (Amersham). Infections of BL6 mouse BMDM and cytokine assays
were performed as previously described (7, 10).
Statement identifying institutional and/or licensing committee approving animal experiments.
Animal handling and experimental procedures were undertaken with strict adherence to ethical
guidelines relevant in both host countries. These are set out by the SFVO and under inspection
by the Department of Security and Environment of the State of Vaud, Switzerland. Experiments
were carried out in strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the United States National Institutes of Health. Animal studies
were approved by the Animal Studies Committee at Washington University (protocol
#20090086) in accordance with the Office of Laboratory Animal Welfare's guidelines and the
Association for Assessment and Accreditation of Laboratory Animal Care International.
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2.7 – Figure Legends
Figure 2-1: Properties of Lbr siRNAs and sRNAs from Lbr and Lgy.
A) Distributions of read lengths of siRNAs or sRNAs mapping to Leishmania genomes
or LRV1s. Shown are 1) AGO1-bound siRNAs (black, solid) or sRNAs (black, dashed)
from WT Lbr M2903 mapping to the Lbr genome, 2) Lgy M4147 sRNAs mapped to the
Lg genome (blue, solid) or LRV1-LgyM4147 (blue, dashed), and 3) Lbr LEM2780
sRNAs mapped to the Lbr genome (green, solid) or LRV1-LbrLEM2780 (green, dashed).
B) Percentage of 23 nt sRNA reads (20-26nt) mapping to transposable elements (TEs,
white), rRNA (red), tRNAs (black), genomic repeat regions (yellow), LRV1 (purple), and
other Leishmania genomic regions (other, gray).
Figure 2-2: RNAi constructs for LRV1 elimination.
A) Schematic of an RNAi “stem-loop” (StL) construct. Each construct includes an
inverted repeated sequence containing 800-1200 bp of the target gene (gene of interest,
GOI) and a hygromycin drug resistance marker (HYGR). The construct is flanked with
sequence of the small subunit ribosomal RNA gene, which allows it to integrate into this
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locus, where it is transcribed at high levels. Splice acceptor (SA) signals within the
construct allow for polyadenylylation and processing.
B) Schematic showing LRV1 genome organization and regions targeted for RNAi StL
constructions (thick bars) from Lbr LEM2700, LEM2780, and LEM3874, and Lgy
M4147 targeted by RNAi (white, capsid; gray, RDRP). The locations of qPCR amplicons
for quantification of LRV1 levels are shown (thin black bars).
Figure 2-3: Loss of LRV1 induced by RNAi
Anti-capsid flow cytometry analysis of LRV1-knockdown lines in Lgy M4147 and Lbr
LEM2780 (top and bottom panels respectively). LRV1 capsid protein levels are
unchanged in GFP65 StL lines, while LRV1 StL lines have undetectable capsid protein.
Red, parent lines; purple, GFP65 StLs (off target control); green, LRV1-negative
controls; light blue, Capsid StL; dark blue, RDRP StL.
Figure 2-4. Overexpression of LRV1-mapping 23 nt sRNAs in LRV1 StL transfectants.
A) Genomic mapping of 23 nt sRNA reads from sRNA sequencing of parental or capsid
StL Lgy M4147 (left) or capsid-RDRP StL Lbr LEM3874 (right) mapping to transposable
elements (TEs, white), rRNA (red), tRNAs (black), genomic repeat regions (yellow),
LRV1 (purple), and other Leishmania genomic regions (other, gray). B) LRV1 mapping
of 23 nt sRNA reads from LRV1StL lines described in panel A (Lgy M4147, top; Lbr
LEM3874, bottom). Light gray trace indicates parental read distributions; dark gray trace
indicates LRV1 StL read distributions. The dark box indicates the region targeted by the
StL stems.
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Figure 2-5: The LRV1 genome is completely lost in most LRV1-StL transfectants
qPCR analysis of LRV1 RNA levels in LRV1 StL transfectant clones of Lbr LEM2700
(A) and Lgy M4147 (B), along with positive and negative controls (+ and – respectively)
and control GFP65 StL transfectants. White bars denote a non-specific qPCR product,
while black bars denote an LRV1-specific amplicons (melt curve analysis). Dashed line
indicates cutoff for designating a clone as LRV1-negative. Error bars are the standard
deviation of three technical replicates for each line.
Figure 2-6: LRV1 elimination results in decreased release of cytokines from infected
macrophages.
TNF-α or IL-6 levels were quantified 24h after infection of macrophages with Lbr
LEM2780 (A) or Lg M4147 (B) parent, GFP65 knockdown control, or LRV1-StL
transfectants. In both studies the LRV1- control was Lgy M4147. For A, results are
averages of two-three technical replicates for two clones of each line. For B, results are
the averages of two technical replicates for three to six clones of each line. NS, not
significant; ** p < 0.01; *** p < 0.0001 by t-test.
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2.9 – Supplemental Table Legends
Supplemental Table 2-1: 23 nt siRNA analysis to Leishmania genome and LRV1.
For Lbr, Lbr M2904 reference genome was used, and for Lgy, a M4147 draft genome (in
preparation) was used. References for viral genomes are sequences reported in this work.
Supplemental Table 2-2: Distributions of reads mapped to Lbr and Lgy genomes for Ago1-bound
siRNAs, 23 nt (20-26 nt) and 33 nt (30-36 nt ) sRNAs.
Supplemental Table 2-3: Primer sequences used to amplify regions of LRV1 for cloning into
stem-loop constructs.
Supplemental Table 2-4: Primer sequences used to measure LRV1 RNA levels by qPCR.
2.10 – Supplemental Figure Legends
Supplemental Figure 2-1: Properties of Lbr siRNAs and 23 nt sRNAs from Lbr and Lgy.
This figure shows mapping of the indicated small RNAs after ‘collapsing’ the data to
remove duplicate reads. Shown are the percentages of 23 nt sRNA reads (20-26nt)
mapping to transposable elements (TEs, white), rRNA (red), tRNAs (black), genomic
repeat regions (yellow), LRV1 (purple), and other Leishmania genomic regions (other,
gray). A) As in Figure 1B, mappings in WT parent lines. B) As in Figure 4A, comparing
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parental lines with capsid StL Lgy M4147 (left) or capsid-RDRP StL Lbr LEM3874
(right).
Supplemental Figure 2-2: Mapping of 23nt sRNA reads (20-26 nt) from the respective parasite
lines to LRV1-LbrLEM2700 (A), LRV1-LbrLEM2780(b) (B), LRV1-LbrLEM3874 (C), and
LRV1-LgyM4147 (D).
Reads mapping to the positive strand, (light gray); negative strand, (dark gray).
Supplemental Figure 2-3: Capsid protein is lost in Lgy M4147 capsid StL transfectants.
Three GFP65 StL control clones and six Capsid StL clones were evaluated. Top panel:
Western blot analysis was performed using g018d53 anti-capsid polyclonal antibody
(35). The arrow marks the location of the capsid protein band. Bottom panel: Ponceau S
stain of protein gel.
Supplemental Figure 2-4: qPCR analysis of LRV1 RNA levels in LRV1 StL clones of L.
braziliensis strain LEM2780 (A), L. braziliensis strain LEM3874 (B), and re-cloned L.
guyanensis M4147 RDRP StL c3 (C).
White bars denote a non-specific product; black bars denote an LRV1-specific product
(melt curve analysis). Dashed line indicates cutoff for designating a clone as LRV1negative. Error bars are the standard deviation of three technical replicates for each line.
Supplemental Figure 2-5: Infection of macrophages by Lbr LEM2700 (A) and Lgy M4147 (B).
TNF-α or IL-6 levels were quantified 24h after infection of macrophages with Lbr (A) or
Lgy (B) parasites. NI, not infected; LRV1+ or LRV1-, infected with Lgy M4147 LRV1+
or LRV1-negative cells; GFP65 StL transfectants; and RDRP StL or capsid StL
transfectants. A) Results are the averages of two technical replicates of two clones per
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line. Dark gray bars, experiment performed using WT macrophages; light gray bars,
experiment performed using TLR3 knockout macrophages. B) Results are the averages of
two technical replicates for each representative clone indicated. Lines found to be LRV1+
by qPCR are denoted by black bars; white bars are lines found to be LRV1-negative by
qPCR.
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Supplemental Table 2-1
A. Total Reads.
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40,384,483
19
20
(73.0%)
(27.3%)
(52.7%)
(0.20%)
34,959,518
5,121,894
25,361,713
326,021
48,615,815
20
20
(71.9%)
(14.7%)
(72.5%)
(0.93%)
25,591,362
4,052,707
16,756,188
347,022
36,543,649
19
19
(70.0%)
(15.8%)
(65.5%)
(1.36%)
37,159,548
1,261,927
25,489,186
660,143
55,220,664
15
13
(67.3%)
(3.40 %)
(68.6 %)
(1.78%)

Genomemapping
reads 3'
extension
base A-TC-G (%)
43-41-8-8
43-41-7.98.1
43-40-7.88.2
44-41-6.67.4
32-33-1915

B. Collapsed Reads

Sample

Lbr

Total
reads
(raw)

Total Trimmed
Reads aligned
to the Leish.
genomes +
viruses

2,327,188

1,038,131

Aligned
33 nt peak
reads to
Leishmania
(%
alignable
reads)
68,895

Aligned 23
nt peak reads
to
Leishmania
(% alignable
reads)

Aligned
23 nt peak
reads to
LRV1
(% 23 nt
reads)

776,204

n/a
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Percent
Percent with
with 3’
3’ extension
extension
(Leishmania)
(LRV1)
37

n/a

Genomemapping
reads 3'
extension
base A-TC-G (%)
35-35-15-

M2903a
Lbr
LEM2700
Lbr
LEM2780b
Lbr
LEM3874
Lgy
M4147
a

2,948,017
3,439,169
2,379,761
1,437,673

(44.6%)
1,206,587
(40.9%)
1,777,142
(51.7%)
1,224,741
(51.5%)
752,464
(52.3%)

Lbr M2903 SSU:IR2-LUCSR.
to similar levels.

b

(6.64%)
127,998
(10.6%)
150,229
(8.45%)
105,696
(8.63%)
152,059
(20.2%)

(74.8 %)
758,664
(62.9 %)
1,050,094
(59.1 %)
632,961
(51.7%)
358,039
(47.6%)

18,642
(1.54%)
61,753
(3.47%)
48,287
(3.94%)
43,099
(5.73%)

35

36

33

34

31

32

22

22

15
34-34-1616
34-34-1616
35-35-1515
30-28-2220

The sum of reads mapping to LRV1-LbrLEM2780(a) and (b) are shown, which map quantitatively
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Supplemental Table 2-2
Lbr M2903

Lgy M4147

AGO1bound
siRNAs

23 nt
(20-26 nt)
sRNAs

33 nt
(30-36 nt)
sRNAs

23 nt
(20-26 nt)
sRNAs

33 nt
(30-36 nt)
sRNAs

20,029,304

19,447,509

1,827,623

37,159,548

1,261,927

Transposable
elements
SLACS
TATE

33.9
45.1

26.9
53.1

1.2
5.2

59.8
10.7

0.25
0.32

Repeats
Misc.
TAR
TAS
CIR

5.8
4.7
4.2
5.1

5.0
4.2
5.1
4.6

7.7
0.08
20.3
0.09

1.1
4.0
4.8
0.0

2.4
0.38
6.5
0.0

Structural RNAs
tRNAs
rRNAs

0.12
0.42

0.75
0.47

32.1
29.4

9.9
5.5

75.4
14.6

Alignable reads
Percent mapping
to:

Transposable elements, repeats and structural RNAs were classified as defined in the Methods
and by Atayede et al (26)
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Supplemental Table 2-3
Parasite
strain

Target

Construct
ID
B6910

Capsid
Lbr
LEM2700

B6908
RDRP
B7061
Capsid

Lbr
LEM2780

B7062
RDRP

Lbr
LEM3874

Capsid
/
RDRP

B7268

B7066
Capsid
Lgy
M4147

B7063
RDRP

Stem
length

Name
pIR2HYGLRV1_LbrLEM2700_CapsidStL(A)

943
bp

pIR2HYGLRV1_LbrLEM2700_RDRPStL(A)

1143
bp

pIR2HYGLRV1_LbrLEM2780_CapsidStL(A)

835
bp

pIR2HYGLRV1_LbrLEM2780_RDRPStL(A)

794
bp

pIR2HYGLRV1_LbrLEM3874_StL(A)

1000
bp

pIR2HYGLRV1_LgyM4147_CapsidStL(A)

926
bp

pIR2HYGLRV1_LgyM4147_RDRPStL(A)

829
bp
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Sequence
5’-CGCTAGTCTAGAATACTACAGCAAACATGTTTCG
5’-CGCTAGTCTAGACAAGGTGTCTGTTGGGTTCGAT
5’-CGCTAGTCTAGAATGTGCTTCAAACTTGAAGATG
5’-CGCTAGTCTAGATAGCAGCAATCTAACGACCTGC
5’-CCAGCTTGGGATCAATTTGCGG
5’-GGACATCTCCATCAGCCGATGA
5’-GTGAGGATGAGTTGCGCGCTGC
5’-ATTGCTAAGTAGACTGTTTGCG
5’-GGCTAGTCTAGA GTCGTGCGATCTATTCCATCCT
5’-GGCTAGTCTAGATTAGTGCTTATGTTAGGATCAG
5’-CTTCTCCTTTACGTGCCAGC
5’-GCGCATTGTTGTCCACTCAA
5’-CTTGCTAGGTCGTGGGGTGA
5’-ACCAACATGCATAGACGTGG

Supplemental Table 2-4

KMP-11
L. braziliensis
LEM2700

F
R
F
R

L. braziliensis
LEM2780
L. braziliensis
LEM3874
L. guyanensis
M4147

F
R
F
R
Set 1
F
Set 1
R
Set 2
F
Set 2
R
Set 3
F
Set 3
R

5’-GCCTGGATGAGGAGTTCAACA
5’-GTGCTCCTTCATCTCGGG
5’CATCCTGCTGAGTTGACTTCATAC
5’GTCACACCTTGTGATGACATTGC
5’GTCATTACGAGGTGTGATGGAAT
5’-GGTAACGCGCCATCACACAGT
5’-GAATATGCTCTCCGACCGGTTG
5’AATTCTCGCAGCCACCCCACAG
5’-CTGACTGGACGGGGGGTAAT
5’-CAAAACACTCCCTTACGC
5’CACGCTAGATGAGTACATCTGG
5’-GTAGTTGCGGAATCTGACG
5’GGTAATATCACGCAGTGTAAGC
5’-GACACCACCTCTAAGACACG
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Supplemental Figure 2-1
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Supplemental Figure 2-4
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Supplemental Figure 2-5
Lbr LEM2700

Lgy M4147

400
300
200

200
100

100
103

103
102

LRV1WT
GFP StL

LRV1+ LRV1- GFP RDRP Capsid
StL
StL
StL

101

NI

NI

102

83

Capsid StL

IL-6 (pg/mL)

104
IL-6 (pg/mL)

Black bars: LRV1+
White bars: LRV1-

300

RDRP StL

TNF-α (pg/mL)

Dark gray: WT macrophages
Light gray bars: TLR3 KO macrophages

TNF-α (pg/mL)

400

500

Chapter 3: Knockout of Leishmania guyanensis Argonaute1 has little effect on LRV1 levels
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Preface
The majority of experiments in this chapter were designed, performed, and analyzed by EAB.
SMB supervised the work and contributed to study design. Suzanne Hickerson assisted with
mouse virulence experiments. The first draft of this chapter was written by EAB and the final
version presented here incorporates comments from SMB. This chapter is being prepared for
publication.
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3.1 – Abstract
Many isolates of Leishmania (Viannia) parasites harbor the dsRNA virus Leishmania
RNA Virus 1 (LRV1), which is associated with increased disease severity in animal models and
humans, and with drug resistance and treatment failure in humans. Interestingly, LRV1 survives
in the face of an active RNAi pathway, which many organisms use as an antiviral mechanism. To
determine whether the Leishmania RNAi pathway functions in control of LRV1, we knocked out
the Argonaute1 (AGO1) gene from the LRV1-containing L. guyanensis strain M4147. Loss of
AGO1 resulted in a 3.8-fold increase in transposable element transcripts and loss of transgenedriven RNAi, indicating that the mutant parasites are RNAi-deficient. While in many organisms
loss of RNAi results in dramatic increases in virus levels, there was only a 35% increase in
LRV1 RNA after loss of AGO1. Virulence experiments in a mouse model of infection indicate
that, while loss of AGO1 had no effect on virulence in the absence of LRV1, Δago1 lines with
LRV1 had 2-fold higher parasitemia and induced lesions 25% larger than WT at the peak of
infection. These experiments suggest that AGO1-dependent RNAi is likely not the main
mechanism by which LRV1 levels are controlled, and further experiments are needed to identify
antiviral pathways in Leishmania. Further, they suggest that even small changes in LRV1 level
can result in changes in virulence.
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3.2 – Introduction
Leishmania are single-celled eukaryotes spread by sand flies that cause the disease
leishmaniasis. These parasites are endemic to tropical and sub-tropical regions around the world,
with an estimated 1-1.5 million infections and 20,000-40,000 deaths per year (1), many of which
go unreported. Leishmania parasites can harbor a dsRNA virus, Leishmania RNA Virus (LRV)
(2, 3). This genus of viruses has been found in both New World and Old World Leishmania
species (4–6), but is most frequently reported as the virus species LRV1 in Leishmania (Viannia)
subgenus parasites, including L. braziliensis and L. guyanensis. Infection with LRV1 is
persistent, and virus particles are not infectious (7); rather, the virus is transmitted vertically
through cell division, and virus strains have in fact co-evolved with their parasite hosts (8). The
presence of LRV1 has been shown to increase parasite virulence in mice (9), and to correlate
with treatment failure (10, 11), disease recurrence (11, 12), and the development of
mucocutaneous disease (13, 14) in humans. Because of the potential for LRV1 to contribute to
disease severity, a greater understanding of the interaction between parasite and virus, including
mechanisms by which the virus is maintained and controlled, would be beneficial. Disruption or
exploitation of these interactions could provide therapeutic benefit in leishmaniasis cases where
LRV1 is present.
In many organisms, including insects, fungi, and plants, the RNA interference (RNAi)
pathway is known to be antiviral (15–17). RNAi is a conserved pathway found throughout
eukaryotes that uses dsRNA to degrade a complementary ssRNA. The RNaseIII family protein
Dicer cleaves long dsRNA into short interfering RNAs (siRNAs), which are loaded into the
RNA-Induced Silencing Complex (RISC), which contains an Argonaute family protein. Perfect
complementarity between the siRNA and a target ssRNA results in cleavage of the target by
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Argonaute, and ultimately degradation of the target RNA. RNA viruses have dsRNA stages of
their replication cycles, either in the form of a dsRNA genome or replication intermediates,
which can serve as a substrate for Dicer. The resulting siRNAs can then target the viral mRNA
for degradation. In organisms with antiviral RNAi, mutations to Dicer and/or Argonaute result in
increased virus titers and pathology upon virus infection (18–20). Similarly, introduction of
Dicer and Argonaute from Saccharomyces castellii into the RNAi-null S. cerevisiae results in the
loss of L-A virus infection in the majority of cells (21).
The role of RNAi in control of viruses in protozoa, however, has not been extensively
studied. While many Leishmania species have lost the genes required for RNAi, Viannia
subgenus parasites have retained an active RNAi pathway (22). Previous work from our lab
found small RNAs with LRV1 sequence in LRV1-infected L. guyanensis and L. braziliensis
parasites (23), and we further showed that LRV1 is eradicated from L. braziliensis and L.
guyanensis parasites when additional pressure is placed on the virus using transgene-driven
RNAi (23). Together, these results suggest that the LRV1 genome serves as a substrate for the
RNAi pathway to generate siRNAs; further, it suggests that the LRV1 transcript is a target for
the RNAi pathway, resulting in siRNA-directed cleavage by AGO1. This RNAi-mediated
downregulation of LRV1 levels could be a mechanism by which Leishmania (Viannia) parasites
control LRV1 replication.
To further probe the role of the RNAi pathway in LRV1 infection, we knocked out
Argonaute 1 (AGO1), which previous work from our lab and others has shown to be required for
RNAi activity (22, 24), from LRV1-containing L. guyanensis. Ago1-deficient parasites were
viable and lacked active RNAi. These parasites exhibited a small but significant increase in
LRV1 levels; concurrently, Δago1 parasites were more virulent in mice when LRV1 was present,
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but not in its absence. Therefore, Argonaute 1-dependent RNAi is unlikely to be the primary
method of control of LRV1 in Leishmania guyanensis parasites.
3.3 – Results
3.3.1 – Generation of Δago1 parasites
We began by knocking out the AGO1 gene in a luciferase (LUC)-expressing clone of L.
guyanensis (Lgy) strain M4147 (hereafter referred to as “WT”) by successive homologous
recombination, replacing each copy of AGO1 with an antibiotic resistance gene (Figure 1A).
Confirmation of proper integrations by PCR is shown in Figure 1B & C. Three double
replacement clones were obtained that lacked detectable AGO1 sequence by PCR in isolated
genomic DNA (Figure 2A). Two clones were selected for further experimentation. Both Δago1
clones lacked detectable AGO1 protein by Western blot using an anti-AGO1 antibody raised
against L. braziliensis AGO1 (Figure 2B, lanes 2 and 5).
To complement the knockout, we integrated an N-terminal Ty1-tagged LgyAGO1 into the
18S ribosomal RNA locus of L. guyanensis Δago1 cells. This tag has been used successfully with
LbrAGO1 in L. braziliensis and results in functional protein (24). Complemented lines
(+AGO1c) expressed AGO1 protein near wild-type levels (Figure 2B, lanes 3, 4, 6, 7). As genes
are transcribed at high levels from the 18S rRNA locus (25, 26), one might expect AGO1 protein
levels to be increased above WT. Instead, this is evidence of the post-transcriptional gene
regulation that is common in Leishmania parasites (27, 28). It also suggests that AGO1 cannot be
easily over-expressed in L. guyanensis.
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3.3.2 – Δago1 parasites are insensitive to RNAi driven by a transgene
Previous work has shown that loss of AGO1 in L. braziliensis and the related parasite
species Trypanosoma brucei results in a loss of RNAi activity (24, 29). In Leishmania (Viannia)
species, transgene-driven RNAi is achieved by engineering an inverted repeat that contains
sequence of the gene to be knocked down (stem-loop, StL) and integrating it into the small
subunit (18S) ribosomal RNA locus of the parasite genome (22). To verify the loss of transgenedriven RNAi activity in the Δago1 lines, we transfected a StL construct targeting the luciferase
ORF (LUCStL), which was present in the WT prior to knockout of AGO1. In WT parasites,
luciferase activity of the LUCStL-transfected line was 97% lower than that of the untransfected
luciferase-expressing line (Figure 3A). This is less than the 300-fold reduction in luciferase
activity we have previously shown in L. braziliensis, but in line with results in L. guyanensis that
showed a 96% reduction in luciferase activity (22). This further supports our previous
conclusions that the RNAi pathway is somewhat less efficient in L. guyanensis than in L.
braziliensis. In contrast, luciferase activity was unchanged in Δago1 parasites (Figure 3A),
indicating that transgene-driven RNAi activity is lost in these lines.
3.3.3 – Δago1 parasites accumulate transposable element RNA
Previous work in T. brucei (29) and L. braziliensis (24) showed that loss of AGO1 results
in the loss of siRNAs derived from transposable elements (TEs) and increased TE transcript
levels. To confirm loss of RNAi activity on endogenous targets in our L. guyanensis AGO1
knockout, we evaluated SLACS and TATE transcript levels by sequencing and qPCR.
We depleted ribosomal RNA from total RNA isolated from WT, Δago1, and +AGO1c
parasites and subjected these to Illumina sequencing. The fraction of reads mapping to two
control genes, glucose-6-phosphate dehydrogenase and the large subunit of RNA polymerase II,
90

were the same across the three genotypes. The proportion of reads mapping to SLACS was not
affected by the loss of AGO1, but the proportion of reads mapping to TATE significantly
increased in the Δago1 line and returned to the level of the WT line upon complementation
(Figure 3B). To further confirm these findings, we prepared cDNA from total RNA for the WT
line, Δago1, and +AGO1c and performed qPCR using primers specific for SLACS and TATE.
As with RNAseq, SLACS levels were unaffected by the loss of AGO1, but TATE levels more
than tripled in the Δago1 samples compared to the WT line and returned to the level of the WT
line with complementation (Figure 3C). Reasons for the discrepancy between SLACS and TATE
will be explored in the Discussion.
Because the Δago1 parasites lack AGO1 proteins, have increased transposon levels, and
are insensitive to transgene-driven RNAi, we conclude that they are functionally RNAi-deficient.
Likewise, because AGO1 protein is expressed at WT levels and TATE RNA returns to WT
levels in the +AGO1c complemented line, we conclude that the complemented line is RNAiproficient.
3.3.4 – Knockout of AGO1 did not deregulate other Leishmania genes
Previous work in L. braziliensis and L. guyanensis found that very few siRNAs originate
from protein-coding genes (23, 24), suggesting that RNAi does not regulate these RNAs. We
compared the number of RNAseq reads mapping to Leishmania genes for WT and Δago1 lines to
determine if any were affected by the loss of AGO1. In this comparison, any data points that
diverge from the best fit line are differentially expressed between the two samples. Because the
RNA we sequenced was depleted of rRNA, we anticipated that levels would be somewhat
variable; therefore, we omitted rRNA genes from our analysis. Further, we omitted LUC from
the analysis due to its high expression (data not shown). As expected, AGO1 levels were
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dramatically reduced in the Δago1 cells (Figure 4, arrow). While a number of TE elements were
more highly expressed in Δago1 cells (Figure 4, red dots), no other gene appeared to be
dysregulated in the absence of RNAi (Figure 4, blue dots). For reference, the highly expressed
genes in both samples are alpha-tubulin. These data are preliminary, and more clones are
currently being sequenced in order to allow statistical analysis of differential expression. The
lack of an effect on global gene expression levels following knockout of AGO1 further confirms
that RNAi is not involved in the regulation of these loci.
3.3.5 – Minimal change in LRV1 levels on loss of AGO1
In other organisms, mutation of RNAi pathway components results in increases in virus
titer by up to 1,000-fold (18, 30–34). If the RNAi pathway plays a role in controlling LRV1
levels, then loss of AGO1 should result in an increase in LRV1 levels. To determine whether this
occurred, we analyzed capsid protein level by flow cytometry using a polyclonal antibody raised
against the capsid protein found in L. guyanensis strain M4147 (5). The WT line, Δago1, and
+AGO1c parasites were indistinguishable from one another (Figure 5a), indicating that a loss of
RNAi activity did not result in increased translation of viral protein.
To determine whether LRV1 RNA levels were likewise unchanged, we performed qPCR
using primers specific to LRV1. We found that the Δago1 parasites had ~35% higher LRV1
RNA levels than did the WT line, and that this increase was eliminated in the complemented
lines (Figure 5b). While the increase in LRV1 levels observed in the knockout was statistically
significant, such a small effect is unlikely to indicate a major mechanism of virus control.
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3.3.6 – LRV1 capsid knockdown transgene does not reduce LRV1 levels in Δago1 parasites
Previous work from our lab has shown that LRV1 can be eliminated from RNAicompetent Leishmania by stable integration into the parasite genome of a stem-loop containing
sequence from LRV1 (23). We proposed that this occurred through massive overproduction of
siRNAs targeting LRV1. If this were the case, then LRV1 StL constructs should not reduce
LRV1 levels in RNAi-deficient Δago1 parasites. Indeed, integration of the CapsidStL construct
did not reduce LRV1 protein levels as assessed by flow cytometry, or RNA levels as assessed by
qPCR (Figure 6). Instead, Δago1 CapsidStL lines had ~33% higher LRV1 RNA than the WT
(RNAi-competent) line, similar to levels seen for the Δago1 alone (Figure 6b).
3.3.7 – Virulence of Δago1 parasites is elevated compared to WT
In the LRV1-negative L. braziliensis strain M2903, Δago1 parasites have decreased
virulence and metastasis in mouse footpad infections (Hickerson & Beverley, unpublished data).
We predicted that loss of AGO1 in L. guyanensis would, in the absence of LRV1, result in a
similar virulence defect, but that the elevated levels of LRV1 in the Δago1 line would reduce this
loss of virulence or even make this line more virulent that the WT line. To untangle the
respective contributions of RNAi and LRV1 to virulence, we generated LRV1-negative clones of
the WT, Δago1, and +AGO1c lines using the small molecule 2’C-methyladenosine (2CMA).
Previous work in the lab has shown that short-term treatment with a low dose of 2CMA leads to
a heterogeneous population of cells, some of which have lost LRV1 (35). This population can be
sub-cloned to generate isogenic lines that bear and lack LRV1. We injected 2CMA-treated
parasites of each genotype, both LRV1+ and LRV1-negative clones, into the hind footpad of
C57B/6 mice and monitored infection by measuring lesion size (a measure of pathology) and
luciferase activity (a measure of parasitemia).
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As expected, LRV1-negative clones of each line were less virulent than were the LRV1+
clones (Figure 7). Somewhat to our surprise, there was no significant difference between the
Δago1 line and either the WT or complemented line in the absence of LRV1. In contrast, in the
presence of LRV1, the Δago1 line was more virulent than either the WT or complemented line at
the peak of infection, with 25% higher footpad swelling and ~2-fold higher parasitemia in the
Δago1 parasites than the WT.
Previous work has shown that infection of IFN-γ –deficient mice with L. guyanensis
results in a chronic infection and a tendency for parasites to metastasize to the tail and/or
uninjected foot (36). To determine whether the loss of AGO1 (and increase in LRV1) affected
metastasis, we injected the same 2CMA-treated lines used above into IFN-γ -/- mice. A number of
mice developed severe infections and had to be sacrificed before metastases could develop
(Figure 8A). Of the remaining mice, infection with parasites containing LRV1 was more likely to
lead to tail metastasis than infection with LRV1-negative parasites (Figure 8B). In the LRV1negative lines, loss of AGO1 did not appear to affect the development of metastases, similar to
the virulence data in WT mice. In contrast, infections with Δago1 parasites were more likely to
metastasize than WT in the presence of LRV1. This data is preliminary, and these experiments
will have to be repeated with a lower inoculum to reduce mouse mortality and obtain highconfidence data.
3.4 – Discussion
In our experiments, knockout of AGO1 from L. guyanensis parasites resulted in ablation
of the RNAi pathway, as occurred in L. braziliensis. In the knockout parasites, introduction of a
stem-loop targeting the luciferase ORF had no effect on luciferase activity, while in the WT line
the same construct results in a greater than 95% reduction in luciferase activity (Figure 2A).
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Likewise, levels of the TATE element transcript tripled, indicating that control of endogenous
targets was disrupted (Figure 2B & C).
Interestingly, SLACS levels did not appear to change with loss of AGO1in these
experiments, whereas they were clearly affected by loss of AGO1 in L. braziliensis (24). It is
unclear why this should occur. It is not likely due to the level of expression, as there was not a
large discrepancy in the proportion of RNAseq reads mapping to SLACS compared with TATE
(there were 2-fold more TATE-mapping reads) (Figure 2B), and reads mapped to each TE at
levels higher than any of the housekeeping genes that we examined. Sequencing of sRNAs in L.
guyanensis revealed that a large proportion of sRNAs originate from SLACS (23), so
presumably they should be capable of repressing SLACS transcripts. Instead, it may be an
artifact of the methods used, as neither RNAseq nor qPCR can differentiate between large
degradation products and full transcripts. We have previously shown that qPCR over-estimates
the level of an RNA undergoing knockdown (22) compared with the level of expression
determined by Northern blot. It is possible that our analysis overestimated the level of full
transcript in WT and +AGO1c lines; further work would be required to confirm this.
Because of the substantial effect of RNAi on virus levels in other systems, we
hypothesized that loss of AGO1 would result in a large increase in LRV1 levels, to the point that
it could have been lethal. Not only were Δago1 parasites viable, the increase in LRV1 RNA was
much smaller than expected, only 35% over the level in the WT line (Figure 3). Further, the
parasites do not appear to accumulate increasing levels of LRV1 RNA during continued culture,
indicating that the 35% increase represents a new “set point” level of LRV1. While this increase
(and subsequent decrease upon complementation) was statistically significant, this small of an
effect does not support a substantial role for Ago1-dependent RNAi in the control of LRV1. It
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does not, however, rule out a role for AGO1 in control of LRV1, either. We hypothesized that
loss of AGO1 could result in uncontrolled virus replication, resulting in loss of parasite viability.
If this occurred, only parasites that had developed a compensatory mechanism for controlling
LRV1 levels would survive to be evaluated; perhaps the clones analyzed in this work have such a
compensatory mechanism. Alternatively, small changes can have large effects over long
timescales. It is possible that this small increase in LRV1 is too mild a stress to measure in a
laboratory setting, but is substantial enough to support the maintenance of LRV1 over millions of
year of evolution.
In previous work, we showed that the introduction of the CapsidStL construct into the
WT line resulted in a loss of LRV1 (23). As transgene-driven RNAi was ablated in the Δago1
line we expected that the StL construct would be non-functional, and indeed introduction of the
CapsidStL construct into the Δago1 line did not affect LRV1 levels (Figure 4). These results
confirm the AGO1-dependency of the CapsidStL and suggest that the interaction between LRV1
and the RNAi pathway functions differently in the presence of the StL construct than in its
absence. Our previous work showed that the CapsidStL construct results in massive overproduction of LRV1-mapping sRNAs (23); perhaps there is a maximum level of RNAi pressure
that LRV1 is able to withstand, and the levels of anti-LRV1 siRNAs produced under normal
conditions do not meet this threshold.
While Δago1 L. braziliensis parasites had decreased virulence in the mouse model of
infection, this did not occur in LRV1-negative L. guyanensis; instead, the Δago1 line was not
significantly different from the WT line (Figure 5A & B). There are two possibilities why this
may occur. First, it appears that RNAi is somewhat less efficient in L. guyanensis than in L.
braziliensis (22). It is possible that this less-efficient RNAi pathway has less of an effect on
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virulence than the more active L. braziliensis pathway. Second, this may suggest that RNAi
regulates a virulence-associated endogenous target in L. braziliensis but not in L. guyanensis.
In contrast, loss of AGO1 in the presence of LRV1 resulted in an increase in virulence
(Figure 5C & D). This is likely due to the increased levels of virus in LRV1+ Δago1 parasites
compared to WT. Previous reports found that the presence of LRV1 significantly increased the
virulence of L. guyanensis parasites in mouse models of infection (9). Additionally, previous
work in strains of L. aethiopica containing LRV2 showed that the inflammatory response in
macrophages was correlated with viral load (6). The previous studies relied on different strains
with varying LRV1 burdens, and some of the observed differences in virulence could be due to
parasite genetic factors. In our experiments, we examined two isogenic lines with different levels
of LRV1; to our knowledge, this is the first experiment of its type. As relatively small increases
in LRV1 resulted in observable increases in virulence, these results suggest that it is possible to
improve patient outcomes by reducing the level of LRV1 even partially in patient infections.
Many RNA viruses infecting plants and insects encode Viral Suppressors of RNAi
(VSRs) to evade their hosts’ antiviral RNAi pathways (reviewed in Szittya and Burgyan 2013;
Bronkhorst and Van Rij 2014). LRV1 does not appear to have the coding capacity for such a
mechanism, and certainly there is no trans-acting VSR, as L. guyanensis parasites with LRV1
are equally capable of downregulating luciferase by RNAi as an LRV1-negative isogenic line
(22). Additionally, the ability of the LRV1 StL to ablate LRV1 suggested that there was no cisacting VSR; however, the StL generated massive amounts of LRV1-targeting siRNAs, which
could overwhelm any VSR present (23). It is possible that LRV1 encodes a cis-acting VSR
capable of evading the RNAi pathway at natural levels of pressure. If this were the case, loss of
AGO1 would have little effect on LRV1 level.
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Alternatively, it is possible that anti-LRV1 siRNAs are bound to another Argonaute
protein than AGO1. Trypanosomatids have a second Argonaute, termed “Piwi” (so named
because the PAZ domain has a highly divergent sequence and is apparent only by structural
homology (38), leaving only an identifiable Piwi domain), whose function is unknown. Perhaps
anti-LRV1 sRNAs preferentially bind Piwi rather than AGO1, and RNAi control of LRV1
occurs through Piwi, with only incidental regulation via AGO1. Future experiments will be
needed to determine whether this is the case; however, efforts to knock out Piwi in Viannia
subgenus parasites have thus far been unsuccessful, and RNAi knockdown of Piwi did not result
in a decrease in Piwi RNA levels (Appendix C).
It is also possible that RNAi control of LRV1 occurs at the level of Dicer. Perhaps the
LRV1-derived sRNAs, while capable of eliciting downregulation of LRV1 at high
concentrations, don’t efficiently direct cleavage of the LRV1 transcript at physiological levels;
rather, cleavage of the LRV1 dsRNA genome by Dicer is sufficient to inhibit LRV1 replication
and maintain sustainable virus levels. There are some reports in the literature in which loss of
Dicer impacted virus levels more strongly than loss of Argonaute (18, 39, 40). Finally, it is
possible that neither cleavage of the LRV1 dsRNA genome by Dicer, nor cleavage of the LRV1
transcript by AGO1 plays a substantial role in control of LRV1 levels. If this were the case, some
other unknown mechanism would be required to maintain LRV1 at sustainable levels.
3.5 – Materials and Methods
Parasite strains and cell culture
L. guyanensis strain M4147 (MHOM/BR/78/M4147) was obtained from Jean Patterson
(Southwest Foundation for Biomedical Research, San Antonio, Texas) and transfected with
SwaI-linearized B6367 pIR2SAT-LUC(B). Clonal lines were derived, and clone 3 was used in
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further experiments. Parasites were grown in fresh Schneider’s Insect Medium supplemented
with 10% heat-inactivated fetal bovine serum, 100 μM adenine, 5 x 10 -5% hemin, 2 μg/mL
biopterin, 2mM L-glutamine, 500 units/ml penicillin and 50 ug/mL streptomycin.
Selective agents used were nourseothricin sulfate (Gold Biotechnology), blasticidin S
HCl (Fisher Scientific), puromycin dihydrochloride (Sigma-Aldrich), and hygromycing B
(Hygro99, Gold Biotechnology).
Constructs and transfections
1x108 cells were resuspended in 0.5 mL cytomix buffer (120 mM KCl, 150 M CaCl2, 10
mM K2HPO4, 25 mM Hepes, 2 mM EDTA and 5 mM MgCl2, pH 7.6 using KOH), mixed with
10 μg linearized DNA, and electroporated twice in a 4mm gap cuvette at 1400 V and 25 μF,
waiting 10s between zaps. Cells were placed in 10 mL Schneider’s Medium without selection
and allowed to recover overnight.
To generate Δago1 parasites, the blasticidin and puromycin resistance genes were fused
between 823bp of sequence at the 5’ flank and 281bp of sequence at the 3’ flank of the AGO1
gene. These constructs were used to successively replace the two alleles of AGO1. Transfected
cells were plated on semisolid media containing 100 μg/mL nourseothricin and either 10 μg/mL
blasticidin or 20 μg/mL puromycin. Colonies were picked into 1 mL Schneider’s Medium
without selection, expanded to 5 mL Schneider’s Medium with 50 μg/mL nourseothricin and 5
μg/mL of either blasticidin or puromycin, and passaged thusly.
To generate the complemented +AGO1c line, we tagged the N-terminus of the AGO1
gene with the Ty1 epitope (EVHTNQDPLD) and cloned this ORF into a modified pIR1HYG
vector that replaces the BglII cloning site with a PacI site [B7397 pIR1HYG(B-PacI)]. We
linearized this DNA with SwaI and transfected it into Δago1 parasites. Clones were selected on
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semisolid media containing 50 μg/mL nourseothricin and 150 μg/mL hygromycin B and
passaged in liquid Schneider’s Medium containing 25 μg/mL nourseothricin, 2.5 μg/mL
blasticidin, 2.5 μg/mL puromycin, and 50 μg/mL hygromycin B.
B7066 pIR2HYG-LRV1_LgyM4147_CapsidStL(A) and B6486 pIR2HYG-LUCStL(A)
were linearized with SwaI and transfected into Δago1 parasites. Control LUCStL lines were
generated by transfection of B6486 into L. guyanensis M4147 LUC c3. Clonal lines were
selected by limiting dilution in 96-well plates. Transfected cells were allowed to recover
overnight and diluted to 105 cells/mL in Schneider’s Medium containing 50 μg/mL
nourseothricin and 75 μg/mL hygromycin B. 200 μL of cells were seeded into 96-well plates.
Wells that survived selection were expanded and passaged in Schneider’s Medium containing 25
μg/mL nourseothricin and 50 μg/mL hygromycin B, with the addition of 2.5 μg/mL blasticidin
and 2.5 μg/mL puromycin for the Δago1 transfections. Control CapsidStL lines were described
previously (23).
Treatment with 2’C-methyladenosine (2CMA)
Parasites were seeded at 1x105 cells/mL in Schneider’s medium lacking supplemental
adenine and containing 10 μM 2CMA. After 5 cell doublings, cultures were pelleted at 3,000
rpm and resuspended in fresh Schneider’s medium containing adenine without 2CMA. After 48
hours, cells were plated on semisolid media. Colonies were picked into 1 mL Schneider’s
medium, expanded to 5 mL with appropriate selective antibiotics, and evaluated for LRV1 levels
using flow cytometry.
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Western blot
Mouse BB2 antibody was obtained from Sigma-Aldritch. Rabbit anti-H2A (41) and antiAGO1 antibodies were produced by Proteintech. Secondary antibodies used were IRDye800CW
goat anti-mouse and IRDye680RD goat anti-rabbit (LI-COR Biosciences).
5 x 107 cels from mid-log culture were resuspended in 100 μL 1x Laemmli buffer (62.5
μM Tris, pH6.8; 2% SDS; 10% glycerol; 2.5% 2-mercaptoethanol; 0.001% bromophenol blue)
and heated at 95°C for 5 min. Cell lysates were stored at -20°C. Lysates were run on
polyacrylamide (4% stacking, 10% resolving) gels at 200V and proteins were transferred to
nitrocellulose membranes at 60V for 2 hours at 4°C. Membranes were blocked overnight at 4°C
in Odyssey blocking buffer (LI-COR Biosciences). Primary antibodies were incubated at room
temperature for 2 hours at the following dilutions: α-BB2, 1:00; α-H2A, 1:10,000; α-Ago1,
1:1,000. All primary antibody dilutions were made in Odyssey blocking buffer. Membranes were
washed 4 times with PBS-T (0.1% Tween-20 in PBS) for 10 min per wash. Secondary antibodies
were diluted 1:10,000 in Odyssey blocking buffer containing 0.2% Tween-20 and membranes
were incubated for 1 hour at room temperature in the dark. All subsequent steps occurred in the
dark. Membranes were washed again 4 times with PBS-T for 10 minutes/wash and twice with
PBS (no Tween-20). Membranes were scanned using the LI-COR Odyssey Infrared Imaging
System.
Luciferase activity assay
106 log phase cells in 200 μL of Schneider’s Medium were added to a 96-well plate
(Black plate, Corning Incorporated, NY, U.S.A.). D-luciferin (Biosynth AG) was added to a final
concentration of 150 μg/mL and plates were incubated for 1 min. Plates were imaged using a In
Vivo Imaging System (IVIS) photoimager (Perkin Elmer), and luciferase activity quantified as
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photons/s. Each sample was run in duplicate. Three clones each of the WT line and two knockout
clones transfected with empty vector and the LUCStL construct were evaluated.
Flow cytometry
Flow cytometry using the anti-capsid antibody (5) was performed as described previously
(23).
RNA preparation
2.5-3 x 108 log phase promastigotes were spun down and resuspended in 1 mL Trizol
reagent (Ambion, Thermo Fisher Scientific), and 250 μL of dissolved cells were used for each
preparation of total RNA. RNA was isolated using the RNA miniprep kit (Zymo Research),
DNaseI-treated in a 200 μL reaction using 20 Units of enzyme and the supplied buffer (Ambion,
Thermo Fisher Scientific) for 1 hour at 37°C. Enzyme was removed using RNA Clean &
Concentrator - 25 kit (Zymo Research) and eluted in 50 μL nuclease-free water. RNA
concentrations were obtained using the Qubit RNA Broad-Range assay (Thermo Fisher
Scientific) and RNAs were stored at -80°C.
RNA sequencing and bioinformatics analysis
RiboZero RNA libraries were generated from total RNA as described (42). Briefly,
sample integrity was assessed by Agilent Bioanalyzer 2100 (Santa Clara, CA). rRNA was
depleted from 1 mg input RNA with the Ribo-Zero™ rRNA Removal Kit (“RiboZero”) from
EpiCentre (an Illumina company, Madison, WI). RiboZero-depleted RNA was chemically
fragmented to generate fragments ranging from 200-600 nt in length, then made into cDNA with
Superscript III (Life Technologies, Thermo Fisher) and random hexamers followed by a second
strand reaction. cDNA was then end-repaired, A-tailed, and standard Illumina adapters were
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ligated on. Libraries were amplified with primers to incorporate a unique index to each sample.
Equal masses of each library were pooled and sequenced on an Illumina HiSeq2500 platform,
with 2 × 100 base pair paired end reads (Illumina Inc., San Diego, CA).
Data were analyzed using CLC Genomics v9.5.3. Briefly, 5’ and 3’ adaptors were
removed and trimmed reads were mapped to annotated genes and transposable elements from the
L. guyanensis M4147 genome, as well as to LRV1 genes (KX808487) using default RNA-Seq
parameters. Reads mapping to multiple locations were aligned randomly.
cDNA synthesis and qPCR
cDNA was synthesized by reverse transcription using the Superscript III First Strand
Synthesis kit (Thermo Fisher Scientific) according to manufacturer instructions in a 20 μL
reaction containing 0.25 μg purified total RNA. Control reactions contained an equal amount of
RNA but lacked reverse transcriptase enzyme.
Primers used for qPCR can be found in Table 1. Annotated SLACS elements were
aligned to identify consensus regions in common among multiple elements, and primers were
designed to amplify a 97 bp region of this consensus sequence. These primers bind to 7/15
annotated elements, which are responsible for 61,740/88,075 (70.0%) of total SLACS-mapping
sequencing reads. Similarly, TATE elements were aligned to identify common sequences, and
primers were designed to amplify 106 bp of this consensus sequence. These primers bind to
15/53 annotated elements, which are responsible for 210,037/298,077 (70.5%) of TATEmapping sequencing reads. LRV1-specific primers were designed to amplify an approximately
100 bp region of the LRV1 genome. Control primers were designed to amplify approximately
150 bp of the KMP-11 5’ UTR.
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qPCR reactions were performed in MicroAmp Optical 96-well plates or MicroAmp Fast
Optical 96-well plates (Thermo Fisher Scientific) using 20 μL reactions. Each reaction contained
5 μL of ten-fold diluted cDNA, 10 μL of 2x Power SYBER Green Master Mix (Applied
Biosystems, Thermo Fisher Scientific), and primers to a final concentration of 0.2 μM each.
Reactions were run on the ABI PRISM 7000 Sequence Detection System or ABI ViiA 7 RealTime PCR System (Applied Biosystems, Thermo Fisher Scientific). PCR amplifications were as
follows: 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec and 60
°C for 1 min. PCR products were confirmed to be specific by melt curve analysis. +RT reactions
were performed in triplicate and –RT control reaction in duplicate.
Serial 4-fold dilutions of cDNA were used to generate primer efficiency curves for each
primer set on each plate, and relative SLACS, TATE, and LRV1 level was determined using the
Pfaffl method (43). For the SLACS and TATE experiments, three biological replicates of the WT
line, two biological replicates of each of two Δago1 clones, and four +AGO1c clones were
averaged and statistical significance determined by ANOVA followed by the Tukey post hoc
test. For the LRV1 experiment, four biological replicates of the WT line (L. guyanensis M4147
LUC c3), two biological replicates of each of two ago1- clones, and 12 clones of the Ty1-tagged
complemented line were averaged and statistical significance determined by ANOVA followed
by the Tukey post hoc test.
Statement on Institutional and Licensing Committee Approval of Animal Experiments
Animal handling and experiments were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals (44) of the US
National Institutes of Health. Animal studies were approved by the Animal Studies Committee at
Washington University (protocol 20090086) in accordance with the Office of Laboratory Animal
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Welfare’s guidelines and the Association for Assessment and Accreditation of Laboratory
Animal Care International.
Mouse infection
Female C57/B6 mice were obtained from Jackson Laboratories. IFN-γ -/- mice were
obtained from Dr. Herbert Virgin (Washington University School of Medicine, St. Louis, MO)
Parasites were grown to day 2 stationary phase and collected at 1x10 6 cells/50 μL DMEM. Mice
were injected subcutaneously in the left hind footpad with 1x106 parasites using a 30 gauge
needle. Luciferase activity was monitored weekly by imaging using the IVIS (Perkin Elmer).
Briefly, mice were injected intra-peritoneally with 150 mg/kg D-luciferin, potassium salt (Gold
Biotechnology) 10 minutes before imaging. Five minutes before imaging they were
anaesthetized with isofluorane, and anesthesia was continued throughout the procedure. Emitted
photons were quantified using Living Image v2.60.1 software (Perkin Elmer). Lesion size was
measured weekly using calipers.
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3.7 – Table Legends
Table 3-1: Primers used in qPCR analysis of SLACS, TATE, and LRV1 RNA levels.
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3.8 – Figure Legends
Figure 3-1: Confirmation of AGO1 replacement by PCR.
A) Schematic of replacement of AGO1 by drug resistance cassettes.
B) Schematic of PCR primer binding sites for the confirmation of integration. For each
reaction, one primer binds within the drug resistance gene; the other binds to a region of
the flanking region outside the targeting construct. Expected PCR product size is
indicated.
C) Integration PCR products confirming replacement. Left, replacement with BSDR to
generate the heterogygote; right, replacement with PACR to generate the knockout. NTC,
no-template control.
Figure 3-2: Replacement of AGO1 alleles results in Δago1 parasites.
A) PCR failed to amplify the AGO1 gene in L. guyanensis knockout clones 15, O, and R,
as well as L. braziliensis strain M2093 Δago1 (Lbr Δago1), but not in the L. guyanensis
AGO1 heterozygote. NTC, no template control.
B) AGO1 protein was undetectable by Western blot in Δago1 clones and present at WT
levels in +AGO1c complemented lines. Loading control, α-Histone H2A antibody.
Figure 3-3: Δago1 parasites are functionally RNAi-deficient.
* p<0.05; **** p<0.0001.
A) Δago1 parasites transfected with a transgenic RNAi construct targeting luciferase
(LUCStL) have no reduction in luciferase activity compared to empty vector control.
B) Fraction of RNAseq reads mapping to SLACS and TATE transposable elements, as
well as to Argonaute and two housekeeping genes, glucose-6-phosphate dehydrogenase
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(G6PD) and the large subunit of RNA polymerase II (RNAPII-LS). Reads mapped at
similar frequencies to SLACS and the two housekeeping genes between the WT, Δago1,
and +AGO1c lines. TATE-mapping reads were significantly higher in the Δago1 line.
C) Relative level of SLACS and TATE transposable element RNA by qPCR. SLACS
levels were similar between the lines, while TATE levels were increased in Δago1.
Figure 3-4: Comparison of global gene expression between WT and Δago1 parasites.
Average read counts of two biological replicates are plotted for each genotype. Red, TE
genes; blue, all other genes. rRNA genes and LUC were removed from the analysis. The
location of the AGO1 data point is indicated.
Figure 3-5: Knockout of AGO1 results in small increases in LRV1.
A) Flow cytometry of WT line (red), Δago1 (green), +AGO1c (purple), and LRV1negative (black) parasites using an anti-capsid antibody. Traces are representative of 3-4
clones/biological replicates.
B) LRV1 RNA levels determined by qPCR. Averages and standard deviations are of 4-12
biological replicates/clones. * p<0.05
Figure 3-6: The CapsidStL transgenic RNAi construct is non-functional in Δago1 parasites.
A) Flow cytometry of WT line (red), Δago1 (green), Δago1 + CapsidStL (purple),
LRV1-negative (black), and WT + CapsidStL (blue) parasites using the anti-capsid
antibody. Traces are representative of 2-6 clones/biological replicates.
B) LRV1 RNA levels determined by qPCR. Averages and standard deviations are of 2-6
biological replicates (WT) or independent clones (Δago1 CapsidStL). **** p<0.0001.
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Figure 3-7: Virulence of Δago1 parasites in the presence and absence of LRV1.
Infections in WT mice with Δago1 parasites have similar virulence in the absence of
LRV1 (top panel), while Δago1 parasites are more virulent in the presence of LRV1
(bottom panel). Parasitology was evaluated by luciferase activity (panels A & C) and
pathology by lesion size (panels B & D). Averages and standard deviations are of 3
experiments with two clones per group, 4 mice per clone. #, significance of Δago1 vs
WT; +, significance of WT vs +AGO1c; *, significance of Δago1 vs +AGO1c. * p<0.05;
** p<0.01; **** p<0.0001.
Figure 3-8: LRV1+ parasites are more likely to metastasize than LRV1-negative parasites in
IFN-γ-/- mice.
A) Mouse survival curve of lines evaluated.
B) Number of tail metastases per mouse.
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Chapter 4: Popping DNA out of the Leishmania genome – a control for mutants with
dominant phenotypes
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Preface
The experiments in this chapter were designed, performed, and analyzed by EAB under the
supervision of SMB. The first draft of the chapter was written by EAB, and the final version
presented here incorporates comments from SMB.
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4.1 – Abstract
Here we present a method for short-term expression of a gene or RNAi transgene in Leishmania
(Viannia) parasites. We show that parasites transfected with these constructs display a mutant
phenotype, and revert to a wild-type phenotype following removal of the construct. This method
provides a tool to determine the essentiality of genes, which could not previously be sufficiently
proven in L. (Viannia) species.
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4.2 – Introduction
The process of culturing cell lines in the laboratory leads to mutations and gene
expression alterations that affect cell growth and biology (1–4). If these changes occur during the
course of planned genetic manipulations, they can confound interpretation of the results of the
experiment. To combat this, one must take steps to separate effects of the planned manipulations
from culture artifacts. For example, when genes are knocked out, it is standard procedure to
complement the mutant by expression of the deleted gene. If the complemented line reverts to a
WT phenotype, one can be reasonably certain that any phenotype observed in the mutant is due
to the loss of the gene under investigation.
Similar controls are less common during the expression of dominant genes, including the
expression of dominant negative mutants or heterologous genes. Typically, multiple independent
mutants are evaluated to rule out random mutations. This, however, does not control for
compensatory mutations.
Many Leishmania species, such as L. major, L. mexicana, and L. donovani, support the
replication of circular extrachromosomal elements called episomes (5–8). In these species, shortterm expression of genes can be achieved by transfection of an episome that confers resistance to
a selective agent, and that can then be lost after removal of selective drug pressure. By
expressing dominant genes from an episome, one can confirm that an observed phenotype is
gene-specific by selecting for cells that have lost the episome and confirming that they have a
WT phenotype.
These episomes, however, do not work well in Leishmania (Viannia) species (9),
possibly because transcription from these episomes occurs from both strands (10). This likely
results in long dsRNA that enters the RNAi pathway, which is present in Viannia species, but not
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Leishmania (Leishmania) species (9, 11). As a result, any genes expressed from the episome,
including those conferring resistance to a selection agent, are likely silenced. Because of this,
genes must be stably integrated into the parasite genome to attain expression, which is
effectively a permanent modification.
Here we describe an analogous method of gene expression for use in Leishmania.
“Popout” constructs integrate into the parasite genome and confer GFP expression, allowing
cells to be rapidly scored for presence or absence of the construct. We show that popout
constructs carrying an RNAi transgene targeting the paraflagellar rod 2 (PFR2) gene trigger
downregulation of PFR2, and that loss of the construct returns cells to a wild-type phenotype.
4.3 – Results
4.3.1 – Construction of a removable expression construct
We had three criteria for the design of our expression construct: 1) stable integration into
the parasite genome; 2) a propensity for spontaneous loss; and 3) a rapid and facile method to
identify parasites that had lost the construct. To accomplish this, we cloned the GC-rich GFP+
ORF (12) into the “B” cloning site of pIR3 and pIR3-GW(A) plasmids (Figure 1A). pIR3
plasmids are derivatives of pIR1 (11), and replace the L. pifanoi CYS2 intergenic region of IR1
with the L. braziliensis alpha-tubulin intergenic region. These plasmids integrate into the 18S
small subunit ribosomal RNA array by homologous recombination, where they are transcribed at
high levels (13). The pIR3-GW(A) plasmid uses Gateway technology (Invitrogen, Thermo
Fisher Scientific) to facilitate cloning of an inverted repeat (stem-loop, StL). These StL
constructs are used to trigger transgene-driven RNAi in Leishmania (Viannia) species (9, 14).
In principle, we expected these constructs to behave in a manner analogous to the pXG
episome (15, 16) (Figure 1B). Briefly, integration of a pIR3-GFP+(B) construct into the
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Leishmania genome would cause expression of three genes: one conferring resistance to
selection antibiotic; GFP; and the desired gene or StL. Transfectants could be selected either by
culturing with the selective antibiotic or by single-cell sorting for GFP-positive cells. Removal of
drug selection would allow the integrated DNA to be lost by gene conversion – “popped out” –
at which time cells would no longer express GFP, the antibiotic resistance gene, or the transgene
or StL. Single-cell sorting for GFP-dim cells would allow recovery of clonal populations that no
longer contain the construct. Due to the ability of these constructs to be readily lost, we have
termed them “pop-out constructs.”
4.3.2 – Knockdown of paraflagellar rod 2 (PFR2) using a popout construct efficiently
downregulates PFR2 expression
To test the functionality of pop-out constructs, we targeted the paraflagellar rod 2
(PFR2) gene by RNAi in WT L. braziliensis strain M2903 using a pop-out StL construct. We
previously showed that knockdown of this gene results in loss of the paraflagellar rod structure
and defective motility (9), similar to deletion mutants in L. mexicana (17, 18). We integrated the
PFR2StL(A)-GFP+(B) construct or a GFP-only control into the L. braziliensis genome and
obtained clonal lines by drug selection on semisolid media. Transfectants expressed GFP at high
levels, and cell pellets were visibly green. PFR2StL(A)-GFP+(B) clones had a ~80% reduction
in PFR2 RNA compared to cells expressing GFP alone (Figure 2).
4.3.3 – Removal of PFR2 StL returns cells to WT phenotype in L. braziliensis
We withdrew drug selection from the PFR2StL(A)-GFP+(B) and the GFP-only control
lines to enable cells to lose the integrated DNA. A substantial GFP-negative population arose
within two passages without selection, or roughly 12 cell doublings (Figure 3). We single-cell
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sorted for GFP-positive and GFP-negative cells to obtain clonal lines with the constructs
integrated and popped out, respectively. Hereafter, clones with an integrated construct are
labeled “SSU:Construct” (ex, SSU:GFP+(B)); clones with a construct popped out are labeled
“PO:Construct (ex, PO:GFP+(B)).
Cell survival following sorting was markedly higher for GFP-negative clones than for
GFP-positive clones (78.8 ± 7.6% vs. 37.1 ± 8.9%, p<0.0001). After the cultures grew out we
tested clones for GFP expression; 37 of 38 clones had the expected level of GFP expression. A
single GFP-low clone expressed high levels of GFP; this clone was likely a result of imperfect
sorting.
We next performed PCR on genomic DNA from the GFP-positive SSU:PFR2StL(A)GFP+(B) and GFP-negative PO:PFR2StL(A)-GFP+(B) clones to confirm the presence/absence
of the StL construct. We were able to amplify PCR products confirming both 5’ and 3’
integration of the PFR2StL(A)-GFP+(B) construct for six of eight SSU:PFR2StL(A)-GFP+(B)
clones (Figure 4A). Unexpectedly, we amplified the 5’ and 3’ integration products from six of
nine popped-out PO:PFR2StL(A)-GFP+(B) clones, as well (Figure 3B). This suggested that,
even though the clones did not express GFP, they still retained portions of the StL construct. The
three PO:PFR2StL(A)-GFP+(B) clones that were confirmed to have lost the construct had PFR2
mRNA levels similar to that of SSU:GFP+(B) and PO:GFP+(B) clones (Figure 4B).
Finally, we functionally evaluated the SSU:PFR2StL(A)-GFP+(B) and PO:PFR2StL(A)GFP+(B) clones for loss of PFR2 protein. We expected that, since PFR2 RNA levels rebounded
following pop-out, protein levels would as well. In this situation, PO;PFR2StL(A)-GFP+(B)
lines would have a WT phenotype. EM imaging of SSU:PFR2StL(A)-GFP+(B) cells revealed a
lack of paraflagellar rod structure, which was clearly visible in both SSU:GFP+(B) and
128

PO:PFR2StL(A)-GFP+(B) cells (Figure 5, top). Finally, substantially fewer cells swam
normally in the SSU:PFR2StL(A)-GFP+(B) line than either the SSU:GFP+(B) or
PO:PFR2StL(A)-GFP+(B) line; the SSU:GFP+(B) line and PO:PFR2StL(A)-GFP+(B) line had
comparable proportions of cells swimming normally (Figure 5, bottom). These results are in
agreement with our previous knockdown of PFR2 (9). Further, they support the use of popout
constructs to return cells to a WT phenotype.
4.4 – Discussion
In our tests of the popout system using the PFR2StL(A)-GFP+(B) construct, we
successfully showed that 1) StL constructs using this system are functional in the downregulation
of their target; 2) popout constructs can be lost from the Leishmania genome; and 3) following
popout, expression from the construct ceases, and cells become phenotypically wild-type.
There are a few considerations to keep in mind when performing these experiments. First,
cell survival was lower following single-cell sorting for integrated (GFP-expressing) cells than
for popped-out (GFP-negative) cells. This may have occurred because GFP-expressing cells
were sorted into culture media containing selective antibiotic to preserve integration of the
construct; GFP-negative cells were sorted into culture media lacking selection. Survival of GFPexpressing cells could likely be increased by sorting into culture media lacking antibiotic and
resuming selection once cell density has increased.
Second, a large fraction of the GFP-negative cells analyzed retained portions of the StL
construct. This demonstrates the importance of thoroughly validating any clones obtained;
fortunately, the validation is easily accomplished with a simple PCR reaction. The presence of
portions of the construct but absence of GFP expression suggests that GFP expression may be
deleterious. It is possible that high levels of GFP act as negative selection, and cells that eject the
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GFP ORF have a selective advantage. Continued culture with selective antibiotic maintained
high levels of GFP expression in the vast majority of cells, suggesting that loss of GFP and drug
resistance occurs simultaneously.
There are a number of publications of transgenic Leishmania parasite lines expressing
GFP from the 18S rRNA locus (19–22). In most instances, the authors report stable expression of
GFP, even after prolonged removal of drug selection. However, their data show small
populations of GFP-negative cells within “GFP-expressing” populations (less than 1% to more
than 10% of total cells). In our hands, cells cultured with selection had proportions of GFPnegative cells in this range (Figure 3). In contrast, up to 40% of cells lost GFP expression after
we removed selection. Of these, the majority (two thirds) of cells tested retained portions of the
construct integrated into the parasite genome. It is possible that, when expressed from our
constructs, GFP expression was less stable in the absence of drug selection. The other groups
used different expression vectors in their experiments, with different intergenic regions driving
trans-splicing and polyadenylation. As gene regulation in Leishmania primarily occurs posttranscriptionally and relies heavily on untranslated regions (reviewed in (23–25)), this could
affect the steady-state level of protein expression.
Popout constructs have many potential uses. For experiments utilizing StL constructs,
popout of the construct would confirm that any observed phenotype is due to the presence of the
construct rather than due to culture artifacts or compensatory mutations. Additionally, popout
constructs driving expression of genes could be of particular use. For example, they could drive
the expression of Cas9 until gene editing is successfully completed, at which time the Cas9
construct could be popped out, eliminating any off-target effects due to the presence of the
nuclease.
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Further, since Leishmania (Viannia) species appear unable to support the replication of
episomes (9), popout constructs could enable functional tests of essentiality. In other Leishmania
species, essentiality can be confirmed using an episome sort method, wherein a gene is expressed
from an episome that also carries the GFP ORF during replacement of chromosomal alleles (15,
16, 26). After a chromosomal null mutant is obtained, selection maintaining the episome is
removed, and cells are sorted on the basis of GFP expression. If GFP-dim cells survive, and have
lost resistance to the selective agent, then the episome is no longer present and the gene is not
essential. If, however, few GFP-dim cells survive, and those that do are still resistant to the
selective agent, then the episome is still present, and the gene is likely essential.
Because of the inability to perform these experiments in Viannia subgenus species, genes
must be presumed essential if knockout or knockdown fails to yield viable mutants. This
presumption is not always accurate; there have been instances in which genes presumed essential
by this criterion were successfully knocked out using the episome sort protocol (16, 27). Now,
the gene to be knocked out can be cloned into the popout construct and transfected into parasites.
The construct would integrate, and the gene would be expressed ectopically while the alleles
from the native locus are replaced. After a chromosomal knockout is obtained, the ectopic copy
would be popped out. This procedure would facilitate the generation of “difficult” mutants or
rule out technical hurdles in the attempted generation of those mutants.
While this system was designed with Leishmania (Viannia) species in mind, it should
work in any Leishmania species, including those for which the episome sort works well. For
experiments requiring high expression of a gene, or little inter-clone variation in expression (13),
the integrating popout constructs are likely a better choice, as episomes copy number can vary
from cell to cell (5, 6).
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4.5 – Materials and Methods
Parasite strains and cell culture
L. braziliensis strain M2903 (MHOM/BR/75/M2903) was obtained from Diane
McMahon-Pratt (Yale University). Parasites were grown in fresh Schneider’s Insect Medium
supplemented with 10% heat-inactivated fetal bovine serum, 100 μM adenine, 5 x 10 -5% hemin,
2 μg/mL biopterin, 2mM L-glutamine, 500 units/ml penicillin and 50 ug/mL streptomycin.
Constructs and transfections
The GFP+ ORF was amplified by PCR using primers B6857 and B6858 (5’ –
ATCGATAAGATCTCCACCATGGTGAGCAAGGGCGAG / 5’ –
ATCGATAAGATCTTTACTTGTACAGCTCGTCCATGC), which flank the ORF with ClaI
and BglII sites, A-tailed, and cloned into pGem-T (Promega). The ORF was released from
B7379 pGEM-GFP+ with BglII and ligated into the BglII site of B7089 pIR3HYG to generate
pIR3HYG-GFP+(B). The GFP+ ORF was released from B7379 pGEM-GFP+ with ClaI and
ligated into the ClaI site of B7381 pIR3HYG-GW(A) to generate B7405 pIR3HYG-GW(A)GFP+(B). A 718 bp region of PFR2 was amplified with primers B3515 and B3517 (5’ –
CGCTAGTCTAGATTACGCTACGCAGAAAGAGAAG / 5’ –
CGCTAGTCTAGAGCCGTCCTCCACCTCCTCCGCG) and cloned into pCR8/GW/TOPO
(Invitrogen, Thermo Fisher Scientific) according to the manufacturer instructions. The PFR2
sequence was transferred to pIR3HYG-GW(A)-GFP+(B) using LR Clonase II (Invitrogen,
Thermo Fisher Scientific) in an overnight reaction at room temperature (RT); the reaction was
terminated by digestion with proteinase K for 1 hr at 37 ℃.
Transfections were performed as described previously (9, 11). Following transfection,
cells were plated on semisolid media containing 15 µg/mL hygromycin B (Gold
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Biotechnologies). Colonies were picked and grown to stationary phase in 1 mL of media and
passaged thereafter in 5 mL of media containing 10 µg/mL hygromycin B.
RNA and cDNA preparation and qPCR
2.5-3x108 cells were pelleted and dissolved in 1mL Trizol reagent (Ambion, Thermo
Fisher Scientific). 250 µL of dissolved cells were used to isolate total RNA with the RNA
miniprep kit (Zymo Research). RNAs were digested with 20 Units of DNaseI (Ambion, Thermo
Fisher Scientific) in a 200 µL reaction using the supplied buffer and purified using the RNA
Clean & Concentrator kit (Zymo Research) and eluted in 50 µL of nuclease-free water.
cDNA was synthesized by random hexamer-primed reverse transcription using the
Superscript III First-Strand Synthesis kit (Thermo Fisher Scientific) in 20 µL reactions
containing 0.25 µg RNA. Control reactions contained an equal amount of RNA but omitted the
reverse transcriptase enzyme.
qPCR reactions were performed using 5 µL of ten-fold diluted cDNA in a 20 µL reaction
containing 10 µL of 2x Power SYBR reaction mix (Applied Biosystems, Thermo Fisher
Scientific) and primers (Table 2)to a concentration of 0.2 µM each in MicroAmp Optical 96-well
plates (Thermo Fisher Scientific). Reactions were run on the ABI PRISM 7000 Sequence
Detection System. PCR amplifications were as follows: 50 °C for 2 min and 95 °C for 10 min
followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. PCR products were confirmed to
be specific by melt curve analysis. +RT reactions were performed in triplicate and –RT control
reactions in duplicate.
On each plate, 5-fold dilution series were performed for each primer set to calculate
primer efficiencies, and relative PFR2 level calculated using the Pfaffl method (28) using
amplification of KMP-11 as an internal control. The data are averages and standard deviations of
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3-6 independent clones, and significance was calculated by t-test (Figure 2B) or ANOVA
followed by the Tukey post hoc test (Figure 2D).
Removal of StL construct, flow cytometry, and cell sorting
Cells containing a StL construct were split to 105 cells/mL in Schneider’s medium
lacking selection and GFP expression monitored by flow cytometry. Parallel cultures under drug
selection were used as a comparison. When a GFP-negative population appeared in the cultures
lacking selection, clonal lines were obtained by single-cell sorting.
Log-phase cells were resuspended in phosphate-buffered saline, passed through a
CellTrics 50 µm filter (Partec) to remove clumps, and single cells were recovered on the basis of
GFP expression using a Beckman Coulter MoFlo cell sorter. Individual cells were placed into
wells of a 96-well plate containing 200 µL of Schneider’s Insect Medium containing no selective
antibiotic (GFP-negative cells) or 10 µg/mL hygromycin B (GFP-positive cells) and incubated at
27 ℃ for 10 days before parasite growth was scored. Wells were expanded to 5 mL with or
without antibiotic, as appropriate, and passaged thusly.
Genomic DNA preparation and PCR
108 cells were pelleted and washed with phosphate buffered saline, resuspended in 0.5
mL TELT lysis buffer (50mM Tris HCl, pH 8.0; 62.5 mM EDTA, pH 9.0; 2.5M LiCl; 4% v/v
Triton X-100), incubated 5 min at RT, and extracted twice with an equal volume of
phenol:chloroform (1:1). Genomic DNA was ethanol precipitated and resuspended in TE
containing 20 µg/mL RNase A.
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Genomic DNA was ten-fold diluted and 1 µL used in a 25 µL PCR reaction using
KlenTaq-LA polymerase. Primers used were: 5’ integration, B2618 and B3515 (5’ –
ACATCAGACGTAATCTGCCGC / 5’ –
CGCTAGTCTAGATTACGCTACGCAGAAAGAGAAG); 3’ integration, B3517 and B2619 (5’
– CGCTAGTCTAGAGCCGTCCTCCACCTCCTCCGCG / 5’ –
CGACTTTTGCTTCCTCTATTG). PCR products were run on 1% agarose gel and visualized
with ethidium bromide staining.
Transmission electron microscopy
For ultrastructural analyses, samples were fixed in 2% paraformaldehyde/2.5%
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM sodium cacodylate buffer, pH
7.2 for 1 hr at room temperature. Samples were washed in sodium cacodylate buffer and
postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 hr. Samples were then rinsed
extensively in dH20 prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc.,
Redding, CA) for 1 hr. Following several rinses in dH20, samples were dehydrated in a graded
series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut
with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained
with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron
microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera
and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn,
MA).
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Swimming assay
Log-phase cell culture was placed in a hemocytometer and 150 cells were visually scored
on the basis of swimming ability. A focal plane between the bottom of the cell and coverslip was
used to avoid counted cells adhering to either surface as immotile. Non-adjacent fields of view
were examined to minimize re-counting of motile cells. Cells were scored as immotile if flagellar
beating resulted in tumbling or in lack of forward motion.
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4.7 – Table Legends
Table 4-1: Primers used in qPCR analysis of PFR2 levels.
4.8 – Figure Legends
Figure 4-1: The popout construct system.
A) Schematic of IR3-GFP+(B) and IR3-GW(A)-GFP+(B) constructs carrying resistance
to hygromycin B (HYGR). Constructs carry a sequence from the 18S rRNA locus that
enables integration into the parasite genome by homologous recombination and splice
acceptor sites (SA) that permit proper trans-splicing and polyadenylation of transcribed
RNA. The GFP+ ORF is inserted into the B cloning site, while the A site remains
available for cloning of a gene of interest (GOI) or an RNAi transgene targeting the GOI.
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B) Workflow for the use of popout constructs.
Figure 4-2: qPCR analysis of PFR2 levels following integration of the PFR2StL(A)-GFP+(B)
construct.
The PFR2StL(A)-GFP+(B) construct efficiently suppresses PFR2 expression while
integrated. **** p≤0.0001.
Figure 4-3: Withdrawal of drug selection from cells containing an integrated GFP+(B)
orPFR2StL(A)-GFP+(B) construct allows for the accumulation of a GFP-negative population.
Cells were grown for two passages (~12 cell doublings) with or without hygromycin B
selection and analyzed by flow cytometry. Shown is one representative clone out of three
examined for each construct.
Figure 4-4: Confirmation of the loss of PFR2StL(A)-GFP+(B) following popout.
A) PCR amplification across the integration site after sorting for GFP expression. Six of
nine GFP-negative clones amplified both integration PCR products, indicating that the
PFR2StL(A)-GFP+(B) construct was still present despite the lack of GFP expression.
B) qPCR analysis of PFR2 levels following popout of PFR2StL(A)-GFP+(B) and
control GFP+(B) constructs. *** p<0.001; **** p≤0.0001; all other comparisons NS.
Figure 5: SSU:PFR2StL(A)-GFP+(B) parasites lack a paraflagellar rod structure and are
defective in swimming.
Transverse (top) and longitudinal (middle) sections of flagella imaged by transmission
electron microscopy of SSU:GFP+(B) control, SSU:PFR2StL(A)-GFP+(B), and
PO:PFR2StL(A)-GFP+(B) cells. The paraflagellar rod structure is indicated (PFR).
Bottom: fraction of promastigote cells that swim normally in culture.
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Table 4-1
Target
KMP-11
PFR2

Primer ID
B5023
B7412
B3638
B3639

Sequence
5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA
5’-GGTGACGATGCGGGTACC
5’- CAGACGGAGGACGAGAACAGGGG
5’- TGGATTGCATCGTGCAGGCTGTG
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Chapter 5: Conclusions and Future Directions

147

Preface
The first draft of this chapter was written by EAB. The final version presented here incorporates
comments from SMB.
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5.1 – Project Goals
The presence of Leishmania virus 1 (LRV1) profoundly affects the severity of disease
caused by Leishmania (Viannia) parasites (1, 2) and correlates with chronic disease, treatment
failure, and relapse (3–5). Little is known, however, about the mechanisms by which LRV1 copy
number is controlled within the parasite. Disruption of these mechanisms could augment
treatments for leishmaniasis that occurs in the presence of LRV1, with potential for improved
patient outcomes. Until relatively recently, virus infection of protozoa had been a curiosity with
little known relevance to the biology of the host organism. As such, little work has been done to
investigate antiviral mechanisms in these organisms. One way in which the parasite may regulate
the replication of LRV1 is through the RNAi pathway, which serves an antiviral function in
many eukaryotic organisms. The bulk of this work investigates the interaction between LRV1
and the RNAi pathway of L. guyanensis and L. braziliensis parasites. These experiments are
described in Chapters 2 and 3, and in Appendices C and D. In the course of the completion of
this work, I also developed tools for working with Leishmania in the laboratory (described in
Chapter 4 and Appendix B) and identified complications in our understanding of Leishmania
biology (described in Appendices A, E, and F). In this chapter, I will discuss the broader
conclusions of this work, and propose future directions.
5.2 – LRV1 is not immune to RNAi pressure, but Argonaute 1-dependent RNAi plays little
role in control of LRV1
In Chapter 2, we investigated whether LRV1 is processed by the RNAi pathway by
sequencing small RNAs (sRNAs) from infected cell lines. We found that substantial proportions
of the sRNA pool mapped to LRV1, similar to levels seen with an efficiently-silenced luciferase
knockdown reporter. This reporter elicits a 30-fold reduction in luciferase (LUC) activity in L.
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guyanensis and a 300-fold reduction in L. braziliensis (Chapter 3 and ref. 6), so this level of
LRV1-derived sRNA could be evidence of substantial targeting of LRV1 by the RNAi pathway.
When we knocked out AGO1 in L. guyanensis, however, we observed only small effects on
LRV1 levels (Chapter 3). All RNAi in Leishmania is believed to occur through the activity of
AGO1 (7, 8); therefore, if RNAi played a role in control of LRV1, we expected to see a much
larger effect.
This apparent contradiction could be explained if the LRV1-derived sRNAs are not true
siRNAs, and do not associate with AGO1 to direct cleavage of the LRV1 transcript. I do not
think this scenario is likely. While we did not definitively prove that the LRV1-derived sRNAs
are true siRNAs, we showed that the sRNA pool that we sequenced resembles siRNAs in size
and chemical composition. Specifically, both sRNA and siRNA lengths ranged from 20-26 nt
with a mode of 23 nt. Both contained untemplated bases at the 3’ end. Finally, the sRNAs map to
genomic loci in the same proportions as do AGO1-bound siRNAs. Therefore, there is no reason
to suspect that the LRV1-derived sRNAs would not be bioactive and capable of reducing LRV1
gene expression, thereby reducing LRV1 levels. Loss of AGO1 is known to destabilize the
siRNAs that bind to it (7, 8), so we could use the Δago1line to confirm that the sRNAs derived
from LRV1 are true siRNAs. Specifically, we plan to evaluate the level of LRV1-derived sRNAs
by Northern blot in the WT and Δago1 lines of L. guyanensis. If the levels of LRV1-derived
sRNAs fall in the Δago1 line, it would suggest that they are stabilized by AGO1 and are
therefore siRNAs.
I consider it more likely that a combination of transcript abundance and protection within
the protein capsid is responsible for the relative insensitivity of LRV1 to AGO1-dependent
RNAi. As described in the introduction (Chapter 1), LRV1 replicates by transcribing a plus150

strand and extruding it into the cytoplasm, where it is translated and encapsidated. After
encapsidation, the minus-strand is synthesized, regenerating the dsRNA genome. Because of
this, some fraction of the LRV1 transcript is enclosed within the capsid and therefore is
inaccessible to cytoplasmic complexes, such as AGO1-siRNA and ribosomes. Work in T. brucei
showed that siRNAs co-sediment with actively translating ribosomes (9), so exclusion of
ribosomes likely would further prevent the transcript from encountering AGO1. The dynamics of
transcript encapsidation have not been investigated. It is unknown how long a transcript is
exposed to the cytoplasm (and AGO1), or what fraction of transcripts become encapsidated. If
unprotected LRV1 transcripts are relatively rare, then encounters between them and AGO1
proteins loaded with anti-LRV1 siRNAs would be relatively infrequent. Further studies into the
dynamics of encapsidation would be required to determine whether this is a plausible mechanism
for the evasion of AGO1-dependent RNAi.
We further showed in Chapter 2 that introduction of an RNAi transgene (stem-loop
construct, StL) targeting LRV1 resulted in total loss of the virus from cells. Concomitantly, the
proportion of sRNAs derived from LRV1 increased dramatically. This is consistent with the
above hypothesis that the LRV1 transcript is protected from cleavage by AGO1 within the
capsid. The increase in LRV1-targeting siRNAs would increase the likelihood that a newlysynthesized transcript encounters a molecule of AGO1 loaded with an anti-LRV1 siRNA before
it is encapsidated. As the degradation of free transcript increased, translation of LRV1 protein
would decrease. As the level of protein translation decreased, fewer transcripts would be
protected, and more would be cleaved by AGO1. Eventually, there would be insufficient
transcript levels to maintain LRV1. By this hypothesis, loss of AGO1 should lead to substantial
increases in LRV1 level. Without the cleavage of free transcript by AGO1, more protein should
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be translated and more transcripts should be encapsidated, leading to even higher levels of
transcription and translation. Alternative mechanisms for limiting translation of the LRV1
transcript will be discussed later in this chapter.
It remains possible that cleavage of the LRV1 dsRNA genome by Dicer, or of the
transcript by Piwi, plays a substantial role in control of LRV1. I was unable to probe this
conclusively in this work due to technical difficulties (Appendix C), but the advent of CRISPR
technology will likely make the generation of these mutants much simpler. By generating single
and double mutants of the two Dicer genes, we can determine whether Dicer cleavage of the
LRV1 genome reduces virus replication. Further, while we previously were unable to generate
Piwi-null mutants in L. braziliensis, the increased efficiency of CRISPR may facilitate this in the
future.
5.3 – An alternative mechanism for control of LRV1
If further work reveals that control of LRV1 does not occur primarily via the RNAi
pathway, LRV1 could be maintained at sustainable levels through a balance of replication and
degradation. There are two main features of LRV1 would contribute to this balance:
First, the LRV1 transcript is not capped or trans-spliced. This presents two hurdles to
virus replication. First, the transcript cannot efficiently recruit ribosomes for translation of its
gene products. The 5’ UTR of the LRV1 transcript contains an internal ribosome entry site
(IRES) that is about 5% as efficient as a trans-spliced transcript at recruiting ribosomes (10),
resulting in less translation and therefor slower replication. Second, the lack of a cap structure
exposes the LRV1 transcript to degradation by RNases. There are six XRN family 5’-3’
exoribonuclease homologs in Leishmania, one of which is known to play a role in degrading
mRNA(11, 12). It is reasonable to suspect that one or more of these may degrade LRV1
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unencapsidated transcripts.
Second, in addition to the possible degradation of LRV1 transcripts by exoribonucleases,
cleavage of the LRV1 transcript by a mechanism other than AGO1 is known to occur. Prior work
in LRV1 from the Patterson lab described a “short transcript” 320 nt in length that was produced
by in vitro transcription from sucrose gradient-purified virions, and that was also present in
living cells (13). This short transcript is generated via site-specific cleavage of the 5’ UTR of the
LRV1 transcript by the viral capsid protein (14, 15). This would limit the accumulation of fulllength dsRNA genome, as any dsRNA generated using cleaved transcript as a template would be
missing a portion of its sequence. Further, the LRV1 IRES loses substantial activity with the
deletion of just 120 nt (10) from the 5’ end of the transcript. Therefore, this cleavage could serve
as a double hit – reduction in full length genome, and reduction in protein translation. At the time
of its discovery, this cleavage activity was hypothesized to act as a check on virus replication
(14).
I favor the hypothesis that LRV1 is controlled by a balance of replication and degradation
not involving RNAi. This hypothesis is attractive because it would be effective independent of
the species of Leishmania. RNAi is active only in the Viannia subgenus species; if RNAi played
a substantial role in the control of LRV1, then a separate mechanism would likely be required for
the control of LRV2 in L. major and other species of the Leishmania subgenus. In addition, this
hypothesis addresses the lack of impact of AGO1 on control of LRV1. As the number of LRV1
virions rises following loss of AGO1, so too would the cleavage of the transcript, limiting LRV1
accumulation.
This hypothesis also does not rule out a role for RNAi in control of LRV1, as the two
mechanisms may be somewhat redundant in Viannia subgenus species. When both mechanisms
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are present, loss of one may have minimal impact on virus levels. In this scenario, loss of AGO1
has only a small impact on LRV1 levels while the virus is capable of self-regulation. If the
transcript cleavage activity were ablated, loss of AGO1 may increase LRV1 levels to a much
greater extent. The RNA sequence required for cleavage of the LRV1 transcript has been
mapped. One could, in principle, mutate this sequence to investigate whether the cleavage
activity restricts virus replication and whether this activity and RNAi are redundant. However, in
the absence of a reverse genetics system in LRV1, these hypotheses remain difficult to test.
5.4 – LRV1 may be unstable in some Leishmania strains
In Appendix C, I showed that LRV1 was unstable in the WT line of L. guyanensis
M4147. When I examined this line for capsid protein levels by flow cytometry, I observed a
heterogeneous distribution with a sizeable fraction of cells stained similarly to an LRV1-negative
control. When this line was cloned (whether following transfection or not), many clones (15/42,
35.7%) of clones were uniformly LRV1-negative; these presumably arose from LRV1-negative
cells within the original population. Of the clones that contained LRV1, a 17/42 (40.5%)
displayed heterogeneity in LRV1 level similar to the parent/uncloned population. Even one of
the clones that initially appeared homogeneously LRV1+ became heterogeneous over time in
culture. This may have occurred in other LRV1+ clones were they cultured long enough, but I
did not systematically test this. In contrast, the lab has worked extensively with a LUCexpressing clone of this strain which has a uniform, high level of LRV1 capsid staining.
The instability of LRV1 in the WT line was not apparent until now because previous
work with WT examined LRV1 on a population level. For example, dsRNA bands were
visualized from total RNA, LRV1 sequence was amplified by PCR, capsid protein was
visualized by Western blot, or virions were purified from cell culture (16–19). Because many of
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the cells in the population contain LRV1, these experiments identified the strain as LRV1+ but
could not detect LRV1-negative cells in the population. The flow cytometry assay was developed
by Matt Kuhlmann in our lab (20), but we were exclusively using the LUC-expressing clone and
had never analyzed the WT.
This observation does explain a lingering discrepancy in the field, however. The
Patterson lab identified an LRV1-negative isogenic clone of L. guyanensis M4147 that arose in
culture (21). This clone was isolated following transfection with a plasmid conferring resistance
to hygromycin B, and they hypothesized that drug selection mediated the loss of LRV1. We were
unable to replicate this; however, we were using other parasite strains or the LUC-expressing
clone. It is possible that their LRV1-negative clone originated as an LRV1-negative cell in the
WT population prior to plating, as occurred in my DCL knockout experiments.
This heterogeneity in LRV1 level has not been observed in any other line we’ve
evaluated by flow cytometry, which includes at least three strains of L. braziliensis. It is unclear
what makes LRV1 stable in these lines, but unstable in L. guyanensis M4147. It is unlikely to be
caused by the difference in species, as LRV1 is stable in the LUC-expressing clone of L.
guyanensis M4147. In addition, it is unclear why the LRV1 is stable in the LUC-expressing
clone, while it was unstable in the clones and transfectants of WT that I obtained. One possible
explanation for this is a difference in the way clones were obtained. The LUC-expressing clone
was isolated by plating on agar plates. At the time I was performing these experiments, agar did
not support growth of Viannia subgenus species, and I obtained clones by limiting dilution. This
strain is not “clumpy,” but I cannot rule out that my clones were not, in fact, mixed populations.
If that were the case, the clones that appeared LRV1+ contained small numbers of LRV1negative parasites, which then increased in proportion during culture. We would likewise expect
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apparently LRV1-negative clones to develop LRV1+ populations during culture; I did not
cultivate LRV1-negative clones long enough to observe this.
5.5 – StL constructs may not be biologically neutral
In the course of this work, I and others in the lab began to notice alterations in
Leishmania biology in the presence of StL constructs. These included the presence of stable
dsRNA derived from the transcribed inverted repeat, defects in the knockdown of additional StL
construct targets, and possibly augmented virulence. In Appendix E, I documented experiments
designed specifically to investigate these observations. I also identified an increase in the level of
TATE transposable elements (TEs) in cells containing a StL construct. This data do not provide
irrefutable evidence that StL constructs are problematic; rather, they suggest that caution is
warranted during their use. Further, as RNAi appears to be more efficient and to play a role in
virulence in L. braziliensis, the presence of a StL construct in this species could be more
problematic than in L. guyanensis.
It is interesting to note that the effects of the presence of StL constructs are similar to
those observed after the knockout of AGO1. In both cases, levels of TATE RNA rose and
knockdown of a luciferase reporter fell, though the magnitudes of these effects were greater in
the Δago1 lines. This leads me to believe that a StL construct functions as a dominant negative
on the RNAi pathway – its presence depletes the ability of the RNAi pathway to knock down
other targets.
Additionally, in both the Δago1 and StL lines, LRV1 levels increased. In Chapter 2 I
documented that the introduction of a StL targeting the LRV1 Capsid or RDRP, but not a control
GFPStL, resulted in loss of LRV1. In fact, LRV1 levels in the GFPStL lines were 20-100%
higher than WT, depending on the strain examined. At the time, we assumed this was the noise
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of the assay; however, the small impact of the loss of AGO1, coupled with the observation that
the GFPStL affected knockdown of LUC, caused me to rethink this assumption. In L. guyanensis
M4147, LRV1 levels rose 35% upon loss of AGO1 and approximately 50% in the presence of
the GFPStL. The data from the two experiments were analyzed differently, and the StL
experiment examined fewer biological replicates. Because of this, the magnitudes of the two
experiments cannot be directly compared, but the data suggest that the effect is similar.
Together, this supports the hypothesis that AGO1-dependent RNAi has some function,
albeit small, in reducing LRV1 levels in Leishmania (Viannia) species. The presence of the
GFPStL impairs the regulation of other RNAi targets, and in its presence, LRV1 levels
increased. If RNAi were not involved in control of LRV1, then the presence of the GFPStL
would not have affected LRV1 levels.
5.6 – New tools for the study of Leishmania
During the course of my experiments, I required tools for working with Leishmania that
did not yet exist. It was through these needs that the work described in Chapter 4 and Appendix
B arose.
During the RNaseIII experiments detailed in Appendix B, my transfections yielded many
colonies, but initial screens did not identify any successful transfectants. Because of this, I
needed a less cumbersome method to enable me to evaluate relatively large numbers of clones.
The existing protocol required 1-2 weeks in culture and 11 mL of medium for each clone
screened; by reducing these requirements I could save substantial time and materials. The
“quick, crude gDNA prep” protocol that I developed reduces the media requirement by 10 mL
and the time requirement by up to a week in culture. This allowed me to save approximately 300
mL of media on this experiment, and perhaps more importantly, allowed me to quickly conclude
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that the experiment was unlikely to succeed. If this protocol becomes widely used in the lab for
integrations that are predicted to be rare, the cumulative time and materials savings could be
substantial.
I developed the crude gDNA prep protocol to a stage where it was functional in my
hands, but there are aspects of the protocol that could be optimized. For example, the crude
gDNA isolated in my protocol is not reliably stable beyond one day; increasing the stability of
the gDNA in storage would increase its utility. One way to do this would be to incorporate a
phenol:chloroform extraction, but the volumes are likely to small for this to be feasible.
Increasing the volume would require either using more culture volume (more material and more
time) or diluting the gDNA, which would necessitate adding an ethanol precipitation step.
Instead, my protocol should be viewed as preliminary screening to identify promising clones.
These can then be grown to a larger culture volume to prepare “clean,” stable gDNA.
The popout constructs detailed in Chapter 4 and used in Appendix E arose out of our
concern that the presence of a StL construct may not be neutral beyond its capacity to
downregulate a target. We intended for LRV1StL parasites to be used to further probe the role of
LRV1 in parasite biology and virulence because of a lack of isogenic lines. In order for this to be
possible, however, parasite biology could not be altered by the LRV1StL construct. I developed
the popout system both to 1) test the effect of the presence of the StL; and 2) remove the
LRV1StL from parasites to create truly isogenic lines. This system works in principle: the StL
construct is functional, and one can easily obtain cells that have lost it. However, there are signs
that care must be taken with these lines.
First, a very large percentage (up to 40%) of L. braziliensis PFR2StL(A)-GFP+(B) cells
lost GFP expression when selection was withdrawn, but a sizeable fraction (6/9) of these retained
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fragments of the StL construct integrated into the parasite genome. I suspect that the very high
level of GFP expression selects for the loss of GFP by any means possible. I did not observe this
phenomenon with the L. guyanensis CapsidStL(A)-GFP+(B) lines. In order for GFP-expressing
L. braziliensis cells to be on the scale of the x-axis, I have to reduce the sensitivity of the flow
cytometer approximately five-fold from settings I use to analyze L. guyanensis cells (data not
shown). At the same time, less than 5% of L. guyanensis cells were GFP-negative following two
passages without selection, and none of these contained the stable dsRNA that is characteristic of
an integrated StL construct. This suggests that GFP is expressed less strongly in L. guyanensis
than L. braziliensis, which may have helped the full construct remain integrated.
Second, a fraction of the L. guyanensis CapsidStL(A)-GFP+(B) clones had elevated
doubling times in culture and were avirulent in mice. While Leishmania cultured for long periods
of time often lose virulence, we have not typically observed this in Viannia subgenus species,
such as L. guyanensis. Many groups have found that high levels of GFP expression do not affect
parasite virulence (22–24). Rather, it is possible that perturbations induced by single-cell sorting
contributed to the loss of virulence. It may be wise to systematically test whether clones obtained
by cell sorting are more likely to lose virulence compared to clones obtained by limiting
dilutions or plating. Regardless, special attention should be paid to characteristics such as
doubling time to minimize the possibility of infecting mice with “dud” clones.
5.7 – Conclusions
Through this work, I investigated the role of the RNAi pathway in control of LRV1 in
Leishmania (Viannia) parasites. I found that parasites containing LRV1 produce abundant virusderived sRNAs, and that LRV1 can be eliminated by RNAi targeting. In contrast, endogenous
RNAi has little effect on virus levels. Additional studies investigating the roles of other RNAi
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pathway components were inconclusive. These experiments have deepened our understanding of
parasite-virus interactions, and provided a starting point for further work on this topic. Further, I
developed new tools for the study of Leishmania (Viannia) parasites, including a protocol for the
isolation of genomic DNA from small numbers of parasites and a construct that facilitates
removal of transfected DNA integrated into the parasite genome. Finally, I determined that
increased caution may be warranted during RNAi experiments, as the StL construct may disrupt
global RNAi within the cell. This knowledge will aid the study of Leishmania (Viannia)
parasites going forward, and facilitate a wide range of investigations.
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Appendix A: Chromosome 11/AGO1 locus architecture
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Preface
The experiments in this appendix were designed, performed, and analyzed by EAB under the
guidance of SMB. The first draft was written by EAB and the final version presented here
incorporates comments from SMB.
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A1 – Introduction
Previous work in the lab generated a Δago1 parasite line in L. braziliensis strain M2903.
This line was functionally RNAi-deficient, both as assessed by RNAi reporters (Notton, Lye, and
Beverley, unpublished data) and in terms of endogenous knockdown of transposable elements
(1); ectopic expression of the AGO1 gene restored RNAi function. Together, these data
suggested that the AGO1 gene was replaced as anticipated. However, during generation of this
parasite line, the lab was unable to confirm proper integration of the knockout constructs at the
3’ end into the AGO1 locus. This suggested that the assembly of this genomic region was
incorrect.
Further, when I was cloning constructs to knock out AGO1 in L. guyanensis, I discovered
that there was an approximately 800 nt sequence just 3’ of the AGO1 ORF that was repeated in
two other loci on chromosome 11. It is likely that the length of the repeat caused an error in
assembly of these regions. Because I would need to confirm the integration of my knockout
constructs into the AGO1 locus, I set about determining which sequence was immediately 3’ of
the AGO1 gene and confirming the integration of the Δago1 line of L. braziliensis.
A2 – Results
A2.1 – The L. braziliensis and L. guyanensis genome assemblies are improperly assembled
To determine whether genes on chromosome 11 in L. braziliensis M2903 and L.
guyanensis M4147 were arranged as annotated in the L. braziliensis M2904 assembly, I used
PCR to amplify across each individual repeat. I designed primers to bind to unique sites 5’ and 3’
of each repeat, and set up reactions containing each possible primer pair. The general scheme of
primer binding is shown in Figure 1. For both species, PCR products of the expected size were
obtained for the following primer combinations: a/d; c/b; and e/f (Figure 2). Other primer
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combinations did not give PCR products of the expected size (data not shown). This suggests
that the loci surrounding these intergenic regions are laid out as in Figure 3.
The AGO1 replacement cassettes are properly integrated in the Δago1 line of L. braziliensis
I next used PCR amplification to confirm the integration of the constructs used to knock
out AGO1 in L. braziliensis strain M2903. I paired forward primers that hybridize to the drug
resistance genes used in the AGO1 replacements with the proper reverse primer (primer d) that
hybridizes to unique sequence 3’ of the repeat (Figure 4A). These PCR reactions gave products
of the expected size (Figure 4B), indicating that the knockout constructs were properly integrated
into the correct genomic locus in this parasite line.
A2.2 – PacBio sequencing of L. guyanensis confirms chromosome 11 gene arrangement
Since this work was completed, the L. guyanensis genome was sequenced on the PacBio
platform. PacBio sequencing generates very long reads, which facilitates the assembly of
repetitive elements. While the PacBio assembly does not precisely match my predicted
arrangement of genes (compare Figure 3 with Figure 5, bottom), it is consistent with the results
of my primer amplification experiments. Each of the regions of mis-assembly aligns to regions
of the L. braziliensis assembly that contained sequencing gaps or the large repeat. These
situations are known to contribute to difficulties in generating assemblies (2, 3). I identified other
mis-assemblies due to sequencing gaps and gene families along the chromosome, as well. More
surprisingly, chromosome 11 in the PacBio assembly contains a 90.7 kb sequence at the 5’ end
that is annotated in the L. braziliensis assembly as chromosome 19. This sequence contains 31
genes, none of which are annotated as part of L. guyanensis chromosome 19 in the PacBio
assembly. This may be a sequencing artifact, or it may represent a true difference between the
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two species, such as a chromosomal translocation. Further experiments will be required to
differentiate between the two possibilities.
A3 – Discussion
Results from PCR amplification suggest that the presence of the 800nt repeat in
chromosome 11 caused errors in the L. braziliensis strain M2904 genome assembly. Broadly,
this particular mis-assembly is unlikely to dramatically impair study of these organisms, as it
affects only a handful of loci. In the instance of the study of AGO1, however, it proved to be a
stumbling block. Fortunately, the existing Δago1 line of L. braziliensis had the anticipated and
proper replacement of AGO1 with drug resistance genes. Further, I was able to use this new data
in the successful generation of the Δago1 line in L. guyanensis (see Chapter 3).
Whole genome sequencing of L. guyanensis M4147 using the PacBio platform revealed
that there were additional errors in the L. braziliensis M2904 assembly. These errors were due to
sequencing gaps, and to the presence of gene families. Chromosome 11 is not likely to be the
only instance of these types of sequencing errors in the L braziliensis M2904 genome, so it’s
reasonable to assume that similar errors occur throughout the genome. Because the majority of
genes on chromosome 11 were arranged as expected, however, the L. braziliensis M2904
assembly is likely sufficient in most cases for planning genetic manipulations of Leishmania
(Viannia) parasites. In cases where the L. braziliensis assembly is not sufficient, or cases where
extra certainty is desired, a PacBio assembly such as the L. guyanensis M4147 assembly will
provide a more accurate view of the parasite genome.
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A4 – Materials and Methods
Chromosome 11 sequences
The L. braziliensis strain M2904 genome assembly (Genbank accession ID:
GCA_000002845.2) was used to identify the repeat regions on chromosome 11 by BLAST
search and to design primers to these regions. The entire intergenic regions containing the
repeats were extracted and labeled Intergenic Regions 1 (IR1), 2 (IR2), and 3 (IR3). The
chromosomal locations of these regions are listed in Table 1.
Primers
Oligonucleotide primers were designed to hybridize to unique regions 5’ and 3’ of each
repeat region. Primer sequences can be found in Table 2, along with the locations they bind
according to the annotated genome. Also included in the table are primers that bind to the drug
resistance ORFs used in the knockout of AGO1 from L. braziliensis.
PCR analysis of gDNA
Genomic DNA (gDNA) was isolated from the WT and Δago1 lines of L. braziliensis
strain M2903 and from L. guyanensis strain M4147. Briefly, 108 parasites were lysed in TELT
buffer (50mM Tris HCl, pH 8.0/62.5 mM EDTA, pH 9.0/2.5M LiCl/4% Triton X-100) and
protein was removed by extraction twice with phenol:chloroform:isoamyl alcohol (25:24:1).
Nucleic acids were concentrated by ethanol precipitation and RNA removed by digestion with 20
μg/mL RNaseA.
Purified gDNA was used as the PCR template at a final dilution of 1:500 in PCR
reactions containing:1x KTLA buffer; 200 μM dNTPs; 400 μM each primer; 1M betaine; and
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Klen-Taq LA polymerase to a final dilution of 1:500 in a 50 μL reaction. PCR products were
analyzed by agarose gel electrophoresis.
A5 – Table Legends
Table A1: Chromosome 11 intergenic regions containing the approximately 800 nt repeat.
The open reading frames (ORFs) annotated to be either side of each intergenic regions
are specified, as well as the nucleotide positions of the intergenic regions.
Table A2: Primers used to decipher the genomic architecture of chromosome 11.
Primer orientation, sequence, and binding location on chromosome 11 are specified.
A6 – Figure Legends
Figure A1: Regions of chromosome 11 surrounding 800nt repeats.
Repeats are depicted as black boxes labeled “R”, as annotated in the L. braziliensis
M2904 assembly. Primer binding sites are indicated (a-f).
Figure A2: PCR products obtained for L. guyanensis M4147 and L. braziliensis M2903 WT
parasites.
PCR products using genomic DNA from L. guyanensis (left) and L. braziliensis (right),
indicating successful amplification across the repeated region.
Figure A3: Inferred genomic arrangement surrounding repeated regions on chromosome 11.
Repeats are depicted as black boxes. Primers that successfully amplified a PCR product
of the expected size are indicated (a-f).
Figure A4: Confirmation of proper integration of AGO1 knockout cassettes in L. braziliensis
M2903.
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A) Primer combinations for the confirmation of AGO1 replacements. Forward primers
bind within the drug resistance cassette, and were paired with reverse primer d.
B) PCR products of the expected size were amplified from the Δago1 line of L.
braziliensis M2903, confirming the proper integration of the replacement constructs used
to generate the line.
Figure A5: Arrangement of genes on chromosome 11 surrounding repeat regions according to
the L. guyanensis PacBio genome assembly.
Errors in the L. braziliensis M2904 assembly of chromosome 11 (top) occur around
regions containing sequencing gaps (gray boxes) and the repeat (black boxes). Bottom,
chromosome 11 as ordered in the L. guyanensis PacBio assembly. In the PacBio
assembly, gray boxes do not denote sequencing gaps, but rather regions where
sequencing gaps occurred in the L. braziliensis assembly (for reference). Vertical lines
between the two assemblies indicate how regions within the chromosome differ. Primer
pairs that amplified the expected product are shown as arrows connected by solid lines.
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Table A1
ORF annotated 5’ of IR

IR1
IR2
IR3

LbrM11_V2_0360
(Ago1)
LbrM11_V2_0460
LbrM11_V2_0670

Intergenic region
Intergenic region
beginning nucleotide ending
nucleotide
162020
164762

ORF annotated 3’
of IR

219117
310863

LbrM11_V2_0470
LbrM11_V2_0680

226131
317855
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LbrM11_V2_0370

Table A2
Primer
ID
B4911

Orientation

Sequence

Reverse

B4912

Forward

B4922

Reverse

B4923

Reverse

B5080

Forward

B5081

Forward

B5102

Forward

B5104

Forward

5’CACATTGTTCTCGCTTCCTGC
5’GCATGCGCTCTGCACTATTTG
5’TCGGAAGAGGGGGGTACGGC
5’GCCACAGCAATGACCCTTCT
5’CGGTCCAAGTTTTGGTGAGG
5’TGTGGCCCAGTTGTGAGTTG
5’ACTCGCCGATAGTGGAAACC
5’CATTTTACTGGGGGACCTTGT
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Genomic
location
163160-163140

Region of
binding
IR1

162247-162267

IR1

315393-315374

IR3

224162-224143

IR2

221499-221518

IR2

312694-312713

IR3

NA

HYGR

NA

BSDR

Figure 1
A
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Figure 2

L. guyanensis M4147

4912/4923: 1621 bp

L. braziliensis M2903
Expected bands:
5080/4911:1941 bp
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5081/4922: 2700 bp

Figure 3
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Figure 4
A

B

Expected bands:
HYGR: 1904 bp
BSDR: 2101 bp
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Figure 5
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Appendix B – Development of a quick, crude Leishmania gDNA prep protocol
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Preface
The protocol presented here was developed by EAB under the supervision of SMB. The first
draft of this appendix was written by EAB and the final version presented here incorporates
comments from SMB.
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B1 – Introduction
The standard protocol for molecular validation of transfectants involves purification of
genomic DNA (gDNA) from parasites followed by PCR amplification across the integration site.
Previously, to obtain sufficient cells for gDNA purification, colonies were picked from semisolid
agar plates, cells grown in 1 mL medium without selection to high parasite density (3-7 days),
expanded to 10 mL with selective antibiotic and grown to high parasite density (2-5 days), and
finally pelleted and the gDNA purified. In total, it requires 1-2 weeks of growth in culture, and
11 mL of medium for each clone to be evaluated. When large numbers of colonies must be
screened, this constitutes a large commitment of resources and time.
To reduce the consumption of medium and the time required to screen clones, I
developed a protocol to quickly isolate gDNA of sufficient quality to use as a PCR template from
small numbers of Leishmania cells, as little as 200 μL of dense culture (2 x 106 – 2 x 107 cells,
depending on species), with a minimal hands-on time commitment. This allows us to screen
large numbers of clones at the 1 mL stage, and only expand promising clones to 10 mL for
further analysis. It has a high rate of success – in my largest experiment using this method, I
prepared gDNA from 24 clones, and a positive control PCR product was amplified in all 24
reactions (Figure 1).
There is undoubtedly room in the protocol for optimization, but it is sufficient for the
purpose it was developed for.
B2 – Protocol
1) Grow cells to high density (late-log phase)
2) Pellet desired number of cells and wash with 0.5 volumes PBS.
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3) Resuspend cells in 0.2 volumes lysis buffer (1% Triton X-100 in PBS containing 50
μg/mL proteinase K).
4) Incubate at 37 degrees C for 1 hour.
5) Heat-inactivate the proteinase K at 95 ℃ for 10 min.
6) Pellet any cell debris in table-top microcentrifuge at full speed for 5 min.
Use 2 μL of the supernatant as template in a 50 μL PCR reaction.
Crude gDNA samples can be stored at -20 ℃ for use later that day, but do not give reliable
amplification after overnight storage.
B3 – Figure Legend
Figure B1: Positive control PCR product was amplified from crude genomic DNA preparations
from 24 of 24 transfectants.
The WT line contained IR2SAT-LUC(B) integrated into the 18S rRNA small subunit
locus, and primers bound either side of the site of integration. M, dsDNA ladder (the 1kb
band is indicated); (+), positive control gDNA prepared via a “clean” protocol using
Triton X-100/LiCl lysis followed by phenol:chloroform extraction; (-) no-template
negative control.
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Figure B1
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Appendix C – Disruption of Dicers and Piwi
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Preface
The experiments described in this appendix were designed, performed, and analyzed by EAB.
SMB supervised the work and contributed to study design. The first draft was written by EAB,
and the final version presented here incorporates comments from SMB.
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C1 – Introduction
In Chapter 3, I hypothesized that the parasite RNAi pathway played a role in containing
replication of LRV1 to levels that the cell could sustain, permitting persistent infection. Loss of
Argonaute 1 (AGO1) did not produce the expected dramatic increase in LRV1 levels, suggesting
that if a substantial antiviral role for RNAi exists in Leishmania, it likely is AGO1 independent
(Chapter 3). To determine whether any other components of the RNAi pathway play a role in
control of LRV1, I attempted to deplete the levels of these other components by gene knockout
and/or RNAi knockdown. These components are illustrated in Figure 1.
There remains a second Argonaute family protein in Leishmania whose function is
unknown (1). Previous work in the Beverley lab suggested that this protein (known as Piwi) is
localized to the mitochondrion, and efforts to knock it out in L. braziliensis M2903 were
unsuccessful (Tsang, Anderson, and Beverley, unpublished data). It is unclear what role, if any,
RNAi might play in mitochondrial function. However, RNAi knockdown of PIWI impaired
concurrent knockdown of luciferase (Lye and Beverley, unpublished data), an effect similar to
what was seen with knockdown of AGO1 (2). While this may suggest that Piwi plays a role in
the RNAi pathway, other possibilities not involving RNAi have not been eliminated and may be
more likely. Nonetheless, it is possible that Piwi has a more substantial role than AGO1 in
defense against viruses.
Alternatively, experiments in other organisms suggest that Dicer can, in some cases, play
a role equal to or larger than Argonaute in defense against viruses (3–5). Leishmania (Viannia)
parasites encode two Dicer proteins, and work in Trypanosoma brucei suggests that the functions
of these proteins have specialized to some extent (6). Perhaps inactivation of the LRV1 genome
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through cleavage by one or both Dicer is sufficient to limit LRV1 replication. In this situation,
the resulting siRNAs may have minimal impact on LRV1 levels.
In this appendix, I present studies investigating the role of Piwi and Dicer proteins in the
control of LRV1 in L. guyanensis. I first attempted to generate Dicer1 (DCL1) and Dicer2
(DCL2) null mutants; however, technical hurdles resulted in the abandonment of this approach.
RNAi knockdown of DCL1, DCL2, and PIWI did not affect LRV1 levels; however, it is unlikely
that knockdown resulted in sufficient loss of function for an effect to be visible. No conclusions
could be drawn from this work on the role of Dicer proteins or Piwi in control of LRV1.
C2 – Results
C2.1 – LRV1 is unstable in WT L. guyanensis M4147
We first attempted to knock out the DCL1 and DCL2 genes individually by homologous
recombination, replacing each allele with a drug resistance gene. We performed the initial rounds
of replacement for each of DCL1 and DCL2 in WT L. guyanensis M4147 and obtained four
heterozygous mutant clones for DCL1 (two with a PACR replacement and two with a HYGR
replacement) and one heterozygous mutant clone for DCL2 (BSDR replacement). Each
heterozygous mutant clone had the expected PCR products confirming proper integration of the
knockout cassettes (Figure 1). When I performed flow cytometry using the anti-capsid antibody,
however, the WT parent and mutant clones were either LRV1-negative or a mixed population of
LRV1-positive and LRV1-negative cells (Figure 2A). In an attempt to obtain homogeneous
LRV1+ populations, I re-cloned the WT parent and two heterogeneous DCL1 replacement clones
(one PACR replacement and one HYGR replacement) by limiting dilution. I evaluated LRV1
levels in 8-12 clones per genotype by flow cytometry (Figure 2B). The majority of clones were
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either LRV1-negative or mixed populations, but a few clones appeared to be approximately
homogeneous LRV1-positive.
C2.2 – DCL1 double replacement clones retain a copy of the DCL1 ORF
I performed a second round of replacement in a DCL1 PACR replacement subclone that
appeared to be LRV1-positive (clone 2.6, Figure 2B) and obtained six double replacement
clones. Transfectants were evaluated by drug resistance and PCR tests for the presence of the
DCL1 ORF and proper 3’ integration of the replacement cassette. Five of six clones were
properly integrated at the 3’ end, but all six retained a copy of DCL1 (Figure 3). Chromosome
23, where DCL1 is located, is predicted by sequencing read depth to be trisomic (Shaik and
Beverley, unpublished data). The presence of a third copy of the DCL1 ORF suggests that the
gene is present in at least three copies, requiring a third round of replacement in order to generate
a null mutant.
C2.3 – Apparently-homogeneous lines develop substantial LRV1-negative populations over time
When I evaluated the double replacement clones for LRV1 level by flow cytometry, the
parent heterozygote that had previously appeared LRV1-positive (Figure 2B) was now
heterogeneous (Figure 4). This suggested that either a small LRV1-negative population had been
present previously or that LRV1 is intrinsically unstable in this line. Two double replacement
clones were LRV1-negative, one was heterogeneous, and three were approximately LRV1positive (Figure 4). Because the double replacement clones are not null mutants and the parent
heterozygote developed a substantial LRV1-negative population, the LRV1-negative double
replacement clones likely arose from LRV1-negative parent cells.
C2.4 – Knockdown of PIWI and DCL1/2 was inefficient and did not affect LRV1 level
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Because of the instability of LRV1 in the WT L. guyanensis, I switched to a clone that
had been transfected with a construct that confers luciferase expression and resistance to
nourseothricin (SATR). Previous work in the lab has demonstrated this clone to harbor a single
LRV1-positive population, and transfectants similarly do not show instability in LRV1 levels (7,
8). Leishmania have a limited number of available selection markers, which would make
generating a DCL1/2 double null mutant challenging in this genetic background. Because of this,
I used RNAi-of-RNAi to reduce levels of DCL1, DCL2, and PIWI. The lab has previously used
this approach to investigate the role of AGO1 in the RNAi pathway (2).
Integration of DCL1-, DCL2-, and PIWI-targeting stem-loop (StL) constructs reduced
mRNA levels of their targets by 0-55% (Figure 5). The PIWIStL construct failed to reduce PIWI
mRNA levels at all, while the DCL2StL construct halved DCL2 mRNA levels, and knockdown
of DCL1 was intermediate between the two. Analysis of LRV1 level in knockdown lines by flow
cytometry showed no change in LRV1 levels upon integration of the StL constructs (Figure 6).
C3 – Discussion
Heterogeneity in LRV1 level in the WT L. guyanensis M4147
L. guyanensis M4147 WT, unexpectedly, was a mixed population of LRV1-positive and
LRV1-negative cells. It is unlikely that this represents contamination with another strain or
species of LRV1-negative parasites, as transfectants and clones of this line exhibited a wide
range of LRV1 levels: LRV1-negative, heterogeneous, and LRV1-positive clones were readily
obtained (Figure 2A and data not shown). If the LRV1-negative populations of the original WT
line were merely the result of contamination or a mixed isolate, we would expect to obtain clones
and transfectants that were LRV1-positive and LRV1-negative. We would not expect to obtain
clones resembling the original line, with both LRV1-positive and LRV1-negative populations.
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Further, when we re-cloned and subsequently transfected a heterozygous Dcl1 mutant, some of
the resulting clonal lines displayed heterogeneity similar to the WT line (Figure 2B and Figure
4). For the observed heterogeneity to persist through three cloning steps makes contamination
unlikely to be the cause by parsimony. In addition, a clone that initially appeared to be LRV1positive developed substantial LRV1-negative populations over time in culture (compare Figure
2B, green trace with Figure 4, red trace). This suggests that the cell-to-cell heterogeneity in
LRV1 level stems from an inherent instability in LRV1.
Because of this apparent instability of LRV1, the WT line of L. guyanensis M4147 is not
a good candidate for further work exploring effects on LRV1 levels, whether in regard to the role
of RNAi or other applications, including screening for antiviral compounds. It is unknown why
LUC c3, which is derived from the WT line, has stable levels of LRV1, but this line is a better
candidate for further study. Alternatively, L. guyanensis M4147 obtained from other sources may
have stable, uniform LRV1 presence.
Investigations into the role of Dicers and Piwi were inconclusive
Two rounds of replacement generated multiple clones with two copies of Dcl1 replaced
by drug resistance genes; however all of these retained a copy of Dcl1. Aneuploidy can signal
that a gene is essential in Leishmania (9–11); however, it is unlikely that Dcl1 is essential in L.
guyanensis, as Dcl1 mutants were viable in the related organism Trypanosoma brucei (6). In
addition, L. guyanensis parasites are viable after knockout of Argonaute1, which ablates the
parasite RNAi pathway (Chapter 3). Instead, it is more likely that chromosome 23 is trisomic, as
predicted. Therefore, three rounds of replacement will be required to obtain a Dcl1KO line.
Previous work in T. brucei found that the two Dicer proteins have some overlap in the
substrates from which they produce siRNAs (6, 12). For example, loss of either Dcl1 or Dcl2
189

affects the accumulation of siRNAs derived from the CIR147 repeat element and from
chromosomal inverted repeats (12). As Dcl1 protein is predicted to localize to the cytoplasm
(13), we might expect this protein to play a predominant role in control of LRV1, which also
localizes to the cytoplasm (14). We cannot rule out, however, that the presence of Dcl2 will
compensate for loss of Dcl1. It may therefore be necessary to generate a double knockout in
order to observe an effect on LRV1 levels, which would require five rounds of replacement and
five different drug resistance cassettes. There are only six drug resistance cassettes commonly
used in Leishmania, all of which would be required to generate a double knockout in the LUC c3
background (which already contains a SATR cassette). In order to complement the mutant, the
double knockout line would have to be cultured without selection for a time in the hope that gene
conversion would replace one of the drug resistance genes with another, freeing it to be used to
complement the knockout. This protracted approach is beyond the scope of this thesis.
To circumvent this hurdle, I changed tactics to knocking down Dcl1, Dcl2, and Piwi by
RNAi. This RNAi-of-RNAi approach is somewhat counter-intuitive, as the activity of the target
is required for knockdown. Because of this, we expect less knockdown that would ordinarily be
achieved with other, non-RNAi genes. It has been successfully used, however, in the
establishment of AGO1 in the Leishmania RNAi pathway (2) and of Dcl1 in the Trypanosoma
RNAi pathway (13).
RNA levels fell by 55% at best (Dcl2) and, at worst, were unchanged (Piwi) following
knockdown (Figure 5). This is likely to be an underestimate of knockdown at the RNA level, as
the lab has previously documented the presence of large degradation intermediates by Northern
blot (2). These degradation products would be amplified by PCR, even though they would not be
competent for translation. A better estimate of knockdown could be achieved by Northern blot,
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but more relevant would be Western blot analysis of knockdown at the protein level. Previous
work in the lab showed that efficient knockdown at the RNA level did not guarantee equivalent
reductions in protein level (2). Since Dcl1, Dcl2, and Piwi are predicted to play a role in the
RNAi pathway, and are therefore required for knockdown of Dcl1, Dcl2, and Piwi, it is unlikely
that protein levels would be dramatically reduced.
Regardless of the precise level of knockdown attained, LRV1 levels were unchanged
following knockdown of each gene (Figure 6). This could be due to some combination of
insufficient knockdown, redundancy between Dicer proteins, and/or a lack of involvement of the
proteins in control of LRV1. Concurrent knockdown of both Dcl genes could circumvent the
issue of redundancy, but more effective may be a combination knockout-knockdown approach,
wherein, for example, Dcl1 is knocked out and Dcl2 is simultaneously knocked down. In the
absence of the redundant protein, knockdown may confer sufficient reductions in RNAi to reveal
a role for Dcl proteins in control of RNAi. Since this approach would still confer only a partial
phenotype, however, any lack of effect on LRV1 levels would not be meaningful.
Alternately, CRISPR technology could be harnessed to delete all copies of a gene in a
single transfection, using a single drug resistance marker. If this becomes routinely available in
Leishmania, the double knockout could be generated rapidly and complemented to confirm any
observed phenotypes.
C4 – Materials and Methods
Parasite strains and in vitro culture
L. guyanensis M4147 (MHOM/BR/78/M4147) was obtained from Jean Patterson (Texas
Biomedical Research Institute, San Antonio, Texas). I transfected this line with the linear 18S
rRNA-targeting SwaI fragment from B6367 pIR2SAT-LUC(B) (30), and clonal lines were
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derived and validated. Either the WT parental line or the luciferase-expressing clone 3 was used,
as indicated. Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10%
heat-inactivated fetal bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2
mM L-glutamine, 500 units/ml penicillin and 50 μg/mL streptomycin, and selective drugs as
indicated below.
Constructs
To knock out DCL1 and DCL2, genes conferring resistance to blasticidin S HCl (BSDR),
puromycin (PACR), and nourseothricin (SATR), hygromycin B (HYGR), as well as DNA regions
flanking the DCL1 and DCL2 ORFs were amplified by PCR (from B6173 pIR1BSD, B6176
pIR1PAC, B6351 pIR2SAT, B6441 pIR2HYG, and L. guyanensis M4147 WT genomic DNA,
respectively) using Phusion polymerase and the primers found in Table 1. PCR products were
gel-purified and used as templates in fusion PCR reactions. Reactions contained the 5’ flanking
region forward primer, 3’ flanking region reverse primer, and 5µL each of 5’ flanking region,
drug resistance ORF, and 3’ flanking region PCR products. Fusion PCR products were gelpurified, ligated into pCR-Blunt using the Zero-Blunt PCR Cloning Kit (Thermo Fisher
Scientific), and used to transform TOP10 chemically competent cells. Transformants were
selected on 100 μg/mL kanamycin, colonies picked, and DNAs confirmed by restriction digest
and sequencing.
StL constructs to knock down DCL1, DCL2, and PIWI genes were similar to other RNAi
constructs described in this document and elsewhere (7). “Stems” comprised of 600-900 bp
regions of each ORF were amplified by PCR from L. guyanensis M4147 WT genomic DNA
using the primers listed in Table 1 and KlenTaq-LA polymerase. Products were gel purified
using the Qiaquick Gel Extraction kit (Qiagen), and ligated into pCR8/GW/TOPO (Thermo
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Fisher) in a 10 min reaction at room temperature (RT). Stems were transferred into pIR3HYGGW(A) using LR Clonase II (Thermo Fisher) in overnight reactions at RT. Reactions were
quenched by addition of proteinase K and incubation at 37°C for 1 hour. Constructs were
confirmed by restriction digest.
Transfections
Stable transfections were performed as previously described (2, 7, 15). Clonal lines were
obtained either by plating on semisolid media with 150 µg/mL hygromycin B (RNAi
knockdowns) or by limiting dilution in liquid media with 5 μg/mL puromycin, 50 μg/mL
nourseothricin, 5 μg/mL blasticidin S HCl, or 75 μg/mL hygromycin B, as appropriate
(knockouts). Transfectants were grown to stationary phase in 1 mL media and passaged
thereafter in 10 mL media with selective drugs, as appropriate for the construct. When the
luciferase-expressing line was used, plates and liquid media also contained 50 μg/mL or 25
μg/mL nourseothricin, respectively.
Flow cytometry
Flow cytometry using the anti-capsid antibody (16) was performed as described
previously (7).
RNA preparation and qPCR
RNA was prepared as described previously (7). qPCR primers were designed to amplify
~100 bp regions of the appropriate ORF that lie outside the regions targeted by the StL construct
(Table 2). qPCR reactions were performed with cDNA templates in 20 µL total reaction volume
using the Power SYBR Green Master Mix (Thermo Fisher), 5 µL of ten-fold diluted cDNA, and
final primer concentrations of 0.2 µM. Reactions were run on the ABI PRISM 7000 Sequence
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Detection System (Applied Biosystems, Thermo Fisher). PCR amplification conditions were as
follows: 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec and 60
°C for 1 min. PCR products were confirmed to be specific by melt curve analysis. Amplification
of KMP-11 was used to normalize parallel reactions. +RT reaction were performed in triplicate
and –RT reactions in duplicate. A 10-fold dilution series was used to calculate primer efficiency
and relative RNA calculated using the Pfaffl method (17).
C5 – Table Legends
Table C1: Primers used in the cloning of constructs to knock out Dicer 1 and 2 and to knock
down Dicer 1, Dicer 2, and Piwi.
Restriction sites to enable release of the knockout cassette from the plasmid are
underlined. Linker regions enabling fusion PCR are in bold.
Table C2: Primers used for qPCR of Dicer 1, Dicer 2, and Piwi.
C6 – Figure Legends
Figure C1: Schematic of RNAi pathway components Dicer1, Dicer2, Ago1, and Piwi in L.
guyanensis.
Figure C2: Confirmation of DCLl1 (A) and DCL2 (B) single replacement by PCR. Primers
amplify across the site of integration.
Figure C3: LRV1 levels by flow cytometry using an anti-capsid antibody.
A) Substantial variability in LRV1 level is present in the WT and single replacement
clones following transfection. Shown are representative clones. Black, LRV1-negative
control; red, WT; blue, heterogeneous DCL1+/- clone; green, LRV1-negative DCL1+/clone.
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B) Re-cloning of a DCL1+/- clone generates sub-clones with substantial variability in
level of LRV1. Representative clones are shown. Black, LRV1-negative control; purple;
LRV1-negative subclone; green, LRV1-positive sub-clone; blue, heterogeneous subclone.
Figure C4: Confirmation PCR reactions following transfection of HYGR replacement construct
into PACR replacement of DCL1.
Left, amplification across site of integration. Right, amplification of DCL1 ORF. NTC,
no-template control reaction. HYGR single replacement was used as a positive control (+).
Figure C5: DCL1 double replacement clones display substantial variability in level of LRV1 as
assessed by flow cytometry.
Black, LRV1-negative control; red, single replacement parent; green, LRV1-positive
clone; purple, LRV1-negative clone; blue, heterogeneous clone.
Figure C6: qPCR analysis of DCL1 (A), DCL2 (B), and PIWI (C) mRNA levels after knockdown
relative to untransfected cells.
Averages and standard deviations are of two biological replicates of the parent line and
six independent clones of each knockdown.
Figure C7: Knockdown of DCL1, DCL2, and PIWI has no effect on LRV1 protein levels as
assessed by flow cytometry.
Representative clones are shown. Black, LRV1-negative control; red, untransfected
parent line; green, Dcl1StL; blue, Dcl2StL; purple, PiwiStL.
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Table C1
Gene

Region
Primer
Primer Sequence
amplified orientation
ID
DCL1
5’
Forward B6825 5’- CTCCAGCTGATTAAGGTGATGTG -3'
flanking
Reverse B6826 5’- CGTCAGCCCGCACCGTTACCGCTACTGAGGGTGGCTGGC -3'
3’
Forward B6827 5’- GCACCTTACGTGGGATCTCGGGCTCACCCTACCCGCC -3'
flanking
Reverse B6829 5’- GCAAGTTCGACGAGCTCGC -3'
DCL2
5’
Forward B6830 5’- CCATGCAGGTATCGATTCTCTG -3'
flanking
Reverse B6832 5’- CGTCAGCCCGCACCGTTACCCACCTCCACCCCGTAGACC -3'
3’
Forward B6833 5’- GCACCTTACGTGGGATCTCGAGGGAAAAAAGGGCCAAGAG -3'
flanking
Reverse B6835 5’- GAGGGCAGGAAGAGCAGG -3'
R
BSD
ORF
Forward B2642 5’- GGTAACGGTGCGGGCTGACGCCACCATGGCCAAGCCTTTGTCTCA
-3'
Reverse B2556 5’- CGAGATCCCACGTAAGGTGCTTAGCCCTCCCACACATAACCAGAG
-3'
R
HYG
ORF
Forward B4076 5’- GGTAACGGTGCGGGCTGACGCCACCATGAAAAAGCCTGAACTC 3'
Reverse B2562 5’- CGAGATCCCACGTAAGGTGCCTATTCCTTTGCCCTCG -3'
R
PAC
ORF
Forward B2557 5’- GGTAACGGTGCGGGCTGACGCCACCATGACCGAGTACAAGCCC 3'
Reverse B2558 5’- CGAGATCCCACGTAAGGTGCTCAGGCACCGGGCTTGCG -3'
SATR
ORF
Forward B4077 5’GGTAACGGTGCGGGCTGACGCCACCATGAAGATTTCGGTGATCCCTG
-3'
Reverse B4078 5’- CGAGATCCCACGTAAGGTGCTTAGGCGTCATCCTGTGCTCCC -3'
DCL1
ORF
Forward B3724 5’- CGTGGCGACTGAGCCGATCC -3’
(stem)
Reverse B3727 5’- AACGGCAGCGAAGGACGTGG -3’
DCL2
ORF
Forward B3984 5’- GAGACACGGATTCCTGTCGCTG -3’
(stem)
Reverse B3973 5’- GCACATACATGTGCACAATCTC -3’
PIWI
ORF
Forward B5371 5’- TGCTGAACTCGATTCACACGCTCC -3’
(stem)
Reverse B5376 5’- CAGCATATCGCCAATATCATGG -3’
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Table C2
Target
DCL1
DCL2
PIWI
KMP11

Orientation
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer ID
B3344
B7524
B7419
B7420
B7427
B7428
B5548
B5549

Sequence
5’- GGTCTACAAGCCGGAGGATT -3’
5’- GGTCGCTTCTCGGTACCGTAC -3’
5’- GCCAACAGATTGTCATAAGG -3’
5’- GGATGAGCACTTGCATGG -3’
5’- GGTGCAAGGGAAGACTGGC -3’
5’- CCACAAAGACGGCCTGTACC -3’
5’- GCCTGGATGAGGAGTTCAACA -3’
5’- GTGCTCCTTCATCTCGGG -3’
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Appendix D: Expression of bacterial RNaseIII
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Preface
The experiments in this appendix were designed and performed by EAB under the guidance of
SMB. The first draft was written by EAB and the final version presented here incorporates
comments from SMB.
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D1 – Introduction
We previously showed that a substantial number of sRNAs are generated from LRV1 in
Leishmania parasites (1). Loss of Argonaute1, however, did not elicit the expected increase in
LRV1 level (this work, Chapter 3). This suggested that Argonaute1 is not involved substantially
in control of LRV1. The presence of sRNAs derived from LRV1 implied that Dicer proteins
cleaved the LRV1 dsRNA genome; perhaps this cleavage was sufficient to control LRV1
replication without contribution from Argonaute. To test this, I attempted to over-express
RNaseIII in LRV1+ L. guyanensis.
In most organisms, Dicer proteins contain two RNaseIII domains, a dsRNA binding
domain (dsRBD), a helicase domain, a Piwi/Argonaute/Zwille (PAZ) domain, and a DUF283
domain (2, 3). Work on the Dicer proteins of the relative parasite Trypanosoma brucei, however,
has identified only the two RNaseIII domains (4, 5). In other systems, bacterial RNaseIII
proteins have shown promise in degradation of RNA viruses. Langenberg et al. found that
expression of E. coli RNaseIII in Nicotiana tabacum conferred increased resistance to a number
of plant viruses, but also resulted in stunting (6). Lee et al. found that expression of E. coli
RNaseIII in Bombyx mori resulted in an enhancement of RNAi activity, but also resulted in
nonspecific RNA degradation (7). Together, these results suggest that bacterial RNaseIII proteins
degrade viral dsRNA and/or generate sRNAs capable of entering the RNAi pathway, but also
have the potential to be detrimental to cells.
It is not known which Leishmania Dicer protein, if either, is responsible for control of
LRV1, whether control of LRV1 requires the combined action of both proteins, or whether Dicer
proteins can be overexpressed in Leishmania; therefore, I chose to express bacterial RNaseIII
proteins from Escherichia coli and Staphylococcus aureus in L. guyanensis. In theory, this
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should increase the cleavage of the LRV1 dsRNA genome, potentially resulting in loss of the
virus. I was unable, however, to obtain viable RNaseIII-expressing parasites.
D2 – Results
D2.1 – Heterologous expression of bacterial RNaseIII proteins is likely toxic to Leishmania
I transfected SwaI-linearized IR3HYG(empty), IR3HYG-Ecoli_RNaseIII(B), and
IR3HYG-Saureus_RNaseIII(B) into a luciferase-expressing clone of L. guyanensis strain
M4147. Transfection of the empty vector positive control yielded 4-10 times more colonies than
transfection of the RNaseIII-bearing DNA (Table 1). This disparity in the number of colonies
obtained can signal that the gene product being delivered is toxic. PCR reactions to confirm
integration at the 3’ end of the construct yielded a product of the expected size (Figure 1A). I
performed PCR reactions on genomic DNA to confirm integration at the 5’ end using a forward
primer binding outside the targeting region and a reverse primer binding to the RNaseIII ORF;
these reactions did not yield any product, even after optimization of reaction conditions (data not
shown). To confirm that the RNaseIII ORF was present in the cells, I attempted to amplify the
RNaseIII ORF from six clones of each RNaseIII construct. However, the expected PCR product
did not amplify from any sample (data not shown). I repeated the transfection, and again, the
positive control DNA yielded 10-fold higher numbers of colonies (Table 1). I did not attempt the
integration PCR reactions, but again, none of the RNaseIII-transfected colonies examined
contained the RNaseIII ORF by PCR (Figure 1B & C, data not shown), but control PCR
reactions amplified a fragment of the luciferase construct in all DNAs. In total, I screened 18
colonies transfected with the E. coli gene and 34 colonies transfected with the S. aureus gene.
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D3 – Discussion
This experiment attempted to increase RNaseIII activity in LRV1-positive L. guyanensis
parasites through the heterologous expression of bacterial RNaseIII genes. I was unable,
however, to recover viable cells with the RNaseIII ORF integrated, which suggests that it is toxic
when expressed at the levels obtained by integration into the parasite 18S rRNA locus.
The colonies that arose following transfection may have integrated the RNaseIII
construct and ejected the RNaseIII ORF by rearrangement; in this situation, the cells would have
carried the drug resistance gene. Indeed, PCR reactions to confirm 3’ integration use a forward
primer binding to the HYGR gene, and generated a product of the expected size. This suggests
that these clones may have contained the HYGR gene and therefore been transfectants, but
ejected the RNaseIII ORF. My lack of success in amplifying a 5’ integration PCR product using
a primers that binds to the RNaseIII ORF supports this conclusion. I could have further
confirmed this by attempting to amplify the HYGR gene, but since none of the clones contained
the RNaseIII ORF, I did not feel a need to.
If this experiment were attempted again, more success might be had by integrating
RNaseIII into a lower-expression locus, such as the alpha-tubulin locus. Additionally, this
experiment would benefit from an inducible system, in which transcription could be initiated
only when desired and the level of transcription better controlled.
D4 – Acknowledgements
Thanks to Jean Patterson (Southwest Foundation for Biomedical Research) for providing
parasite strains and to Gautam Dantas (Washington University School of Medicine) for
providing S. aureus genomic DNA. Thanks to Nicole McAllister, who performed the cloning of
the RNaseIII constructs.
211

D5 – Materials and Methods
Parasites and in vitro culture
Leishmania guyanensis strain M4147 was obtained from Jean Patterson (Southwest
Foundation for Biomedical Research, San Antonio, Texas). This line was transfected with the
linear 18S rRNA-targeting SwaI fragment from B6367 pIR2SAT-LUC(B), and clonal lines were
derived, validated, and used in these experiments. Parasites were grown in fresh Schneider’s
Insect Medium supplemented with 10% heat-inactivated fetal bovine serum, 100 μM adenine, 10
μg/mL hemin, 2 μg/mL biopterin, 2 mM L-glutamine, 500 units/ml penicillin and 50 μg/mL
streptomycin, and selective drugs as indicated below.
RNaseIII constructs
Staphylococcus aureus genomic DNA was obtained from Dr. Gautam Dantas
(Washington University School of Medicine) and Escherichia coli genomic DNA was isolated
from strain K12. Briefly, bacterial cultures were pelleted, resuspended in lysis buffer (0.6% SDS
and 0.12 mg/mL proteinase K in TE), and incubated at 37°C for 1 hour. DNA was extracted with
phenol:chloroform (1:1), ethanol precipitated, and the pellet dissolved in TE. RNaseIII genes
were amplified from bacterial genomic DNA using Phusion polymerase and the primers listed in
Table 2 and ligated into the BglII site of pIR3HYG. RNaseIII ORFs were confirmed by
sequencing.
Transfection
Stable transfections were performed as previously described(8, 9). After overnight
recovery, clonal lines were obtained by spreading ⅙ of the transfected cells per plate on
semisolid media with 50 μg/mL nourseothricin and 150 µg/mL hygromycin B. Colonies were
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picked into 1 mL media without selection and passaged thereafter in 10 mL media with 50
µg/mL hygromycin B.
Leishmania genomic DNA isolation and PCR
200 µL dense culture was pelleted, washed with phosphate buffered saline, and
resuspended in 40 µL lysis buffer (1% Triton X-100 in PBS containing 50 μg/mL proteinase K).
Samples were incubated at 37 ℃ for 1 hour and heat-inactivated at 95 ℃ for 10 min. 2 µL of
genomic DNA was used in 50 µL PCR reactions. DNA was pooled (3 samples/pool) and PCR
performed to amplify the RNaseIII ORF using the primers in Table 2. Genomic DNA from each
sample was assayed for quality by amplification of a control PCR product.
D6 – Table Legends
Table D1: Colonies per µg of DNA obtained from transfection with positive control IR3YG and
RNaseIII constructs.
The number of plates used in each attempt in given in parentheses. For each attempt,
transfected cells were allowed to recover overnight, and ⅙ of each transfection was
spread per plate.
Table D2: Primers used for cloning of RNaseIII genes from E. coli and S. aureus.
BglII sites indicated in bold; 6x His tag indicated in italics; Kozak sequence indicated by
underlining.
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D7 – Figure Legends
Figure D1: Confirmation of transfectants by PCR amplification of genomic DNA.
A) PCR reactions to confirm 3’ integration of RNaseIII constructs. The forward primer
binds to the HYGR ORF and the reverse primer binds 3’ of the targeting region. 12 of 12
clones amplified a product of the expected size.
B) In S. aureus RNaseIII-transfected cells, a control PCR reaction amplified a portion of
the luciferase construct from all genomic DNAs tested.
C) Genomic DNA from clones transfected with the S. aureus RNaseIII construct was
pooled (3 clones/pool) and PCR performed to amplify the RNaseIII ORF. Plasmid DNA
was used as a positive control (+).
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Table D1

IR3HYG
IR3HYG-Ecoli_RNaseIII
IR3HYG-Saureus_RNaseIII

Colonies per µg transfected DNA
1st transfection
2nd transfection
85.8
16.9
10
0.7
17.5
1.2
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Table D2
Target
E. coli

Primer ID
B7014
B7015

S.
aureus

B7016
B7017

Sequence
5’-aaaaaAGATCTCCACCATGAACCCCATCGTAATTAATC
TTTTTAGATCTTCAGTGGTGGTGGTGGTGGTGTTCCAGCTCCAG
TTTTT
aaaaaAGATCTCCACCATGCACCACCACCACCACCACTCTAAACAA
AAGAAAAGTGAGATAG
TTTTTAGATCTCTATTTAATTTGTTTTAATTGCTTATAGGC
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Figure D1
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Appendix E – Effects of StL constructs on Leishmania biology & virulence
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Preface
The experiments presented in this appendix were designed, performed, and analyzed by EAB
under the guidance of SMB. The first draft was written by EAB, and the final version presented
here incorporates comments from SMB.
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E1 – Introduction
Evidence in the laboratory has accumulated over the last few years to suggest that stemloop (StL) constructs may not be biologically neutral. In this Appendix I will detail experiments
that I have conducted to determine whether the presence of a StL construct integrated into the
parasite genome alters Leishmania biology and virulence. While these results are not conclusive,
they suggest that caution is warranted when StL constructs are used.
E2 – Results
E2.1 – The presence of a StL construct interferes with the effectiveness of a second StL
Previous work in the lab found that the presence of LRV1 had no effect on the efficiency
of the RNAi pathway (1), but this relied on a single LRV1-negative isogenic line. We decided to
use our LRV1-targeting StL constructs to confirm this finding using multiple independent
LRV1-negative clones. We transfected CapsidStL and RNA-dependent RNA polymerase (RDRP)
StL constructs into a clone of L. braziliensis strain LEM2780 containing an integrated luciferase
“self-reporter” (LUCSR) construct. This construct contains the luciferase (LUC) ORF and a
luciferase-targeting StL and integrates into the 18S rRNA locus; L. braziliensis parasites
transfected with this construct have LUC activity more than 100-fold below that of parasites
transfected with the LUC ORF alone. The resulting lines were LRV1-negative as assessed by
flow cytometry using the anti-capsid antibody (Figure 1).
We then evaluated the lines for LUC activity relative to LUC-expressing, LRV1-negative LRV1
StL lines (described in Chapter 2), as well as to untransfected LUC and LUCSR parasites. In
untransfected cells, the LUC line had 143x higher luciferase activity than the LUCSR line; in the
LRV1 StL parasites, the LUC line had 9x higher luciferase activity compared to the LUCSR line
(Figure 2A). To control for non-specific effects of the stem-loop, we also transfected a GFP221

targeting StL construct into the parental LUCSR line and compared LUC activity with LUCexpressing cells carrying the same GFPStL (2). The untransfected LUC cells again had 141x
higher luciferase activity than the untransfected LUCSR cells. The LUC GFPStL cells had 15x
higher luciferase activity that LUCSR GFPStL cells (Figure 2B). This suggests that the reduction
in knockdown of LUC was not specifically caused by knockdown of LRV1, but rather
nonspecifically by the introduction of a second StL construct.
E2.2 – Removal of StL targeting Leishmania RNA virus 1 (LRV1) in L. guyanensis does not
rescue presence of LRV1
I previously described a construct system that enabled integrated IR vectors to be easily
removed from the parasite genome (see Chapter 4), termed “popout constructs.” These constructs
use 18S rRNA sequence to integrate into the parasite genome by homologous recombination and
carry two genes to enable selection: a drug resistance gene and green fluorescent protein (GFP).
After culturing cells without positive selection, a proportion of the cells “pop out” the integrated
construct and can be selected by their lack of GFP expression.
In Chapter 2, we described LRV1StL-generated LRV1-negative lines as “isogenic.”
Ideally, a true isogenic line would no longer contain the RNAi construct. Therefore, we created a
popout version of the Capsid StL construct targeting LRV1 from L. guyanensis strain M4147. In
addition to being truly isogenic, these lines would give us an opportunity to investigate the
effects of the StL construct on Leishmania biology.
I transfected linearized IR3HYG-CapsidStL(A)-GFP+(B) and IR3HYG-GFP+(B) into a
luciferase-expressing clone of L. guyanensis strain M4147 (hereafter, WT). As an LRV1negative control, I also transfected IR3HYG-GFP+(B) into an LRV1-negative line that arose
spontaneously in culture (M4147/HYG) (3). After transfection and subsequent popout, integrated
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clones had GFP expression 300-fold above that of popped out clones (data not shown). In
addition, popped out clones were sensitive to hygromycin B, while integrated clones were
resistant.

Parasites

with

the

CapsidStL(A)-GFP+(B)

construct

integrated

(hereafter,

SSU:CapsidStL(A)-GFP+(B)) and parasites with the CapsidStL(A)-GFP+(B) construct popped
out (hereafter, PO:CapsidStL(A)-GFP+(B)) were LRV1-negative by RT-PCR (Figure 3). WT
cells transfected with the GFP+(B) construct contained LRV1, indicating that expression of GFP
did not induce loss of LRV1 (Figure 3). As PO:CapsidStL-GFP clones are LRV1-negative and
no longer contain the StL construct, they represent truly isogenic LRV1-negative lines.
E2.3 – Integrated StL constructs mobilize transposable elements
The results of the LUC activity assay in L. braziliensis LEM2780 above (Section E2.1)
suggested that the presence of the StL construct non-specifically interferes with the efficiency of
a second StL construct. As the RNAi pathway in Leishmania likely plays a role in the control of
transposable elements (TEs) (2, 4), integration of StL constructs could also result in mobilization
of TEs and a subsequent loss of genome stability. To assess whether this occurred in StL lines,
we sequenced RNA from L. guyanensis SSU:CapsidStL(A)-GFP+(B), PO:CapsidStL(A)GFP+(B), and control SSU:GFP+(B) parasites (Figure 4A), and mapped the reads to the L.
guyanensis and LRV1 genomes. The three lines had a similar proportion of reads mapping to the
housekeeping genes glucose-6-phosphate dehydrogenase and RNA polymerase II large subunit.
Likewise, reads mapped at a similar proportion to SLACS elements. In contrast, reads mapped to
TATE elements at twice the frequency in SSU:CapsidStL(A)-GFP+(B) as in PO:CapsidStL(A)GFP+(B) or the SSU:GFP+(B) control. In SSU:GFP+(B), reads mapped to the entire length of
the LRV1 genome, whereas in SSU:CapsidStL(A)-GFP+(B), reads mapped exclusively to the
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region targeted by the StL construct (Figure 4B). Only 51 of 12,801,644 reads mapped to LRV1
in PO:CapsidStL(A)-GFP+(B); these are likely noise.
We also sequenced small RNAs (sRNAs) isolated from total RNA from these lines and
mapped the 20-26 nt fraction to the L. guyanensis and LRV1 genomes. We have previously
showed that the 20-26 nt fraction of sRNAs are a good proxy for siRNAs (2). Reads mapped to
SLACS and TATE elements at similar proportions between PO:CapsidStL(A)-GFP+(B) and the
SSU:GFP+(B) control (43.7 and 37.8% vs 39.8 and 33.9% of mapped reads for SLACS and
TATE, respectively, in PO:CapsidStL(A)-GFP+(B) vs the SSU:GFP+(B) control) (Figure 4C).
In contrast, sRNA reads from SSU:CapsidStL(A)-GFP+(B) mapped to SLACS and TATE
elements at a frequency ~10% that of the PO:CapsidStL(A)-GFP+(B) or SSU:GFP+(B)
controls. Simultaneously, frequencies of LRV1-mapping reads increased from 4.0% of mapped
reads in the SSU:GFP+(B) control to 86.2% in the SSU:CapsidStL(A)-GFP+(B) line. These
reads mapped exclusively to the region targeted by the StL construct (Figure 4D), similar to what
was seen previously with LRV1 StL constructs (2). Likewise, the few LRV1-mapping reads in
PO:CapsidStL(A)-GFP+(B) mapped to the stem region.
The results of RNA and sRNA sequencing suggested that TATE elements were indeed
mobilized in CapsidStL-containing lines. To confirm, we evaluated lines for SLACS and TATE
transcript levels by qPCR (Figure 5). As was seen with sequencing, SLACS levels were similar
across the lines, while TATE levels were approximately doubled in SSU:CapsidStL(A)GFP+(B) compared to PO:CapsidStL(A)-GFP+(B) or the SSU:GFP+(B) control.
E2.4 – Integrated StL constructs produce stable dsRNA
Other members of the laboratory have identified stable dsRNA in parasites transfected
with StL constructs targeting viral RNAs. These dsRNA species were reverse transcribed,
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cloned, and found to contain sequence from the inverted repeat of the StL construct (Akopyants,
Lye, and Beverley, unpublished data). To examine this, I digested total RNA from parasites
transfected with the CapsidStL(A)-GFP+(B) and control GFP+(B) constructs with S1 nuclease
to determine if this stable dsRNA was present in integrated, but not popped out, StL lines. A
clear LRV1 band was present in the LRV1+ SSU:GFP+(B) and PO:GFP+(B) controls and
absent from SSU:CapsidStL(A)-GFP+(B), PO:CapsidStL(A)-GFP+(B), and LRV1-negative
lines (Figure 6, white arrowhead). Both clones of SSU:CapsidStL(A)-GFP+(B) had visible
dsRNA, which was not present in either of the PO:CapsidStL(A)-GFP+(B) clones (Figure 6,
black arrow).
E2.5 – The presence of a StL construct may affect parasite virulence
It is thought that LRV1 increases parasite virulence by acting as a source of dsRNA,
which is detected by TLR3 (5, 6). In support of this, the addition of LRV1 dsRNA to
macrophages in vitro results in a release of cytokines similar to that observed when the
macrophages are infected with L. guyanensis parasites containing LRV1 (5). It is possible that
the stable dsRNA present in StL lines could serve as a source of dsRNA, similarly affecting
parasite virulence. To test this, we injected the CapsidStL(A)-GFP+(B) popout lines and
controls into the hind footpad of C57/B6 mice and monitored the infections for luciferase activity
(a measure of parasite numbers) and lesion size (a measure of disease pathology).
At least one clone each of SSU:GFP+(B), PO:GFP+(B), and SSU:CapsidStL(A)GFP+(B) failed to induce pathology or accumulate any substantial number of parasites (data not
shown). These clones also had elevated doubling times in culture (data not shown). I concluded
that they were exhibiting culture-induced loss of virulence, and omitted them from further
analysis (7, 8). As expected, LRV1+ controls were significantly more virulent than LRV1225

negative controls, regardless of the presence or absence of GFP expression (Figure 7).
Unexpectedly, both SSU:CapsidStL(A)-GFP+(B) and PO:CapsidStL(A)-GFP+(B) parasites
displayed virulence phenotypes intermediate between the LRV1+ and LRV1-negative controls
(Figure 7). I had expected the PO:CapsidStL(A)-GFP+(B) parasites to behave similarly to
LRV1-negative PO:GFP+(B) controls, as neither group contains LRV1 or expresses GFP.
Possible reasons for this will be explored in the Discussion.
E3 – Discussion
In these experiments, introduction of a StL construct targeting either GFP or LRV1 into
L. braziliensis LEM2780 interfered with the knockdown of luciferase. Additionally, integration
of an LRV1StL popout construct into L. guyanensis resulted in increased levels of transposable
element RNA and an accumulation of stable dsRNA. Both of these phenotypes returned to WT
after the construct was popped out. Finally, the presence of the LRV1StL popout construct in L.
guyanensis may affect parasite virulence, but the data were not conclusive.
The use of popout CapsidStL-GFP+(B) constructs confirms that targeting of LRV1 by
RNAi results in a complete loss of virus. In previous work (see Chapter 2), the StL construct was
irreversibly integrated into the Leishmania genome. We were unable to amplify LRV1 sequence
from cDNA or detect capsid protein by flow cytometry in these lines; however, we could not rule
out that a very low level of LRV1 persisted in these cells, continually knocked down to
undetectable levels. With the removal of the popout StL construct, LRV1 levels did not rebound,
confirming that the virus is eradicated from these cells.
One caveat to these results is that none of the StL constructs used here have a
complementary target in the cell. Transfection of a StL targeting LRV1 results in loss of the
virus, at which time there is no longer any viral transcript present for base paring with anti-LRV1
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siRNAs. Similarly, the control GFPStL was transfected into a cell line that does not express
GFP; therefore, siRNAs produced from that construct do not have a target. There are conflicting
reports in the literature regarding the effect of the presence of target RNA on sRNA stability. On
one hand, Chatterjee and Großhans found that the presence of a cognate target stabilized the let-7
miRNA-AGO complex in C. elegans lysate and protected the miRNA from degradation (9).
Conversely, De et al. found that the presence of a target RNA promoted the release of a miRNA
from human AGO2 (10). If target binding does in fact promote siRNA turnover and degradation
in Leishmania, then the absence of a target could result in an accumulation of AGO1 bound to
StL-derived siRNAs at the expense of other siRNAs. More research will be required to confirm
or refute this hypothesis. Further, more research will be required to extend the effects observed
here to StL constructs targeting endogenous Leishmania genes. For these genes, continuing
transcription of the target gene ensures the presence of the target of the StL-derived siRNAs.
Little conclusive results can be drawn from the investigation of the effect of the StL
construct on parasite virulence. I considered the PO:CapsidStL(A)-GFP+(B) parasites to be a
negative control before the start of the experiment, and expected them to be indistinguishable
from the LRV1-negative PO:GFP+(B) cells. However, they displayed a virulence phenotype
intermediate between the LRV1+ and LRV1-negative controls. It is possible that some lingering
effect of the StL construct persisted in the PO:CapsidStL(A)-GFP+(B) parasites, but I do not
think this is likely. There were at least 80 cell doublings that separated SSU:CapsidStL(A)GFP+(B) and PO:CapsidStL(A)-GFP+(B) lines. I would anticipate this would be more than
enough time for any StL-derived siRNAs or stable dsRNA to be lost by dilution. Indeed, no
stable dsRNA was visible in PO:CapsidStL(A)-GFP+(B) lines following digestion with S1
nuclease, and very few sRNA reads mapped to LRV1.
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Rather, I think it is more likely that these results were due to a technical artifact. A
number of the clones I injected failed to produce a lesion; it is possible that the LRV1-negative
controls were similarly avirulent. Because I was expecting low virulence from these lines, I did
not flag them as problematic. Without confidence in the negative control, I cannot draw any
conclusions. In order to determine whether the StL construct results in increased virulence, new
integrated and popped out clones should be obtained and evaluated. If these do not demonstrate
culture loss of virulence, then we can have confidence in the results.
The presence of a StL construct in Leishmania parasites appears to impair knockdown of
other RNAi targets, lead to the accumulation of stable dsRNA, and may affect virulence of the
parasite. Much of this data is preliminary, and more work will be necessary to attain a high
confidence in these results. For example, I only sequenced RNA from one clone of each line – I
will need to sequence additional clones in order to confirm these results. However, together the
results suggest that caution is warranted when StL constructs are used.
E4 – Materials and Methods
Parasite strains and cell culture
L. braziliensis LEM2780 (MHOM/BO/90/CS) was from Patrick Bastien (Université de
Montpellier, Montpellier, France); L. braziliensis M2903 (MHOM/BR/75/M2903) was from
Diane McMahon Pratt (Yale School of Public Health, New Haven, CT); and L. guyanensis
M4147 (MHOM/BR/78/M4147) and its derivative L. guyanensis M4147/HYG were from Jean
Patterson (Southwest Foundation for Biomedical Research, San Antonio, Texas). L. braziliensis
LEM2780, L. guyanensis M4147, and L. guyanensis M4147/HYG were previously transfected
with SwaI-linearized B6367 pIR2SAT-LUC(B), and clonal lines were used in these experiments.
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L. braziliensis LEM2780 was also separately transfected with SwaI-linearized B6386 pIR2SATLUC(B)-LUCStL(A), and clone 71 was used in this work.
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heatinactivated fetal bovine serum, 100 μM adenine, 5 x 10 -5% hemin, 2 μg/mL biopterin, 2mM Lglutamine, 500 units/ml penicillin and 50 ug/mL streptomycin. Selective agents used were
nourseothricin sulfate (Gold Biotechnology) and hygromycin B (Hygro99, Gold Biotechnology).
Constructs and transfections
B7061 pIR2HYG-LRV1_Lbr2780_CapsidStL(A) and B7062 pIR2HYGLRV1_Lbr2780_RDRPStL(A) were described previously (2). To generate the popout CapsidStL
construct used in L. guyanensis, Gateway cloning reactions were performed between B7059
pCR8-LRV1_LgyM4147_Capsid and B7405 pIR3HYG-GW(A)-GFP+(B) using LR Clonase II
(Thermo Fisher Scientific) in an overnight reaction at room temperature (RT); the reaction was
terminated by digestion with proteinase K for 1 hr at 37 ℃. This yielded B7416 pIR3HYGLRV1_LgyM4147_CapsidStL(A)-GFP+(B).
Transfections were performed as previously described (1, 11). For L. braziliensis
transfections, cells were plated on semisolid media containing 15 µg/mL hygromycin B.
Colonies were picked and grown to stationary phase in 1 mL of media and passaged thereafter in
5 mL of media containing 10 µg/mL (L. braziliensis) hygromycin B. For L. guyanensis,
transfected cells were diluted to 105 cells/mL in Schneider’s media containing 50 µg/mL
nourseothricin and 75 µg/mL hygromycin B. They were diluted 1:10 daily for three days and
GFP-expressing cells were obtained by single-cell sorting.
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Flow cytometry
Flow cytometry using the anti-capsid antibody (12) was performed as previously
described (2, 13).
For single-cell sorting, log-phase cells were resuspended in phosphate-buffered saline,
passed through a CellTrics 50 µm filter (Partec) to remove clumps, and single cells were
recovered on the basis of GFP expression using a Beckman Coulter MoFlo cell sorter. Individual
cells were placed into wells of a 96-well plate containing 200 µL of Schneider’s Insect Medium
and incubated at 27 ℃ for 8 days before parasite growth was scored. Wells were expanded to 5
mL with selection and passaged thusly.
Luciferase activity assay
106 log phase cells in 200 μL of Schneider’s Medium were added to a 96-well plate
(Black plate, Corning Incorporated, NY, U.S.A.). D-luciferin (Biosynth AG) was added to a final
concentration of 150 μg/mL and plates were incubated for 1 min. Plates were imaged using a In
Vivo Imaging System (IVIS) photoimager (Perkin Elmer), and luciferase activity quantified as
photons/s. Each sample was run in duplicate.
StL construct popout
Cells containing a popout StL construct were split to 105 cells/mL in Schneider’s medium
lacking selection and GFP expression monitored by flow cytometry. Parallel cultures under drug
selection were used as a comparison. When a GFP-negative population appeared in the cultures
lacking selection, clonal lines were obtained by single-cell sorting.
Log-phase cells were resuspended in phosphate-buffered saline, passed through a
CellTrics 50 µm filter (Partec) to remove clumps, and single cells were recovered on the basis of
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GFP expression using a Beckman Coulter MoFlo cell sorter. Individual cells were placed into
wells of a 96-well plate containing 200 µL of Schneider’s Insect Medium containing no selective
antibiotic (GFP-negative cells) or 10 µg/mL hygromycin B (GFP-positive cells) and incubated at
27 ℃ for 10 days before parasite growth was scored. Wells were expanded to 5 mL with or
without antibiotic, as appropriate, and passaged thusly.
RNA preparation and cDNA synthesis
2.5-3x108 cells were pelleted and dissolved in 1mL Trizol reagent (Ambion, Thermo
Fisher Scientific). 250 µL of dissolved cells were used to isolate total RNA with the RNA
miniprep kit (Zymo Research). RNAs were digested with 20 Units of DNaseI (Ambion, Thermo
Fisher Scientific) in a 200 µL reaction using the supplied buffer and purified using the RNA
Clean & Concentrator kit (Zymo Research) and eluted in 50 µL of nuclease-free water.
cDNA was synthesized by random hexamer-primed reverse transcription using the
Superscript III First-Strand Synthesis kit (Thermo Fisher Scientific) in 20 µL reactions
containing 0.25 µg RNA. Control reactions contained an equal amount of RNA but omitted the
reverse transcriptase enzyme.
RT-PCR and qPCR
RT-PCR reactions were performed using 1 µL of ten-fold diluted cDNA in 25 µL
reactions to amplify 94 bp of LRV1 or ~400 bp of beta-tubulin sequence. Primer sequences are
located in Table 1. PCR products were run on 2% agarose gels and visualized using ethidium
bromide.
qPCR reactions were performed using 5 µL of ten-fold diluted cDNA in a 20 µL reaction
containing 10 µL of 2x Power SYBR reaction mix (Applied Biosystems, Thermo Fisher
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Scientific) and primers to a concentration of 0.2 µM each in MicroAmp Optical 96-well plates
(Thermo Fisher Scientific). Primer sequences are located in Table 1. Reactions were run on the
ABI PRISM 7000 Sequence Detection System. PCR amplifications were as follows: 50 °C for 2
min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. PCR
products were confirmed to be specific by melt curve analysis. +RT reactions were performed in
triplicate and –RT control reactions in duplicate.
On each plate, 5-fold dilution series were performed for each primer set to calculate
primer efficiencies, and relative RNA level calculated using the Pfaffl method (14) using
amplification of KMP-11 as an internal control. The data are averages and standard deviations of
2-3 independent clones, and significance was calculated by ANOVA followed by the Tukey post
hoc test.
RNA sequencing and bioinformatics analysis
RiboZero RNA libraries were generated from total RNA as described (15). Briefly,
sample integrity was assessed by Agilent Bioanalyzer 2100 (Santa Clara, CA). rRNA was
depleted from 1 mg input RNA with the Ribo-Zero™ rRNA Removal Kit (“RiboZero”) from
EpiCentre (an Illumina company, Madison, WI). RiboZero-depleted RNA was chemically
fragmented to generate fragments ranging from 200-600 nt in length, then made into cDNA with
Superscript III (Life Technologies, Thermo Fisher) and random hexamers followed by a second
strand reaction. cDNA was then end-repaired, A-tailed, and standard Illumina adapters were
ligated on. Libraries were amplified with primers to incorporate a unique index to each sample.
Equal masses of each library were pooled and sequenced on an Illumina HiSeq2500 platform,
with 2 × 100 base pair paired end reads (Illumina Inc., San Diego, CA).
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Data were analyzed using CLC Genomics v9.5.3. Briefly, 5’ and 3’ adaptors were
removed and trimmed reads were mapped to annotated genes and transposable elements from the
L. guyanensis M4147 genome, as well as to LRV1 genes (KX808487) using default RNA-Seq
parameters. Reads mapping to multiple locations were aligned randomly.
S1 nuclease digestion
15 µg of total RNA was digested with S1 nuclease in a 20 µL reaction containing 1x
reaction buffer, 0.6M NaCl, and enzyme at a final dilution of 1:400. Samples were heated to 65
℃ for 5 min prior to addition of the enzyme, then incubated at 37 ℃ for one hour.
Statement on Institutional and Licensing Committee Approval of Animal Experiments
Animal handling and experiments were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals (16) of the US
National Institutes of Health. Animal studies were approved by the Animal Studies Committee at
Washington University (protocol 20090086) in accordance with the Office of Laboratory Animal
Welfare’s guidelines and the Association for Assessment and Accreditation of Laboratory
Animal Care International.
Mouse infections
Female C57/B6 mice were obtained from Jackson Laboratories. Parasites were grown to
day 2 stationary phase and collected at 1x106 cells/50 μL DMEM. Mice were injected
subcutaneously in the left hind footpad with 1x106 parasites using a 30 gauge needle. Luciferase
activity was monitored weekly by imaging using the IVIS (Perkin Elmer). Briefly, mice were
injected intra-peritoneally with 150 mg/kg D-luciferin, potassium salt (Gold Biotechnology) 10
minutes before imaging. Five minutes before imaging they were anaesthetized with isofluorane,
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and anesthesia was continued throughout the procedure. Emitted photons were quantified using
Living Image v2.60.1 software (Perkin Elmer). Lesion size was measured weekly using calipers.
IFN-γ-/- mice were monitored for the development of metastases, and any located on the
uninjected foot were measured using calipers.
E5 – Table Legends
Table E1: RT-PCR and qPCR primer sequences.
E6 – Figure Legends
Figure E1: Integration of a CapsidStL or RDRPStL construct into L. braziliensis LEM2780
previously transfected with a LUCSR construct results in loss of LRV1.
Transfectants (blue, CapsidStL; green, RDRPStL) were evaluated by flow cytometry
using an anti-capsid antibody. WT L. braziliensis LEM2780 (red) and L. braziliensis
M2903 (black) were used as positive and negative controls, respectively.
Figure E2: Integration of a second StL construct impairs knockdown of luciferase.
The luciferase activity of WT, untransfected luciferase-expressing and LUCSR, and
luciferase-expressing and LUCSR parasites carrying a second StL were measured.
A) Parasites transfected with an LRV1-targeting StL Averages and standard deviations
are of six to seven clones of the LRV1StL lines.
B) Parasites transfected with a GFP-targeting StL. Averages and standard deviations are
of three to five clones.
Figure E3: LRV1 is eliminated by transfection of CapsidStL(A)-GFP+(B) into L. guyanensis.
cDNA from two clones of each of the indicated lines was used as template for the PCR
amplification of a fragment of LRV1 (top) or β-tubulin (bottom).
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Figure E4: The levels of RNAseq and sRNAseq reads mapping to TEs is altered in
SSU:CapsidStL(A)-GFP+(B) parasites.
A) RNA was sequenced for the indicated lines and mapped to the L. guyanensis M4147
and LRV1 genomes. The levels of housekeeping genes were not affected by the presence
of the StL construct, but levels of TATE elements increased.
B) Reads mapping to LRV1 mapped to the entire viral genome in SSU:GFP+(B)
parasites, but only to the stem region in SSU:CapsidStL(A)-GFP+(B) parasites.
C) sRNAs were sequenced for the indicated lines and mapped to the L. guyanensis
M4147 and LRV1 genomes. Reads mapping to SLACS and TATE fell 10-fold in
SSU:CapsidStL(A)-GFP+(B) parasites. Levels of LRV1-mapping reads increased 20fold in SSU:CapsidStL(A)-GFP+(B) parasites and fell 400-fold in PO:CapsidStL(A)GFP+(B) parasites compared to SSU:GFP+(B).
D) sRNA reads mapping to LRV1 mapped to the entire viral genome in SSU:GFP+(B)
parasites, but only to the stem region in SSU:CapsidStL(A)-GFP+(B) parasites.
Figure E5: Lines with an integrated CapsidStL(A)-GFP+(B) construct have elevated levels of
TATE RNA.
cDNA from the indicated lines was used as template in qPCR reactions with SLACS- and
TATE-specific primers. Averages and standard deviations are of two clones of
SSU:GFP+(B) and three clones each of SSU:CapsidStL(A)-GFP+(B) and
PO:CapsidStL(A)-GFP+(B). ** p<0.01; all other comparisons NS.
Figure E6: Lines with an integrated StL construct accumulate stable dsRNA.
15 µg of total RNA from two clones of each of the indicated lines was digested with S1
nuclease, the reaction run on a 1.8% agarose gel and stained with ethidium bromide.
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LRV1 genome is indicated by a white arrowhead; stable StL-dependent dsRNA is
indicated by a black arrow.
Figure E7: Tests of the effect of StL constructs on parasite virulence were inconclusive.
A) Luciferase activity of lines containing integrated GFP+(B) or CapsidStL(A)GFP+(B) constructs.
B) Lesion size of lines containing integrated GFP+(B) or CapsidStL(A)-GFP+(B)
constructs.
C) Luciferase activity of lines containing popped out GFP+(B) or CapsidStL(A)GFP+(B) constructs.
D) Lesion size of lines containing popped out GFP+(B) or CapsidStL(A)-GFP+(B)
constructs. Plotted are the geometric means and standard deviations of luciferase activity
and the arithmetic means and standard deviations of lesion size for two independent
experiments. Significance was determined by two-way ANOVA.
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Table E1
Target
LRV1
Β-tubulin
SLACS
TATE
KMP-11

Primer
ID
6423
6424
5023
2110
7900
7901
7906
7907
5023
7412

Orientation

Sequence

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’-GGTAATATCACGCAGTGTAAGC
5’-GACACCACCTCTAAGACACG
5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA
5’-GACAGATCTCATCAAGCACGGAGTCGATCAGC
5’- GTACATACGCAAACGACTCCG
5’-GGTGACATTCCGAATCTTCG
5’- ACCTGCCGCTCTACTCGAC
5’- GGCACCGACTCCTTCATG
5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA
5’- GGTGACGATGCGGGTACC
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Appendix F – Knockdown of IFT genes
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Preface
The experiments described here were conducted as part of a rotation project and will be
incorporated into a future larger publication. I performed experiments designed by Stephen M
Beverley and Lon-Fye Lye. L-FL assisted in data analysis. I wrote the first draft of this
Appendix, and the final version here incorporates comments by SMB.
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F1 – Introduction
The flagellar pocket is the sole site of endo- and exocytosis in trypanosomatids such as
Leishmania (1, 2), and components of sensory pathways such cyclic nucleotide (3, 4) and
calcium signaling (5) are localized to the flagellum. Additionally, the axoneme of the amastigote
flagellum exhibits a microtubule architecture more similar a pattern characteristic of sensory cilia
than of the promastigote flagellum and other motile flagella (6). Finally, Gluenz et al. observed
that the L. mexicana amastigote flagellar tip was frequently in close contact with the
parasitophorous vacuole membrane (6). Because of these observations, it has been hypothesized
that the flagellum of Leishmania could serve an important role in host-parasite interactions.
The Leishmania flagellum is maintained by the collective action of Intraflagelar
Transport (IFT), the mechanism by which flagellar components are shuttled from the cell body to
the tip of the flagellum (anterograde) and back (retrograde). To investigate the role of the
Leishmania flagellum in parasite biology and virulence, we attempted to disrupt its assembly by
knocking down IFT in in a clone of L. braziliensis M2903 adapted for in vitro differentiation into
the amastigote life cycle stage. Inducible RNAi knockdown of IFT in T. brucei disrupted
flagellum formation, reduced cell body size, and induced cell cycle arrest (7). There are
structural differences between Leishmania and Trypanosoma flagella, however, that decrease the
likelihood that IFT disruption in Leishmania will be lethal. The Trypanosoma flagellum is
attached along the length of the cell body, whereas the Leishmania flagellum protrudes freely
from the anterior tip (8). The Trypanosoma flagellum plays crucial roles in defining cell polarity
and directing organelle segregation and cell size during mitosis (9). While there is evidence that
the mitochondrion-kinetoplast-basal body-flagellum complex in Leishmania also plays a role in
directing organelle segregation(10), the different morphology of Leishmania during cell division
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makes it unlikely that the flagellum plays a crucial role in directing cell division (10). Further,
there appears to be some species-specific variation among Leishmania in the timing of flagellar
replication during cell division (10–12), lessening the likelihood that the flagellum serves a
crucial role in cell division.
In our experiments, RNAi knockdown of IFT genes in L. braziliensis failed to generate
viable mutants, whereas transfection of the same knockdown constructs in a Δago1 line yielded
many viable transfectants. Later work in the lab pursued this project further, and the combined
results paint a more complete picture of the role of IFT and the parasite flagellum in biology and
virulence.
F2 – Results
We transfected constructs into L. braziliensis strain M2903 (SA2) to knock down four
different IFT genes: IFT88, IFT122, IFT140, and IFT172. Two genes, IFT88 and IFT172,
belonged to the anterograde pathway, moving cargo from the base of the flagellum to the tip,
while the other two, IFT122 and IFT140, belonged to the retrograde pathway, returning cargo
from the tip of the flagellum to the cell body. In parallel, we transfected the following positive
controls: 1) a construct that enabled luciferase expression (“LUC”); a construct that
simultaneously expressed and knocked down luciferase (“LUCSR”); and constructs that knocked
down the paraflagellar rod proteins (“PFR1StL” and “PFR2StL”), which are known to be not
essential for viability (13, 14). Positive control transfections yielded viable transfectants (Table
1) with the expected phenotypes. Namely, LUC-transfected cells had high luciferase activity,
while LUCSR-transfected cells had activity levels 130-fold lower (Figure 1). PFR1StL- and
PFR2StL-transfected cells were defective in swimming (data not shown). In contrast, no colonies
grew for cells transfected with any IFT StL construct (Table 1).
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To confirm that this inability to recover transfectants was RNAi-dependent, we
transfected IFT122StL, IFT140StL, and IFT172StL, as well as control LUC and LUCSR
constructs, into an Argonaute1 knockout mutant (Δago1) of L. braziliensis M2903. Viable
transfectants were recovered for each construct (Table 2).
F3 – Discussion
While positive control transfections into L. braziliensis M2903 (SA2) were successful,
we were unable to recover viable transfectants after knockdown of IFT genes. This suggested
that parasites were not viable in the absence of these gene products. This was not entirely
unexpected, as IFT knockdown cells in T. brucei are likewise inviable. The essentiality of these
genes was confirmed by transfection of the IFT knockdown constructs into Δago1 cells, which
have a non-functional RNAi pathway, and therefore are insensitive to StL constructs. In this cell
line, we easily obtained transfectants containing the IFTStL constructs, suggesting that the
lethality seen in the SA2 line required an active RNAi pathway, and therefore was due to
knockdown. Because knockdown of four separate genes gave an identical phenotype, this was
unlikely to be due to off-target effects, but rather to loss of IFT, specifically.
Later research in the lab, however, showed this not to be the case. Tiffanie Fowlkes
demonstrated in her dissertation that IFT140 could be knocked out in L. donovani parasites if an
ectopic copy was first provided episomally. After replacement of both chromosomal copies with
drug resistance cassettes, the antibiotic maintaining selection of the episome was removed,
allowing it to be segregated out. Using this technique, she showed that Δift140 promastigote cells
were viable, lacked flagella, and accumulated vesicles in the flagellar pocket. In addition, in vitro
differentiation of Δift140 cells was impaired and the lines were avirulent in a mouse model of
visceral leishmaniasis (15). An analogous essentiality test for RNAi experiments would require
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temporary ectopic expression of the IFT target, recoded to be resistant to knockdown by the StL
construct, such as from a popout construct (see Chapter 4). After integration of the IFTStL
construct, the RNAi-resistant ectopic copy could be removed, and if the gene is essential, no
viable cells would be obtained; if not essential, IFT knockdown cells would be obtained.
Further, Lon-Fye (George) Lye in the lab has been able to recover parasites with some
IFT genes knocked down in L. braziliensis by using shorter “stems” in the StL constructs, which
reduces knockdown efficiency (unpublished data). This approach yielded mutants with shortened
flagella and vesicle accumulation, similar to the Δift140 mutant in L. donovani.
While somewhat unusual, it is not unprecedented for a gene at first to appear essential in
Leishmania, only to prove otherwise using a “gentler” approach such as an episome sort. Efforts
to knock out the hexose transporter GT2 from L. mexicana required the transient overexpression
of a suppressor gene, but after Δgt2 mutants were obtained, the suppressor was no longer
required for viability(16). Similarly, work in our lab investigating LPG4A failed to yield viable
mutants without the expression of the gene from an episome; after knockout of chromosomal
copies of the gene, episomal expression was no longer required for viability (Guo and Beverley,
unpublished data).
F4 – Acknowledgements
Thanks also to Joseph Marcus, who performed the cloning of the IFTStL constructs, and
to Lon-Fye (George) Lye, who followed up on the transfections into Δago1 cells.
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F5 – Materials and Methods
Parasites and in vitro culture
A variant of L. braziliensis strain M2903 adapted to differentiate in culture was obtained
from the laboratory of S.C. Alfieri(17) and plated to generate clonal lines; clone SA2 was used in
the following experiments. The Δago1 line of L. braziliensis was described previously(18).
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heatinactivated fetal bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2 mM Lglutamine, 500 units/ml penicillin and 50 μg/mL streptomycin, and selective drugs as indicated
below.
Stem-loop constructs
Stem-loop constructs were constructed as described previously (19). Specifically, regions
of each IFT gene to be knocked down were amplified by PCR using the primers listed in Table 3
to ultimately generate B6613 pIR2HYG-IFT88StL(A), B6664 pIR2SAT-IFT122StL(A), B6666
pIR2SAT-IFT140StL(A), and B6674 pIR2HYG-IFT172StL(A). B6386 pIR2SAT-LUCStL(A)LUC(B), B6282 pIR1SAT-PFR2StL(A), and B6294 pIR1SAT-PFR1StL(A) were described
previously(14).
Transfection
Stable transfections were performed as previously described(14, 20). After overnight
recovery, ⅙ of the transfected cells were spread per plate on semisolid media with 100 μg/mL
nourseothricin or 30 µg/mL hygromycin B. Transfectants were grown to stationary phase in 1
mL media without selection and passaged thereafter in 10 mL media with 100 µg/mL
nourseothricin or 30 µg/mL hygromycin B.
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Luciferase activity assay
106 log phase cells in 200 μL of Schneider’s Medium were added to a 96-well plate
(Black plate, Corning Incorporated, NY, U.S.A.). D-luciferin (Biosynth AG) was added to a final
concentration of 150 μg/mL and plates were incubated for 1 min. Plates were imaged using an In
Vivo Imaging System (IVIS) photoimager (Perkin Elmer), and luciferase activity quantified as
photons/s. Each sample was run in duplicate. One clone of WT, three clones of LUC-transfected,
and eight clones of LUCSR-transfected cells were evaluated.
F6 – Table Legends
Table F1: Colonies per µg of DNA obtained from transfection of StL constructs into WT L.
braziliensis strain M2903 (SA2).
Also indicated are the number of plates scored, each of which represents 1/6 the total
number of cells from a transfection. The IFT172StL transfection was attempted twice.
Table F2: Colonies per µg of DNA obtained from transfection of StL constructs into Δago1 L.
braziliensis M2903.
Indicated in parentheses are the number of plates scored, each of which represents 1/6 the
total number of cells from a transfection.
Table F3: Primers used in the cloning of StL constructs for the knockdown of IFT genes.
XbaI site underlined.
F7 – Figure Legends
Figure F1: Cells transfected with the positive control LUC and LUCSR constructs displayed the
expected luciferase activity.
Error bars are standard deviation.
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Table F1
Construct
LUC
LUCSR
PFR2StL
PFR1StL
IFT122StL
IFT140StL
IFT88StL
IFT172StL

Colonies per µg DNA
54.6
25.9
3.5
3.9
0
0
0
0
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Table F2
Construct
LUC
LUCSR
IFT172StL
IFT140StL
IFT122StL

Colonies per µg DNA
36.0
24.3
28.9
26.5
46.0
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Table F3
Target
IFT88

Primer ID
B4177
B4178
IFT122 B4181
B4182
IFT140 B4179
B4180
IFT172 B4175
B4176

Sequence
5’ – CGCTAGTCTAGATCGTCGAGCAGATCAATGTC – 3’
5’ – CGCTAGTCTAGAGTAGATGGCCTCCACGTTGT – 3’
5’ – CGCTAGTCTAGATTCACCATTTTGGAGAAGGC – 3’
5’ – CGCTAGTCTAGATTCAAAATGTCTGCTGACGC – 3’
5’ – CGCTAGTCTAGATTGTTTTCGAGACGATGCAG – 3’
5’ – CGCTAGTCTAGACTTCAGTCCCTCAAAGTCGC – 3’
5’ – CGCTAGTCTAGAGCGCCATCAATATGTACGTG – 3’
5’ – CGCTAGTCTAGACACCCAGTTGTTCACCTCCT – 3’
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Figure F1
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